WO2005087733A1 - Biphenyl compounds useful as muscarinic receptor antagonists - Google Patents

Biphenyl compounds useful as muscarinic receptor antagonists Download PDF

Info

Publication number
WO2005087733A1
WO2005087733A1 PCT/US2005/008007 US2005008007W WO2005087733A1 WO 2005087733 A1 WO2005087733 A1 WO 2005087733A1 US 2005008007 W US2005008007 W US 2005008007W WO 2005087733 A1 WO2005087733 A1 WO 2005087733A1
Authority
WO
WIPO (PCT)
Prior art keywords
compound
methyl
ethyl
alkyl
biphenyl
Prior art date
Application number
PCT/US2005/008007
Other languages
French (fr)
Inventor
Mathai Mammen
Yu-Hua Ji
Yongqi Mu
Craig Husfeld
Li Li
Original Assignee
Theravance, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Theravance, Inc. filed Critical Theravance, Inc.
Priority to EP05725269A priority Critical patent/EP1723108A1/en
Priority to JP2007503019A priority patent/JP2007528412A/en
Publication of WO2005087733A1 publication Critical patent/WO2005087733A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Definitions

  • the present invention relates to novel biphenyl compounds having muscarinic receptor antagonist or anticholinergic activity.
  • This invention also relates to pharmaceutical compositions comprising such biphenyl compounds, processes and intermediates for preparing such biphenyl compounds and methods of using such biphenyl compounds to treat pulmonary disorders.
  • Pulmonary or respiratory disorders such as chronic obstructive pulmonary disease (COPD) and asthma
  • COPD chronic obstructive pulmonary disease
  • Muscarinic receptor antagonists are known to provide bronchoprotective effects and therefore, such compounds are useful for treating respiratory disorders, such as COPD and asthma.
  • muscarinic receptor antagonists When used to treat such disorders, muscarinic receptor antagonists are typically administered by inhalation. However, even when administered by inhalation, a significant amount of the muscarinic receptor antagonist is often absorbed into the systemic circulation resulting in systemic side effects, such as dry mouth, mydriasis and cardiovascular side effects.
  • inhaled muscarinic receptor antagonists have a relatively short duration of action requiring that they be administered several times per day. Such a multiple-daily dosing regime is not only inconvenient but also creates a significant risk of inadequate treatment due to patient non-compliance with the required frequent dosing schedule. Accordingly, a need exists for new muscarinic receptor antagonists. In particular, a need exists for new muscarinic receptor antagonists that having high potency and reduced systemic side effects when administered by inhalation. Additionally, a need exists for inhaled muscarinic receptor antagonists having a long duration of action thereby allowing for once-daily or even once-weekly dosing. Such compounds are expected to be particularly effective for treating pulmonary disorders, such as COPD and asthma, while reducing or eliminating side effects, such as dry-mouth and constipation.
  • the present invention provides novel biphenyl compounds having muscarinic receptor antagonist or anticholinergic activity.
  • compounds of the invention are expected to possess high potency and reduced systemic side effects when administered by inhalation and to have a long duration of action. Accordingly, in one of its composition aspects, this invention provides a compound of formula I:
  • this invention is directed to a pharmaceutical composition
  • a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound of formula I or a pharmaceutically acceptable salt or solvate or stereoisomer thereof.
  • Such pharmaceutical compositions may optionally contain other therapeutic agents.
  • this invention is directed to such a pharmaceutical composition wherein the composition further comprises a therapeutically effective amount of a steroidal anti-inflammatory agent, such as a corticosteroid; a ⁇ 2 adrenergic receptor agonist; a phosphodiesterase-4 inhibitor; or a combination thereof.
  • a steroidal anti-inflammatory agent such as a corticosteroid; a ⁇ 2 adrenergic receptor agonist; a phosphodiesterase-4 inhibitor; or a combination thereof.
  • Compounds of this invention possess muscarinic receptor antagonist activity.
  • this invention is directed to a method for treating a pulmonary disorder, the method comprising administering to a patient a therapeutically effective amount of a compound of formula I or a pharmaceutically acceptable salt or solvate or stereoisomer thereof. Additionally, in another of its method aspects, this invention is directed to a method of producing bronchodilation in a patient, the method comprising administering to a patient a bronchodilation-producing amount of a compound of formula I or a pharmaceutically acceptable salt or solvate or stereoisomer thereof.
  • This invention is also directed to a method of treating chronic obstructive pulmonary disease or asthma, the method comprising administering to a patient a therapeutically effective amount of a compound of formula I or a pharmaceutically acceptable salt or solvate or stereoisomer thereof.
  • this invention is directed to a method for antagonizing a muscarinic receptor in a mammal comprising administering to the mammal, a therapeutically effective amount of the compound of formula I. Since compounds of this invention possess muscarinic receptor antagonist activity, such compounds are also useful as research tools.
  • this invention is directed to a method for using a compound of formula I or a pharmaceutically acceptable salt or solvate or stereoisomer thereof as a research tool for studying a biological system or sample, or for discovering new chemical compounds having muscarinic receptor antagonist activity.
  • This invention is also directed to processes and novel intermediates useful for preparing compounds of formula I or a pharmaceutically acceptable salt or solvate or stereoisomer thereof.
  • this invention is directed to a process of preparing a compound of formula I, the process comprising: (a) reacting a compound of formula II with a compound of formula III; (b) coupling a compound of formula IN with a compound of formula N; (c) reacting a compound of formula NI with a compound of formula Nil; (d) reacting a compound of formula II with a compound of formula NIII in the presence of a reducing agent; (e) for a compound of formula I wherein X 1 represents (l-3C)alkylene, reacting a compound of formula VI with a compound of formula IX in the presence of a reducing agent; or (f) for a compound of formula I wherein t is 1 , reacting a compound of formula X with a compound of formula XI in the presence of a reducing agent; and then (g) removing any protecting groups to provide a compound of formula I; wherein compounds of formula I-XI are as defined herein.
  • the above process further comprises the step of forming a pharmaceutically acceptable salt of a compound of formula I.
  • this invention is directed to the other processes described herein; and to the product prepared by any of the processes described herein.
  • This invention is also directed to a compound of formula I or a pharmaceutically acceptable salt or solvate or stereoisomer thereof, for use in therapy or as a medicament.
  • this invention is directed to the use of a compound of formula I or a pharmaceutically acceptable salt or solvate or stereoisomer thereof, for the manufacture of a medicament; especially for the manufacture of a medicament for the treatment of a pulmonary disorder or for antagonizing a muscarinic receptor in a mammal.
  • this invention is directed to novel biphenyl compounds of formula I or pharmaceutically acceptable salts or solvates or stereoisomers thereof. These compounds may contain one or more chiral centers and therefore, this invention is directed to racemic mixtures; pure stereoisomers (i.e., enantiomers or diastereomers); stereoisomer-enriched mixtures and the like unless otherwise indicated.
  • stereoisomer is shown or named herein, it will be understood by those skilled in the art that minor amounts of other stereoisomers may be present in the compositions of this invention unless otherwise indicated, provided that the desired utility of the composition as a whole is not eliminated by the presence of such other isomers.
  • the compounds of formula I also contain several basic groups (e.g., amino groups) and therefore, the compounds of formula I can exist as the free base or in various salt forms. All such salt forms are included within the scope of this invention. Furthermore, solvates of compounds of formula I or salts thereof are included within the scope of this invention. Additionally, where applicable, all cis-trans or E/Z isomers (geometric isomers), tautomeric forms and topoisomeric forms of the compounds of formula I are included within the scope of this invention unless otherwise specified.
  • the compounds of formula I may also include isotopically-labeled compounds, i.e., where one or more atoms have been enriched with atoms having an atomic mass different from the atomic mass predominately found in nature.
  • isotopes that may be incorporated into the compounds of Formula (I) include, but are not limited to, 2 H, 3 H, 13 C, 14 C, 15 N, 18 O and 17 O.
  • the nomenclature used herein to name the compounds of this invention is illustrated in the Examples herein. This nomenclature has been derived using the commercially-available AutoNom software (MDL, San Leandro, California). For example, compounds of formula I wherein W is O have typically been named as ester derivatives of biphenyl-2-ylcarbamic acid.
  • Each R 1 is independently selected from (l-4C)alkyl, (2-4C)alkenyl, (2-4C)alkynyl, (3-6C)cycloalkyl, cyano, halo, -OR la , -C(O)OR l , -SR lc , -S(O)R ld , -S(O) 2 R le , -NR lf R lg , -NR lh S(O) 2 R u , and -NR lj C(O)R lk , examples of which include methyl, fluoro, chloro, bromo, hydroxy, methoxy, amino, methylamino, dimethylamino and the like.
  • each R 2 may be at the 3, 4, 5 or 6-position on the phenylene ring to which it is attached (where the carbon atom on the phenylene ring attached to the nitrogen atom is position 1).
  • Each R 2 is independently selected from (l-4C)alkyl, (2-4C)alkenyl, (2-4C)alkynyl, (3-6C)cycloalkyl, cyano, halo, -OR 2a , -C(O)OR 2 , -SR 2c , -S(O)R 2d , -S(O) 2 R 2e , -NR 2f R 2g , -NR 2h S(O) 2 R 2i , and -NR 2j C(O)R 2k , examples of which include methyl, fluoro, chloro, bromo, hydroxy, methoxy, amino, methylamino, dimethylamino and the like.
  • R 2 are fluoro or chloro.
  • these groups are independently hydrogen, methyl or ethyl.
  • each alkyl and alkoxy group in R 1 , R la"lk , R 2 , and R 2a"2k is optionally substituted with 1 to 5 fluoro substituents.
  • W is O.
  • W is NW a .
  • W represents O.
  • W a is hydrogen or (l-4C)alkyl, examples of which include hydrogen, methyl, ethyl, n-propyl, isopropyl, ra-butyl, sec-butyl, isobutyl and tert-butyl.
  • W is hydrogen or (l-3C)alkyl.
  • W a is hydrogen, methyl or ethyl, particularly hydrogen or methyl
  • W a is hydrogen and NW a is NH.
  • the value for c is 0, 1, 2, 3, 4, or 5; particularly 0, 1, or 2; and more particularly 0 or 1. In one particular embodiment, c is 0.
  • Each R 3 independently represents (l-4C)alkyl or two R 3 groups that are joined to fo ⁇ n (l-3C)alkylene, (2-3C)alkenylene or oxiran-2,3-diyl.
  • each R 3 is independently (l-4C)alkyl, such as methyl, ethyl, n-propyl, isopropyl, n-butyl, -.ec-butyl, isobutyl and tert-butyl.
  • each alkyl group in R 3 is optionally substituted with 1 to 5 fluoro substituents.
  • each R 3 is independently (1-3C) alkyl, and in another embodiment, each R is independently methyl or ethyl.
  • each R 3 is at the 3, 4 or 5- ⁇ osition on the piperidine ring (where the nitrogen atom of the piperidine ring is position 1).
  • R 3 is at the 4-position on the piperidine ring
  • R 3 is at the 1- position of the piperidine ring, i.e., on the nitrogen atom of the piperidine ring thus forming a quaternary amine salt.
  • two R 3 groups are joined to form a (l-3C)alkylene or (2-3C)alkenylene group.
  • two R 3 groups at the 2 and 6-positions on the piperidine ring can be joined to form an ethylene bridge (i.e., the piperidine ring and the R groups form an 8-azabicyclo[3.2.1]octane ring); or two R groups at the 1 and 4-pos ⁇ t ⁇ ons on the piperidine ring can be joined to form an ethylene bridge (i.e., the piperidine ring and the R groups form an l-azabicyclo[2.2.2]octane ring).
  • other R groups as defined herein may also be present.
  • two R 3 groups are joined to form a oxiran-2,3-diyl group.
  • R 3 groups at the 2 and 6-positions on the piperidine ring can be joined to form a 3-oxatricyclo[3.3.1.0 2 ' 4 ]nonane ring).
  • other R 3 groups as defined herein may also be present.
  • the value for m is 0 or 1.
  • m is 0.
  • R 4 represents hydrogen, (l-4C)alkyl, or (3-4C)cycloalkyl. Examples of (l-4C)alkyl include methyl, ethyl, n-propyl, isopropyl, n-butyl, -.ec-butyl, isobutyl and tert-butyl.
  • Examples of (3-4C)cycloalkyl groups include cyclopropyl and cyclobutyl.
  • R 4 is hydrogen or methyl
  • R 4 is hydrogen.
  • the value for s is 0, 1 or 2.
  • a particular value for s is 0 or 1.
  • s is 0.
  • Ar 1 is a phenylene group or a (3-5C)heteroarylene group containing 1 or 2 heteroatoms selected independently from oxygen, nitrogen or sulfur.
  • the phenylene or heteroarylene group may be unsubstituted (q is 0) or substituted with 1, 2, 3, or 4 (q is 1, 2, 3, or 4) R 5 substituents, which are independently selected from halo, hydroxy, (l-4C)alkyl or (l-4C)alkoxy.
  • the value for q is 0, 1, 2, 3, or 4, particularly 0, 1, 2 or 3.
  • q is 0 or 1.
  • each alkyl and alkoxy group in R 5 is optionally substituted with 1 to 5 fluoro substituents.
  • the point of attachment is at any available carbon or heteroatom ring atom.
  • Ar is a phenylene group attached at the meta or para position.
  • Ar 1 is phen-l,3-ylene or phen-l,4-ylene wherein the phenylene group is unsubstituted or substituted with 1, 2 or 3 R 5 substituents.
  • Representative R 5 substituents include fluoro, chloro, bromo, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, -.ec-butyl, tert-butyl, methoxy, ethoxy, isopropoxy, difluoromethyl, trifluoromethyl, 2,2,2-trifluoroethyl and trifluoromethoxy.
  • Ar 1 groups in this embodiment include 2-fluorophen-l,4-ylene, 3-fluorophen-l,4-ylene, 2- chlorophen-l,4-ylene, 3-chlorophen-l,4-ylene, 2-methylphen-l,4-ylene, 3-methylphen-l,4- ylene, 2-methoxyphen-l,4-ylene, 3-methoxyphen-l,4-ylene, 2-trifluoromethoxyphen-l,4- ylene, 3-trifluoromethoxyphen-l,4-ylene, 2,3-difluorophen-l,4-ylene, 2,5-difluorophen- 1,4-ylene, 2,6-difluorophen-l,4-ylene, 2,3-dichlorophen-l,4-ylene, 2,5-dichlorophen-l,4- ylene, 2,6-dichlorophen-l,4-ylene, 2-chloro-5 7 methoxyphen-l,
  • Ar 1 is a (3-5C)heteroarylene group containing 1 or 2 heteroatoms selected independently from oxygen, nitrogen or sulfur; wherein the heteroarylene group is unsubstituted or substituted with 1 or 2 R 5 substituents.
  • Representative heteroarylene groups include divalent species of pyrrole, imidazole, thiazole, oxazole, furan, thiophene, pyrazole, isoxazole, isothiazole, pyridine, pyrazine, pyridazine and pyrimidine, where the point of attachment is at any available carbon or nitrogen ring atom.
  • Ar 1 groups include 2,5-furylene, 2,4- thienylene, 2,5-thienylene, 2,5-pyridylene, 2,6-pyridylene, and 2,5-pyrrolylene.
  • Representative R 5 substituents include fluoro, chloro, methyl, ethyl, n-propyl, isopropyl, n- butyl, isobutyl, -fee-butyl, tert-butyl, methoxy, ethoxy, isopropoxy, difluoromethyl, trifluoromethyl, 2,2,2-trifluoroethyl and trifluoromethoxy.
  • substituted Ar 1 groups include 3-fluoro-2,5-thienylene, 3-chloro-2,5-thienylene, 3-methyl- 2,5-thienylene, 3-methoxy-2,5-thienylene, and 3-methoxy-6-chloro-2,5-pyridylene.
  • Ar 1 represents phen-l,3-ylene, phen-l,4-ylene, 2,4- thienylene, 2,5-thienylene, 2,5-furylene, 2,5-pyridylene, 2,6-pyridylene, or 2,5-pyrrolylene; wherein the phenylene, thienylene, furylene, pyridylene or pyrrolylene group is optionally substituted with 1 or 2 R 5 substituents.
  • Ar 1 is substituted with one R 5 substituent selected from halo and (l-4C)alkoxy.
  • the value for t is 0, 1 or 2.
  • a particular value for t is 1.
  • the value for p is 0, 1, or 2.
  • Each R 6 is independently (l-4C)alkyl, (2-4C) alkenyl, (2-4C)alkynyl, (3-6C)cycloalkyl, cyano, nitro, halo, N,N-di(l-4C)alkylamino(2-4C)alkoxy, -OR 6a , -C(O)OR 6 , -SR 6c , -S(O)R 6d , -S(O) 2 R 6e or - ⁇ R 6f R 6g .
  • Each R 6a , R 6b , R 6c , R 6d , R 6e , R 6f and R 6g as used in R 6 is independently hydrogen, (l-4C)alkyl, (3-6C)cycloalkyl, phenyl or phenyl(l-4C)alkyl, where each phenyl group is unsubstituted or substituted by 1 or 2 substituents independently selected from halo, (l-4C)alkyl and (l-4C)alkoxy.
  • each alkyl and alkoxy group in R 6 and R 6 "6g is optionally substituted with 1 to 5 fluoro substituents.
  • each R 6 independently represents halo, (l-3C)alkyl, or (l-3C)alkoxy, where the alkyl and alkoxy groups are optionally substituted with 1 to 3 fluoro substituents.
  • each R 6 is independently selected from fluoro, chloro, bromo, methyl, methoxy, trifluoromethyl or trifluoromethoxy.
  • R 7 represents hydrogen, (l-4C)alkyl, (3-4C)cycloalkyl, -C(O)(l-4C)alkyl, -(1- 4C)alkyleneC(O)OR 7a , -C(O)heterocyclyl, -C(O)CH( ⁇ H 2 )(l -4C)alkyleneQ, -(1 -
  • Q is a nitrogen- containing substituent selected from -NR 7 R 7c and heteroaryl.
  • Z is a nitrogen-containing substituent selected from -NR 7d R 7e and heterocyclyl.
  • R 7a is hydrogen or (l-4C)alkyl.
  • R 7b , R 7c , R 7d and R 7e independently represents hydrogen, (l-4C)alkyl, (3-6C)cycloalkyl or hydroxyphenyl, and (l-4C)alkyl is unsubstituted or substituted by 1 or 2 substituents selected independently from amido, cyano, furyl, hydroxyl, and methylimidazolyl.
  • the heterocyclyl contains 1 or 2 nitrogen atoms, and is unsubstituted or substituted by 1 or 2 substituents selected independently from hydroxyl, amido, (l-4C)alkoxy, oxo, -S(O) 2 (l- 4C)alkyl, -(CH 2 )O(l-4C)alkyl, -(l-4C)alkyleneOH.
  • -NR 7f R 7g or -C(O)NR 7h R 7i where each of R 7f , R 7g R 7h and R 71 independently represents hydrogen or (l-4C)alkyl.
  • the heteroaryl contains 1 or 2 nitrogen atoms.
  • the heterocyclyl and heteroaryl groups may contain other heteroatoms, in addition to the 1 or 2 nitrogen atoms.
  • the heterocyclyl can be a morpholinyl group.
  • R 7 represents hydrogen, (l-4C)alkyl, or (3-4C)cycloalkyl, examples of which include methyl, ethyl, n-propyl, isopropyl, n-butyl, _?ec-butyl, isobutyl, tert-butyl, cyclopropyl and cyclobutyl.
  • R 7 represents hydrogen or methyl.
  • R 7 is -C(O)(l-4C)alkyl, examples of which include -C(O)CH 3 and -C(O)CH 2 CH 3 .
  • R 7 is -(l-4C)alkyleneC(O)OR 7a .
  • Such exemplary R 7 embodiments include -(CH 2 ) 2 C(O)OH and -(CH 2 ) C(O)OCH 3 .
  • R 7 is -C(O)heterocyclyl.
  • the heterocyclyl contains 1 nitrogen atom, and is unsubstituted or substituted with a hydroxyl.
  • R 7 is -C(O)CH(NH 2 )(l-4C)alkyleneQ.
  • Exemplary Q embodiments include -NR 7b R 7c such as -NH 2 , and a heteroaryl such as pyridyl or imidazolyl.
  • R 7 is -(l-4C)alkyleneC(O)Z, where Z is -NR 7d R 7e , for example -(CH 2 ) 2 C(O)-NR 7d R 7e .
  • R 7d and R 7e are both (l-4C)alkyl, and methyl in particular.
  • R 7d is hydrogen and R 7e is selected from (1- 4C)alkyl (such as methyl and ethyl), (3-6C)cycloalkyl (such as cyclopropyl) and hydroxyphenyl.
  • the (l-4C)alkyl is unsubstituted or substituted with furyl, hydroxyl or methylimidazolyl.
  • R 7 is -(l-4C)alkyleneC(O)Z, and Z is a heterocyclyl, for example -(CH 2 ) 2 C(O)heterocyclyl.
  • the heterocyclyl contains 1 nitrogen atom, such as piperidyl and is substituted with an amido.
  • R 7 is -C(O)(l-4C)alkyleneZ, where Z is -NR 7d R 7e , for example -C(O)CH 2 NR 7d R 7e , -C(O)(CH 2 ) 2 NR 7d R 7e , and -C(O)(CH 2 ) 3 NR 7d R 7e .
  • each of R 7d and R 7e independently represents hydrogen, or (1- 4C)alkyl.
  • R 7d is hydrogen or methyl and R 7e is (l-4C)alkyl substituted with amido, cyano, ftiryl, or hydroxyl.
  • R 7 is -C(O)(l-4C)alkyleneZ, where Z is a heterocyclyl, such as -C(O)(CH 2 )heterocyclyl, -C(O)(CH 2 ) 2 heterocyclyl and -C(O)(CH 2 ) 3 heterocyclyl.
  • the heterocyclyl contains 1 nitrogen atom such as pyrrolidinyl or piperidyl.
  • the heterocyclyl contains 2 nitrogen atoms such as piperazinyl, tetrahydropyrimidinyl and 1,4 diazepanyl.
  • the heterocyclyl is pyrrolidinyl, unsubstituted or substituted with amido or (l-4C)alkoxy such as methoxy.
  • the heterocyclyl is piperidyl unsubstituted or substituted by 1 or 2 substituents selected independently from hydroxyl, amido, or (l-4C)alkoxy such as methoxy.
  • the heterocyclyl is tetrahydropyrimidinyl substituted with oxo.
  • the heterocyclyl is piperazinyl substituted with -S(O) 2 (l-4C)alkyl such as -S(O) 2 CH CH 3 .
  • the heterocyclyl is 1,4 diazepanyl substituted with oxo.
  • R 7 is -S(O) 2 (l-4C)alkyleneZ. where Z is -NR 7d R 7e , such as -S(O) 2 (CH 2 ) 2 NR 7d R 7e .
  • each of R 7d and R 7e independently represents (l-4C)alkyl, where (l-4C)alkyl is substituted with hydroxyl, for example -N(CH 2 CH 2 OH) 2 .
  • R 7 is -S(O) 2 (l-4C)alkyleneZ, where Z is a heterocyclyl, such as -S(O) 2 (CH 2 ) 2 heterocyclyl.
  • the heterocyclyl is piperidyl substituted with hydroxyl, -(l-4C)alkyleneOH such as -(CH 2 ) 2 OH, or -C(O)NR 5h R 5i such as -(CO)N(CH 2 CH 3 ) 2 .
  • the heterocyclyl is piperazinyl, substituted with oxo.
  • X 1 is selected from (l-3C)alkylene, -C(O)(l-3C)alkylene, (l-3C)alkyleneC(O)-, -SO 2 -, -SO 2 (l-3C)alkylene and (l-3C)alkyleneSO 2 -.
  • the alkylene group in any X 1 is optionally substituted with 1 or 2 substituents independently selected from (l-4C)alkyl and -NR X R xb , where R a and R '5 * are independently selected from hydrogen and (l-4alkyl).
  • X 1 is selected from (l-3C)alkylene, -C(O)(l-3C)alkylene, (l-3C)alkyleneC(O)- or -SO 2 -.
  • Examples of particular values for X 1 are -CH 2 -, -CH CH 2 -, -CH 2 C(O)-, -C(O)CH(NH 2 )CH 2 - and -SO 2 -.
  • X 1 is -CH 2 - or -CH 2 CH 2 .
  • the -OH group can be located at the ortho, meta or para position.
  • the -OH group is located at the meta or para position; and in a particular embodiment, the -OH group is located at the para position.
  • a particular group of compounds of interest are compounds of formula I wherein a, b and c are 0; and R 4 is hydrogen or methyl.
  • Another particular group of compounds of interest are compounds of formula I wherein a, b and c are 0; R 4 is hydrogen or methyl; and R 7 is hydrogen or methyl.
  • Another particular group of compounds of interest are compounds of formula I wherein a, b and c are 0; R 4 is hydrogen or methyl; R 7 is hydrogen or methyl; and s is 0.
  • Another particular group of compounds of interest are compounds of formula I wherein a, b and c are 0; R 4 is hydrogen or methyl; R 7 is hydrogen or methyl; s is 0; and t is 1.
  • Another particular group of compounds of interest are compounds of formula I wherein a, b and c are 0; R 4 is hydrogen or methyl; R 7 is hydrogen or methyl; s is 0; t is 1 ; and m is 0.
  • this invention provides a compound of formula la:
  • R , R , R , R , p and q are as defined herein; or a pharmaceutically acceptable salt or solvate or stereoisomer thereof ⁇
  • Another particular group of compounds of interest are compounds of formula la wherein q is 0; or q is 1 or 2 and R 5 is selected independently from halo, (l-4C)alkyl or (1-
  • each alkyl and alkoxy group is optionally substituted with from 1 to 3 fluoro substituents.
  • Another particular group of compounds of interest are compoxmds of formula la wherein q is 1 and R 5 is halo or (l-4C)alkoxy.
  • each of R la , R lb , R lc , R ld , R le , R lf and R lg is independently hydrogen, (l-4C)alkyl or phenyl(l-4C)alkyl; b is 0 or an integer of from 1 to 3; each R 2 is independently selected from
  • R 2a , R 2b , R 2c , R 2d , R 2e , R 2f and R 2g is independently hydrogen, (l-4C)alkyl or phenyl(l-4C)alkyl
  • W represents O or NW a , where W a is hydrogen or (l-4C)alkyl
  • c is 0 or an integer from 1 to 4
  • each R 3 independently represents (l-4C)alkyl
  • m is O or 1
  • R 4 is hydrogen or (l-4C)alkyl
  • s is 0 or 1
  • Ar 1 represents a phenylene group or a (3-5C)heteroarylene group containing 1 or 2 heteroatoms selected independently from oxygen, nitrogen or sulfur; wherein the phenylene or heteroarylene group is substituted with (R 5 ) q where q
  • each R 6 independently represents (l-4C)alkyl, (2-4C)alkenyl, (2- 4C)alkynyl, (3-6C)cycloalkyl, cyano, nitro, halo, N,N-di(l-4C)alkylamino(2-4C)alkoxy, -OR 6a , -C(O)OR 6 , -SR 6c , -S(O)R 6d , -S(O) 2 R 6e or - ⁇ R 6f R 6 ; each of R 6a , R
  • Particular compounds of interest include: biphenyl-2-ylcarbamic acid l-[2-( ⁇ 4-[(4-hydroxybenzylamino)methyl] benzoyl ⁇ methylamino)ethyl]piperidin-4-yl ester; biphenyl-2-ylcarbamic acid l- ⁇ 2-[(4- ⁇ [2-(4-hydroxyphenyl)ethylamino]methyl ⁇ benzoyl)methylamino]ethyl ⁇ piperidin-4-yl ester; > biphenyl-2-ylcarbamic acid l-(2- ⁇ 4-[(4-hydroxybenzylamino)methyl] benzoylamino ⁇ ethyl)piperidin-4-yl ester; biphenyl-2-ylcarbamic acid l-[2-( ⁇ 4-[(3-hydroxybenzylamino)methyl] benzoyl ⁇ methylamino)ethyl]piperidin-4-yl ester; biphenyl-2-y
  • alkyl means a monovalent saturated hydrocarbon group which may be linear or branched. Unless otherwise defined, such alkyl groups typically contain from 1 to 10 carbon atoms.
  • alkyl groups include, by ay of example, methyl, ethyl, n-propyl, isopropyl, n-butyl, -.ec-butyl, isobutyl, tert-butyl, n-pentyl, n-hexyl, n-heptyl, n- octyl, n-nonyl, n-decyl and the like.
  • alkylene means a divalent saturated hydrocarbon group which may be linear or branched. Unless otherwise defined, such alkylene groups typically contain from 1 to 10 carbon atoms.
  • alkylene groups include, by way of example, methylene, ethane- 1,2-diyl ("ethylene”), propane- 1,2-diyl, propane- 1, 3 -diyl, butane- 1,4- diyl, pentane- 1 ,5-diyl and the like.
  • alkoxy means a monovalent group of the formula (alkyl)-O-, where alkyl is as defined herein.
  • Representative alkoxy groups include, by way of example, methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, -.ec-butoxy, isobutoxy, tert-butoxy and the like.
  • alkenyl means a monovalent unsaturated hydrocarbon group which may be linear or branched and which has at least one, and typically 1, 2 or 3, carbon-carbon double bonds. Unless otherwise defined, such alkenyl groups typically contain from 2 to 10 carbon atoms. Representative alkenyl groups include, by way of example, ethenyl, n- propenyl, isopropenyl, n-but-2-enyl, n-hex-3-enyl and the like.
  • alkenylene means a divalent alkenyl group.
  • alkynyl means a monovalent unsaturated hydrocarbon group which may be linear or branched and which has at least one, and typically 1, 2 or 3, carbon- carbon triple bonds. Unless otherwise defined, such alkynyl groups typically contain from 2 to 10 carbon atoms. Representative alkynyl groups include, by way of example, ethynyl, n-propynyl, n-but-2-ynyl, -hex-3-ynyl and the like.
  • alkynylene means a divalent alkynyl group.
  • aryl means a monovalent aromatic hydrocarbon having a single ring (i.e., phenyl) or fused rings (i.e., naphthalene). Unless otherwise defined, such aryl groups typically contain from 6 to 10 carbon ring atoms. Representative aryl groups include, by way of example, phenyl and naphthalene- 1-yl, naphthalene-2-yl, and the like.
  • arylene means a divalent aryl group.
  • azacycloalkyl means a monovalent heterocyclic ring containing one nitrogen atom, i.e., a cycloalkyl group in which one carbon atom has been replaced with a nitrogen atom.
  • azacycloalkyl groups typically contain from 2 to 9 carbon atoms.
  • Representative examples of an azacycloalkyl group are pyrrolidinyl and piperidinyl groups.
  • azacycloalkylene means a divalent azacycloakyl group.
  • Representative examples of an azacycloalkylene group are pyrrolidinylene and piperidinylene groups.
  • cycloalkyl means a monovalent saturated carbocyclic hydrocarbon group. Unless otherwise defined, such cycloalkyl groups typically contain from 3 to 10 carbon atoms.
  • cycloalkyl groups include, by way of example, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and the like.
  • cycloalkylene means a divalent cycloalkyl group .
  • halo means fluoro, chloro, bromo and iodo.
  • heteroaryl means a monovalent aromatic group having a single ring or two fused rings and containing in the ring at least one heteroatom (typically 1 to 3 heteroatoms) selected from nitrogen, oxygen or sulfur. Unless otherwise defined, such heteroaryl groups typically contain from 5 to 10 total ring atoms.
  • heteroaryl groups include, by way of example, monovalent species of pyrrole, imidazole, thiazole, oxazole, furan, thiophene, triazole, pyrazole, isoxazole, isothiazole, pyridine, pyrazine, pyridazine, pyrimidine, triazine, indole, benzofuran, benzothiophene, benzimidazole, benzthiazole, quinoline, isoquinoline, quinazoline, quinoxaline and the like, where the point of attachment is at any available carbon or nitrogen ring atom.
  • heteroarylene means a divalent heteroaryl group.
  • heterocyclyl or “heterocyclic” means a monovalent saturated or unsaturated (non-aromatic) group having a single ring or multiple condensed rings and containing in the ring at least one heteroatom (typically 1 to 3 heteroatoms) selected from nifrogen, oxygen or sulfur. Unless otherwise defined, such heterocyclic groups typically contain from 2 to 9 total ring carbon atoms.
  • heterocyclic groups include, by way of example, monovalent species of pyrrolidine, imidazolidine, pyrazolidine, piperidine, 1,4-dioxane, morpholine, thiomorpholine, piperazine, 3-pyrroline and the like, where the point of attachment is at any available carbon or nitrogen ring atom.
  • heterocyclene means a divalent heterocyclyl or heterocyclic group. When a specific number of carbon atoms is intended for a particular term used herein, the number of carbon atoms is shown in parentheses preceding the term. For example, the term "(l-4C)alkyl” means an alkyl group having from 1 to 4 carbon atoms.
  • salts means a salt which is acceptable for administration to a patient, such as a mammal (e.g., salts having acceptable mammalian safety for a given dosage regime).
  • Such salts can be derived from pharmaceutically acceptable inorganic or organic bases and from pharmaceutically acceptable inorganic or organic acids.
  • Salts derived from pharmaceutically acceptable inorganic bases include ammonium, calcium, copper, ferric, ferrous, lithium, magnesium, manganic, manganous, potassium, sodium, zinc and the like. Particularly preferred are ammonium, calcium, magnesium, potassium and sodium salts.
  • Salts derived from pharmaceutically acceptable organic bases include salts of primary, secondary and tertiary amines, including substituted amines, cyclic amines, naturally-occurring amines and the like, such as arginine, betaine, caffeine, choline, NN-dibenzylethylenediamine, diethylamine, 2-diethylaminoethanol, 2- dimethylaminoethanol, ethanolamine, ethylenediamine, N-ethylmorpholine, N- ethylpiperidine, glucamine, glucosamine, histidine, hydrabamine, isopropylamine, lysine, methylglucamine, morpholine, piperazine, piperadine,, polyamine resins, procaine, purines, theobromine, triethylamine, trimethylamine, tripropylamine, tromethamine and the like.
  • Salts derived from pharmaceutically acceptable acids include acetic, ascorbic, benzenesulfonic, benzoic, camphosulfonic, citric, ethanesulfonic, edisylic, fumaric, gentisic, gluconic, glucoronic, glutamic, hippuric, hydrobromic, hydrochloric, isethionic, lactic, lactobionic, maleic, malic, mandelic, methanesulfonic, mucic, naphthalenesulfonic, naphthalene- 1,5 -disulfonic, naphthalene-2,6-disulfonic, nicotinic, nitric, orotic, pamoic, pantothenic, phosphoric, succinic, sulfuric, tartaric, p-toluenesulfonic, xinafoic and the like.
  • citric, hydrobromic, hydrochloric, isethionic, maleic, naphthalene- 1,5-disulfonic, phosphoric, sulfuric and tartaric acids are particularly preferred.
  • salt thereof means a compound formed when the hydrogen of an acid is replaced by a cation, such as a metal cation or an organic cation and the like.
  • the salt is a pharmaceutically acceptable salt, although this is not required for salts of intermediate compounds that are not intended for administration to a patient.
  • solvate means a complex or aggregate formed by one or more molecules of a solute, i.e. a compound of formula I or a pharmaceutically acceptable salt thereof, and one or more molecules of a solvent.
  • Such solvates are typically crystalline solids having a substantially fixed molar ratio of solute and solvent.
  • Representative solvents include, by way of example, water, methanol, ethanol, isopropanol, acetic acid and the like. When the ' solvent is water, the solvate formed is a hydrate.
  • the term "or a pharmaceutically acceptable salt or solvate or stereoisomer thereof is intended to include all permutations of salts, solvates and stereoisomers, such as a solvate of a pharmaceutically acceptable salt of a stereoisomer of a compound of formula I.
  • therapeutically effective amount means an amount sufficient to effect treatment when administered to a patient in need of treatment.
  • treating means the treating or treatment of a disease or medical condition (such as COPD) in a patient, such as a mammal (particularly a human) that includes: (a) preventing the disease or medical condition from occurring, i.e., prophylactic treatment of a patient; (b) ameliorating the disease or medical condition, i.e., eliminating or causing t regression of the disease or medical condition in a patient; (c) suppressing the disease or medical condition, i.e., slowing or arresting the development of the disease or medical condition in a patient; or (d) alleviating the symptoms of the disease or medical condition in a patient.
  • a disease or medical condition such as COPD
  • a mammal particularly a human
  • leaving group means a functional group or atom which can be displaced by another functional group or atom in a substitution reaction, such as a nucleophilic substitution reaction.
  • representative leaving groups include chloro, bromo and iodo groups; sulfonic ester groups, such as mesylate, tosylate, brosylate, nosylate and the like; and acyloxy groups, such as acetoxy, trifluoroacetoxy and the like.
  • protected derivatives thereof means a derivative of the specified compound in which one or more functional groups of the compound are protected from undesired reactions with a protecting or blocking group.
  • Functional groups which may be protected include, by way of example, carboxylic acid groups, amino groups, hydroxyl groups, thiol groups, carbonyl groups and the like.
  • Representative protecting groups for carboxylic acids include esters (such as a .-methoxybenzyl ester), amides and hydrazides; for amino groups, carbamates (such as tert-butoxycarbonyl) and amides; for hydroxyl groups, ethers and esters; for thiol groups, thioethers and thioesters; for carbonyl groups, acetals and ketals; and the like.
  • Such protecting groups are well-known to those skilled in the art and are described, for example, in T. W. Greene and G. M.
  • amino-protecting group means a protecting group suitable for preventing undesired reactions at an amino group.
  • Representative amino-protecting groups include, but are not limited to, tert-butoxycarbonyl (BOC), trityl (Tr), benzyloxycarbonyl (Cbz), 9-fluorenylmethoxycarbonyl (Fmoc), formyl, trimethylsilyl (TMS), tert- butyldimethylsilyl (TBS), and the like.
  • carboxy-protecting group means a protecting group suitable for preventing undesired reactions at a carboxy group.
  • Representative carboxy-protecting groups include, but are not limited to, esters, such as methyl, ethyl, tert-butyl, benzyl (Bn), jp-methoxybenzyl (PMB), 9-fluroenylmethyl (Fm), trimethylsilyl (TMS), tert- butyldimethylsilyl (TBS), diphenylmethyl (benzhydryl, DPM) and the like.
  • hydroxyl-protecting group means a protecting group suitable for preventing undesirable reactions at a hydroxyl group.
  • hydroxyl-protecting groups include, but are not limited to, silyl groups including tri(l-6C)alkylsilyl groups, such as trimethylsilyl (TMS), triethylsilyl (TES), tert-butyldimethylsilyl (TBS) and the like; esters (acyl groups) including (l-6C)alkanoyl groups, such as formyl, acetyl and the like; arylmethyl groups, such as benzyl (Bn), .-methoxybenzyl (PMB), 9-fluorenylmethyl (Fm), diphenylmethyl (benzhydryl, DPM) and the like. Additionally, two hydroxyl groups can also be protected as an alkylidene group, such as prop-2-ylidine, formed, for example, by reaction with a ketone, such as acetone.
  • TMS trimethylsilyl
  • TES triethylsilyl
  • TBS tert-butyldi
  • the biphenyl compounds of this invention can be prepared from readily available starting materials using the following general methods and procedures or by using other information readily available to those of ordinary skill in the art. Although a particular embodiment of the present invention may be shown or described herein, those skilled in the art will recognize that all embodiments or aspects of the present invention can be prepared using the methods described herein or by using other methods, reagents and starting materials known to those skilled in the art. It will also be appreciated that where typical or preferred process conditions (i.e., reaction temperatures, times, mole ratios of reactants, solvents, pressures, etc.) are given, other process conditions can also be used unless otherwise stated.
  • process conditions i.e., reaction temperatures, times, mole ratios of reactants, solvents, pressures, etc.
  • a compound of formula I is first synthesized with R 7 being hydrogen, i.e., R 7 is hydrogen in the compound of formula III, V, VI, VIII, XI or XII.
  • R 7 is hydrogen in the compound of formula III, V, VI, VIII, XI or XII.
  • This resulting compound can then be reacted further to replace this hydrogen with an R 7 substituent selected from (l-4C)alkyl, -C(O)(l-4C)alkyl, -(1- 4C)alkyleneC(O)OR 7a , -C(O)heterocyclyl, -C(O)CH(NH 2 )(l-4C)alkyleneQ, -(1- 4C)alkyleneC(O)Z, -C(O)(l -4C)alkyleneZ, and -S(O) 2 (l -4C)alkyleneZ.
  • the reaction between the compounds of formula II and III, the leaving represented by Z 1 can be, for example, halo, such as chloro, bromo or iodo, or a sulfonic ester group, such as mesylate or tosylate.
  • P 1 can be, for example, hydrogen, tertbutyldimethylsilyl or benzyl.
  • the reaction is conveniently performed in the presence of a base, for example, a tertiary amine such as diisopropylethylamine.
  • Convenient solvents include nitriles, such as acetonitrile.
  • the reaction is conveniently conducted at a temperature in the range of from 0°C to 100°C.
  • Compounds of formula II are generally known in the art, or can be prepared by deprotecting a compound of formula XII:
  • reaction of a compound of formula IV with a compoxmd of formula V or reactive derivative thereof, P 2 can be, for example, hydrogen, tertbutyldimethylsilyl or benzyl.
  • reactive derivative of compound V it is meant that the carboxylic acid is activated, for example, by forming an anhydride or carboxylic acid halide, such as a carboxylic acid chloride.
  • the carboxylic acid can be activated using conventional carboxylic acid/amine coupling reagents, such carbodiimides, O-(7-azabenzotriazol-l-yl-NN,N',N' tetramethyluronium hexafluorophosphate (HATU) and the like.
  • carboxylic acid/amine coupling reagents such carbodiimides, O-(7-azabenzotriazol-l-yl-NN,N',N' tetramethyluronium hexafluorophosphate (HATU) and the like.
  • This reaction is conveniently performed under conventional amide bond- forming conditions.
  • the process is conveniently conducted at a temperature in the range of from -10°C to l00°C.
  • Compounds of formula IN can be prepared by reacting a compound of formula II with a compound of formula XV: OHC(CH 2 ) m CH 2 ⁇ R 4 P 8 XV wherein P represents hydrogen or an amino-protecting group, such as benzyl, in the presence of a reducing agent, such as sodium triacetoxyborohydride, followed if necessary by removing an ammo-protecting group P by, for example, hydrogenation in the presence ofpalladium.
  • a reducing agent such as sodium triacetoxyborohydride
  • Compounds of formula V can be prepared by reacting a compound of formula VII with a compoxmd of formula XVI: XVI wherein P 9 represents hydrogen or a carboxyl-protecting group, such as methyl or ethyl, followed if necessary by removing the carboxyl protecting group P 9 .
  • the leaving group represented by Z 2 can be, for example, halo, such as chloro, bromo or iodo, or a sulfonic ester group, such as mesylate or tosylate;
  • P can be, for example, hydrogen, tert-butyldimethylsilyl or benzyl.
  • This reaction is conveniently performed in the presence of a base, for example, a tertiary amine such as diisopropylethylamine.
  • a base for example, a tertiary amine such as diisopropylethylamine.
  • Convenient solvents include nitriles, such as acetonitrile.
  • the reaction is conveniently conducted at a temperature in the range of from 0 °C to 100 °C.
  • the compounds of formula VI can be prepared by reacting a compound of formula
  • the reaction is conveniently performed following, for example, the method of process (b) described herein.
  • the reducing agent may be, for example, hydrogen in the presence of a Group VIII metal catalyst, such as palladium, or a metal hydride reducing agent, such as a borohydride, including sodium triacetoxyborohydride.
  • Convenient solvents include alcohols, such as methanol.
  • the reaction is conveniently performed at a temperature in the range of from 0°C to 100°C.
  • the compounds of formula VIII may be prepared by oxidizing a compound corresponding to formula III in which Z 1 represents a hydroxyl group. Such oxidation reactions can be conducted, for example, using sulfur dioxide pyridine complex in dimethylsulfoxide in the presence of a tertiary amine, such as diisopropylethylamine.
  • the reducing agent may be, for example,' hydrogen in the presence of a Group VIII metal catalyst, such as palladium, or a metal hydride reducing agent, such as a borohydride, including sodium triacetoxyborohydride.
  • Convenient solvents include alcohols, such as methanol.
  • Compounds of formula X can be prepared by reacting a compound of formula IV with a compound of formula X7VIII: XVIII in the presence of a coupling agent, such as l-(3-dimethylaminopropyl)-3- ethylcarbodiimide (EDC) and 1-hydroxybenzotriazole hydrate (HOBT).
  • a coupling agent such as l-(3-dimethylaminopropyl)-3- ethylcarbodiimide (EDC) and 1-hydroxybenzotriazole hydrate (HOBT).
  • EDC l-(3-dimethylaminopropyl)-3- ethylcarbodiimide
  • HOBT 1-hydroxybenzotriazole hydrate
  • a compound of formula I may be reacted with bromine to afford a corresponding compound of formula I in which R 2 and or R 6 represent a bromo group.
  • a compound of formula I in which R 7 represents a hydrogen atom may be alkylated to afford a conesponding compoxmd of formula I in which R 7 represents a (1-4C) alkyl group.
  • compositions and Formulations The biphenyl compounds of this invention are typically administered to a patient in the form of a pharmaceutical composition or formulation.
  • Such pharmaceutical compositions may be administered to the patient by any acceptable route of administration including, but not limited to, inhaled, oral, nasal, topical (including transdermal) and parenteral modes of administration. It will be understood that any form of the compounds of this invention, (i.e., free base, pharmaceutically acceptable salt, solvate, etc.) that is suitable for the particular mode of administration can be used in the pharmaceutical compositions discussed herein.
  • this invention is directed to a pharmaceutical composition
  • a pharmaceutical composition comprising a pharmaceutically acceptable carrier or excipient and a therapeutically effective amount of a compound of formula I, or a pharmaceutically acceptable salt or solvate or stereoisomer thereof.
  • pharmaceutical compositions may contain other therapeutic and or formulating agents if desired.
  • the pharmaceutical compositions of this invention typically contain a therapeutically effective amoxmt of a compound of the present invention or a pharmaceutically acceptable salt or solvate or stereoisomer thereof.
  • such pharmaceutical compositions will contain from about 0.01 to about 95% by weight of the active agent; including, from about 0.01 to about 30% by weight; such as from about 0.01 to about 10% by weight of the active agent.
  • any conventional carrier or excipient may be used in the pharmaceutical compositions of this invention.
  • the choice of a particular carrier or excipient, or combinations of carriers or excipients, will depend on the mode of administration being used to treat a particular patient or type of medical condition or disease state.
  • the preparation of a suitable pharmaceutical composition for a particular mode of administration is well within the scope of those skilled in the pharmaceutical arts.
  • the ingredients for such compositions are commercially available from, for example, Sigma, P.O. Box 14508, St. Louis, MO 63178.
  • conventional formulation techniques are described in Remington: The Science and Practice of Pharmacy, 20 th Edition, Lippincott Williams & White, Baltimore, Maryland (2000); and H.C.
  • compositions which can serve as pharmaceutically acceptable carriers include, but are not limited to, the following: (1) sugars, such as lactose, glucose and sucrose; (2) starches, such as corn starch and potato starch; (3) cellulose, and its derivatives, such as sodium carboxymethyl cellulose, ethyl cellulose and cellulose acetate; (4) powdered tragacanth; (5) malt; (6) gelatin; (7) talc; (8) excipients, such as cocoa butter and suppository waxes; (9) oils, such as peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, corn oil and soybean oil; (10) glycols, such as propylene glycol; (11) polyols, such as glycerin, sorbitol, mannitol and polyethylene glycol; (12) estradiols, such as glycerin, sorbitol, mannitol and polyethylene glycol; (12) estradiol, such as
  • compositions of this invention are typically prepared by thoroughly and intimately mixing or blending a compound of the invention with a pharmaceutically acceptable carrier and one or more optional ingredients. If necessary or desired, the resulting uniformly blended mixture can then be shaped or loaded into tablets, capsules, pills, canisters, cartridges, dispensers and the like using conventional procedures and equipment.
  • the pharmaceutical compositions of this invention are suitable for inhaled administration. Suitable pharmaceutical compositions for inhaled administration will typically be in the form of an aerosol or a powder.
  • Such compositions are generally administered using well-known delivery devices, such as a nebulizer inhaler, a metered-dose inhaler (MDI), a dry powder inhaler (DPI) or a similar delivery device.
  • the pharmaceutical composition comprising the active agent is administered by inhalation using a nebulizer inhaler.
  • a nebulizer inhaler typically produce a stream of high velocity air that causes the pharmaceutical composition comprising the active agent to spray as a mist that is carried into the patient's respiratory tract.
  • the active agent when formulated for use in a nebulizer inhaler, is typically dissolved in a suitable carrier to form a solution.
  • the active agent can be micronized and combined with a suitable carrier to fonn a suspension of micronized particles of respirable size, where micronized is typically defined as having about 90% or more of the particles with a diameter of less than about 10 ⁇ m.
  • Suitable nebulizer devices are provided commercially, for example, by PARI GmbH (Starnberg, German). Other nebulizer devices include Respimat (Boehringer frige-heim) and those disclosed, for example, in U.S. Patent No. 6,123,068 to Lloyd et al. and WO 97/12687 (Eicher et al).
  • a representative pharmaceutical composition for use in a nebulizer inhaler comprises an isotonic aqueous solution comprising from about 0.05 ⁇ g/mL to about 10 mg/mL of a compound of formula I or a pharmaceutically acceptable salt or solvate or stereoisomer thereof.
  • the phannaceutical composition comprising the active agent is administered by inhalation using a dry powder inhaler.
  • dry powder inhalers typically administer the active agent as a free-flowing powder that is dispersed in a patient's air-stream during inspiration, hi order to achieve a free flowing powder, the active agent is typically formulated with a suitable excipient such as lactose or starch.
  • a representative pharmaceutical composition for use in a dry powder inhaler comprises dry lactose having a particle size between about 1 ⁇ m and about 100 ⁇ m and micronized particles of a compound of formula I, or a pharmaceutically acceptable salt or solvate or stereoisomer thereof.
  • Such a dry powder formulation can be made, for example, by combining the lactose with the active agent and then dry blending the components.
  • the active agent can be formulated without an excipient.
  • the pharmaceutical composition is then typically loaded into a dry powder dispenser, or into inhalation cartridges or capsules for use with a dry powder delivery device. Examples of dry powder inhaler delivery devices include Diskhaler
  • the pharmaceutical composition comprising the active agent is administered by inhalation using a metered- dose inhaler.
  • metered-dose inhalers typically discharge a measured amount of the active agent or a pharmaceutically acceptable salt or solvate or stereoisomer thereof using compressed propellant gas.
  • pharmaceutical compositions administered using a metered-dose inhaler typically comprise a solution or suspension of the active agent in a liquefied propellant.
  • Any suitable liquefied propellant may be employed including chlorofluorocarbons, such as CC1 3 F, and hydrofluoroalkanes (HFAs), such as 1,1,1,2- tetrafluoroethane (HFA 134a) and 1,1,1,2,3,3,3-heptafluoro-n-propane, (HFA 227).
  • chlorofluorocarbons such as CC1 3 F
  • HFAs hydrofluoroalkanes
  • HFA 134a 1,1,1,2- tetrafluoroethane
  • HFA 227 1,1,1,2,3,3,3-heptafluoro-n-propane
  • co-solvents such as ethanol or pentane
  • surfactants such as sorbitan trioleate, oleic acid, lecithin, and glycerin. See, for example, U.S.
  • a representative pharmaceutical composition for use in a metered-dose inhaler comprises from about 0.01 % to about 5 % by weight of a compound of formula I, or a pharmaceutically acceptable salt or solvate or stereoisomer thereof; from about 0 % to about 20 % by weight ethanol; and from about 0 % to about 5 % by weight surfactant; with the remainder being an HFA propellant.
  • compositions are typically prepared by adding chilled or pressurized hydrofluoroalkane to a suitable container containing the active agent, ethanol (if present) and the surfactant (if present).
  • the active agent is micronized and then combined with the propellant.
  • the formulation is then loaded into an aerosol canister, which forms a portion of a metered-dose inhaler device. Examples of metered-dose inhaler devices developed specifically for use with HFA propellants are provided in U.S. Patent Nos. 6,006,745 to Marecki and 6,143,277 to Ashurst et al.
  • a suspension formulation can be prepared by spray drying a coating of surfactant on micronized particles of the active agent.
  • Suitable pharmaceutical compositions for oral administration may be in the form of capsules, tablets, pills, lozenges, cachets, dragees, powders, granules; or as a solution or a suspension in an aqueous or non-aqueous liquid; or as an oil-in-water or water-in-oil liquid emulsion; or as an elixir or syrup; and the like; each containing a predetermined amount of a compound of the present invention as an active ingredient.
  • compositions' of this invention When intended for oral administration in a solid dosage form (i.e., as capsules, tablets, pills and the like), the pharmaceutical compositions' of this invention will typically comprise a compound of the present invention as the active ingredient and one or more pharmaceutically acceptable carriers, such as sodium turite or dicalcium phosphate.
  • pharmaceutically acceptable carriers such as sodium turite or dicalcium phosphate.
  • such solid dosage forms may also comprise: (1) fillers or extenders, such as starches, lactose, sucrose, glucose, mannitol, and/or silicic acid; (2) binders, such as carboxymethylcellulose, alginates, gelatin, polyvinyl pynolidone, sucrose and/or acacia; (3) humectants, such as glycerol; (4) disintegrating agents, such as agar- agar, calcium carbonate, potato or tapioca starch, alginic acid, certain silicates, and/or sodium carbonate; (5) solution retarding agents, such as paraffin; (6) absorption accelerators, such as quaternary ammonium compounds; (7) wetting agents, such as cetyl alcohol and/or glycerol monostearate; (8) absorbents, such as kaolin and/or bentonite clay; (9) lubricants, such as talc, calcium stearate, magnesium stearate, solid
  • antioxidants include: (1) water-soluble antioxidants, such as ascorbic acid, cysteine hydrochloride, sodium bisulfate, sodium metabisulfate sodium sulfite and the like; (2) oil-soluble antioxidants, such as ascorbyl palmitate, butylated hydroxyanisole (BHA), butylated hydroxytoluene (BHT), lecithin, propyl gallate, alpha-tocopherol, and the like; and (3) metal-chelating agents, such as citric acid, ethylenediamine tetraacetic acid (EDTA), sorbitol, tartaric acid, phosphoric acid, and the like.
  • water-soluble antioxidants such as ascorbic acid, cysteine hydrochloride, sodium bisulfate, sodium metabisulfate sodium sulfite and the like
  • oil-soluble antioxidants such as ascorbyl palmitate, butylated hydroxyanisole (BHA), butylated hydroxytoluene (BHT), lecithin
  • Coating agents for tablets, capsules, pills and like include those used for enteric coatings, such as cellulose acetate phthalate (CAP), polyvinyl acetate phthalate (PVAP), hydroxypropyl methylcellulose phthalate, methacrylic acid-methacrylic acid ester copolymers, cellulose acetate trimellitate (CAT), carboxymethyl ethyl cellulose (CMEC), hydroxypropyl methyl cellulose acetate succinate (HPMCAS), and the like.
  • enteric coatings such as cellulose acetate phthalate (CAP), polyvinyl acetate phthalate (PVAP), hydroxypropyl methylcellulose phthalate, methacrylic acid-methacrylic acid ester copolymers, cellulose acetate trimellitate (CAT), carboxymethyl ethyl cellulose (CMEC), hydroxypropyl methyl cellulose acetate succinate (HPMCAS), and the like.
  • enteric coatings such as cellulose acetate phthal
  • the pharmaceutical compositions of the present invention may also be formulated to provide slow or controlled release of the active ingredient using, by way of example, hydroxypropyl methyl cellulose in varying proportions; or other polymer matrices, liposomes and/or microspheres.
  • the pharmaceutical compositions of the present invention may optionally contain opacifying agents and may be formulated so that they release the active ingredient only, or preferentially, in a certain portion of the gastrointestinal tract, optionally, in a delayed manner. Examples of embedding compositions which can be used include polymeric substances and waxes.
  • the active ingredient can also be in micro- encapsulated form, if appropriate, with one or more of the above-described excipients.
  • Suitable liquid dosage forms for oral administration include, by way of illustration, pharmaceutically acceptable emulsions, microemulsions, solutions, suspensions, syrups and elixirs.
  • Such liquid dosage forms typically comprise the active ingredient and an inert diluent, such as, for example, water or other solvents, solubilizing agents and emulsifiers, such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, oils (e.g., cottonseed, groundnut, corn, germ, olive, castor and sesame oils), glycerol, tetrahydrofuryl alcohol, polyethylene glycols and fatty acid esters of sorbitan, and mixtures thereof.
  • an inert diluent such as, for example, water or other solvents, solubilizing agents and emulsifier
  • Suspensions in addition to the active ingredient, may contain suspending agents such as, for example, ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminium metahydroxide, bentonite, agar-agar and tragacanth, and mixtures thereof.
  • the pharmaceutical compositions of this invention are preferably packaged in a unit dosage form.
  • the term "unit dosage form" means a physically discrete unit suitable for dosing a patient, i.e., each unit containing a predetermined quantity of active agent calculated to produce the desired therapeutic effect either alone or in combination with one or more additional units.
  • such unit dosage forms maybe capsules, tablets, pills, and the like.
  • the compounds of this invention can also be administered transdermally using known transdermal delivery systems and excipients.
  • a compound of this invention can be admixed with permeation enhancers, such as propylene glycol, polyethylene glycol monolaurate, azacycloalkan-2-ones and the like, and incorporated into a patch or similar delivery system. Additional excipients including gelling agents, emulsifiers and buffers, may be used in such transdermal compositions if desired.
  • the pharmaceutical compositions of this invention may also contain other therapeutic agents that are co-administered with a compound of formula I, or pharmaceutically acceptable salt or solvate or stereoisomer thereof.
  • the pharmaceutical compositions of this invention may further comprise one or more therapeutic agents selected from other bronchodilators (e.g., PDE 3 inhibitors, adenosine 2b modulators and ⁇ 2 adrenergic receptor agonists); anti-inflammatory agents (e.g., steroidal anti-inflammatory agents, such as corticosteroids; non-steroidal anti-inflammatory agents (NSAIDs), and PDE 4 inhibitors); other muscarinic receptor, antagonists (i.e., antichlolinergic agents); antiinfective agents (e.g., Gram positive and Gram negative antibiotics or antivirals); antihistamines; protease inhibitors; and afferent blockers (e.g., D 2 agonists and neurokinin modulators), hi one particular aspect of the invention, the compound of the invention is co-administered with a ⁇ adrenergic receptor agonist and a steroidal anti-inflammatory agent.
  • bronchodilators e.g., PDE
  • the other therapeutic agents can be used in the form of pharmaceutically acceptable salts or solvates. Additionally, if appropriate, the other therapeutic agents can be used as optically pure stereoisomers.
  • Representative ⁇ 2 adrenergic receptor agonists that can be used in combination with the compounds of this invention include, but are not limited to, salmeterol, salbutamol, formoterol, salmefamol, fenoterol, terbutaline, albuterol, isoetharine, metaproterenol, bitolterol, pirbuterol, levalbuterol and the like, or pharmaceutically acceptable salts thereof.
  • ⁇ 2 adrenergic receptor agonists that can be used in combination with the compounds of this invention include, but are not limited to, 3-(4- ⁇ [6-( ⁇ (2R)-2-hydroxy-2-[4-hydroxy- 3-(hydroxymethyl)-phenyl]ethyl ⁇ amino)-hexyl]oxy ⁇ butyl)benzenesulfonamide and 3-(-3- ⁇ [7-( ⁇ (2R)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl ⁇ -amino)heptyl]oxy ⁇ - propyl)benzenesulfonamide and related compounds disclosed in WO 02/066422 (Glaxo Group Ltd.); 3-[3-(4- ⁇ [6-([(2R)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl] ethyl ⁇ amino)hexyl]oxy ⁇ butyl)-phenyl]imidazolidine-2,4-di
  • the ⁇ 2 - adrenoreceptor agonist is a crystalline monohydrochloride salt of N- ⁇ 2-[4-((R)-2-hydroxy- 2-phenylethylamino)phenyl]ethyl ⁇ -(R)-2-hydroxy-2-(3-formamido-4-hydroxyphenyl) ethylamine.
  • the ⁇ 2 -adrenoreceptor agonist will be present in the pharmaceutical composition in a therapeutically effective amount.
  • the ⁇ 2 - adrenoreceptor agonist will be present in an amount sufficient to provide from about 0.05 ⁇ g to about 500 ⁇ g per dose.
  • steroidal anti-inflammatory agents that can be used in combination with the compounds of this invention include, but are not limited to, methyl prednisolone, prednisolone, dexamethasone, fluticasone propionate, 6 ⁇ ,9 ⁇ -difluoro-17 ⁇ -[(2-furanyl carbonyl)oxy]-l l ⁇ -hydroxy-16 ⁇ -methyl-3-oxoandrosta-l,4-diene-17 ⁇ -carbothioic acid S- fluoromethyl ester, 6 ⁇ ,9 ⁇ -difluoro-l l ⁇ -hydroxy-16 ⁇ -methyl-3-oxo-17 ⁇ - ⁇ ro ⁇ ionyloxy- androsta-l,4-diene-17 ⁇ -carbothioic acid S-(2-oxo-tetrahydrofuran-3S-yl) ester, beclomethasone esters (e.g., the 17-propionate ester or the 17,21-dipropionate ester), budesonide, flun
  • the steroidal anti- inflammatory agent When employed, the steroidal anti- inflammatory agent will be present in the pharmaceutical composition in a therapeutically effective amount. Typically, the steroidal anti-inflammatory agent will be present in an amount sufficient to provide from about 0.05 ⁇ g to about 500 ⁇ g per dose.
  • An exemplary combination is a compound of formula I, or pharmaceutically acceptable salt or solvate or stereoisomer thereof, co-administered with salmeterol as the ⁇ 2 adrenergic receptor agonist, and fluticasone propionate as the steroidal anti-inflammatory agent.
  • Another exemplary combination is a compound of formula I, or pharmaceutically acceptable salt or solvate or stereoisomer thereof, co-administered with a crystalline monohydrochloride salt of N- ⁇ 2-[4-((R)-2-hydroxy-2-phenylethylamino)phenyl]ethyl ⁇ -(R)- 2-hydroxy-2-(3-formamido-4-hydroxyphenyl)ethylamine as the ⁇ 2 -adrenoreceptor agonist, and 6 ⁇ ,9 ⁇ -difluoro-17 ⁇ -[(2-furanylcarbonyl)oxy]-l l ⁇ -hydroxy-16 ⁇ -methyl-3-oxoandrosta- l,4-diene-17 ⁇ -carbothioic acid S-fluoromethyl ester as the steroidal anti-inflammatory agent.
  • NSAIDs such as sodium cromoglycate; nedocromil sodium; phosphodiesterase (PDE) inhibitors (e.g., theophylline, PDE4 inhibitors or mixed PDE3/PDE4 inhibitors); leukotriene antagonists (e.g., monteleukast); inhibitors of leukotriene synthesis; i ⁇ OS inhibitors; protease inhibitors, such as tryptase and elastase inhibitors; beta-2 integrin antagonists and adenosine receptor agonists or antagonists (e.g., adenosine 2a agonists); cytokine antagonists (e.g., chemokine antagonists such as, an interleukin antibody ( ⁇ lL antibody), specifically, an ⁇ IL-4 therapy, an ⁇ IL-13 therapy, or a combination thereof); or inhibitors of cytokine synthesis.
  • NSAIDs such as sodium cromoglycate; nedocromil sodium; phosphodie
  • representative phosphodiesterase-4 (PDE4) inhibitors or mixed PDE3/PDE4 inhibitors that can be used in combination with the compounds of tins invention include, but are not limited to cis 4-cyano-4-(3-cyclopentyloxy-4- methoxyphenyl)cyclohexan-l -carboxylic acid, 2-carbomethoxy-4-cyano-4-(3- cyclopropylmethoxy-4-difluoromethoxyphenyl)cyclohexan-l-one; c._?-[4-cyano-4-(3- cyclopropylmethoxy-4-difluoromethoxyphenyl)cyclohexan-l-ol]; ct-?-4-cyano-4-[3- (cyclopentyloxy)-4-methoxyphenyl] cyclohexane- 1 -carboxylic acid and the like, or phaimaceutically acceptable salts thereof.
  • PDE4 phosphodie
  • PDE4 or mixed PDE4/PDE3 inhibitors include AWD-12-281 (elbion); NCS-613 (INSERM); D-4418 (Chiroscience and Schering-Plough); CI-1018 or PD-168787 (Pfizer); benzodioxole compounds disclosed in WO99/16766 (Kyowa Hakko); K-34 (Kyowa Hakko); V-11294A (Napp); roflumilast (Byk-Gulden); pthalazinone compounds disclosed in WO99/47505 (Byk-Gulden); Pumafentrine (Byk-Gulden, now Altana); arofylline (Almirall- Prodesfarma); NM554/UM565 (Nernalis); T-440 (Tanabe Seiyaku); and T2585 (Tanabe Seiyaku).
  • muscarinic antagonists i.e., anticholinergic agents
  • muscarinic antagonists include, but are not limited to, atropine, atropine sulfate, atropine oxide, methylatropine nitrate, homatropine hydrobromide, hyoscyamine (d, I) hydrobromide, scopolamine hydrobromide, ipratropium bromide, oxitropium bromide, tiofropium bromide, methantheline, propantheline bromide, anisotropine methyl bromide, clidinium bromide, copyrrolate (Robinul), isopropamide iodide, mepenzolate bromide, tridihexethyl chloride (Pathilone), hexocyclium methylsulfate, cyclopentolate hydrochloride, tropicamide, trihexyphenidyl hydrochloride,
  • antihistamines i.e., Hi -receptor antagonists
  • ethanolamines such as carbinoxamine maleate, clemastine fumarate, diphenylhydramine hydrochloride and dimenhydrinate
  • ethylenediamines such as pyrilamine amleate, tripelei amine hydrochloride and tripelennamine mecanical gulfin
  • alkylamines such as chlorpheniramine and acrivastine
  • piperazines such as hydroxyzine hydrochloride, hydroxyzine pamoate, cyclizine hydrochloride, cyclizine lactate, meclizine hydrochloride and cetirizine hydrochloride
  • piperidines such as astemizole, levocabastine hydrochloride, loratadine or its descarboethoxy analogue, terfenadine and fexofenadine hydrochlor
  • Formulation Example A A dry powder for administration by inhalation is prepared as follows: Ingredients Amount Compound of the invention 0.2 mg Lactose 25 mg
  • a dry powder formulation for use in a dry powder inhalation device is prepared as follows: Representative Procedure: A pharmaceutical composition is prepared having a bulk formulation ratio of micronized compound of the invention to lactose of 1 :200. The composition is packed into a dry powder inhalation device capable of delivering between about 10 ⁇ g and about 100 ⁇ g of the compound of the invention per dose.
  • a dry powder for administration by inhalation in a metered dose inlialer is prepared as follows: Representative Procedure: A suspension containing 5 wt% of a compound of the invention and 0.1 wt% lecithin is prepared by dispersing 10 g of the compound of the invention as micronized particles with mean size less than 10 ⁇ m in a solution formed from 0.2 g of lecithin dissolved in 200 mL of demineralized water. The suspension is spray dried and the resulting material is micronized to particles having a mean diameter less than 1.5 ⁇ m. The particles are loaded into cartridges with pressurized 1,1,1,2-tetrafluoroethane.
  • a pharmaceutical composition for use in a metered dose inhaler is prepared as follows: Representative Procedure: A suspension containing 5 wt% compound of the invention, 0.5 wt% lecithin, and 0.5 wt% trehalose is prepared by dispersing 5 g of active ingredient as micronized particles with mean size less than 10 ⁇ m in a colloidal solution formed from 0.5 g of trehalose and 0.5 g of lecithin dissolved in 100 mL of demineralized water. The suspension is spray dried and the resulting material is micronized to particles having a mean diameter less than 1.5 ⁇ m. The particles are loaded into canisters with pressurized 1,1,1 ,2-tetrafluoroethane.
  • a pharmaceutical composition for use in a nebulizer inhaler is prepared as follows: Representative Procedure: An aqueous aerosol formulation for use in a nebulizer is prepared by dissolving 0.1 mg of the compound of the invention in 1 mL of a 0.9 % sodium chloride solution acidified with citric acid. The mixture is stirred and sonicated until the active ingredient is dissolved. The pH of the solution is adjusted to a value in the range of from 3 to 8 by the slow addition of NaOH.
  • Hard gelatin capsules for oral administration are prepared as follows: Ingredients Amount Compound of the invention 250 mg Lactose (spray-dried) 200 mg Magnesium stearate 10 mg
  • Formulation Example G ispension for oral administration is prepared as follows: Ingredients Amount Compound of the invention 1.0 g Fumaric acid 0.5 g Sodium chloride 2.0 g Methyl paraben 0.15 g Propyl paraben 0.05 g Granulated sugar 25.5 g Sorbitol (70% solution) 12.85 g Veegum k (Nanderbilt Co.) 1.0 g Flavoring 0.035 mL Ingredients Amount Colorings 0.5 mg Distilled water q.s. to 100 mL
  • Formulation Example H An injectable formulation is prepared as follows: Ingredients Amount Compound of the invention 0.2 g Sodium acetate buffer solution (0.4 M) 2.0 mL HCl (0.5 N) or NaOH (0.5 N) q.s. to pH 4 Water (distilled, sterile) q.s. to 20 mL
  • the biphenyl compounds of this invention are expected to be useful as muscarinic receptor antagonists and therefore, such compounds are expected to be useful for treating medical conditions mediated by muscarinic receptors, i.e., medical conditions which are ameliorated by treatment with a muscarinic receptor antagonist.
  • medical conditions include, by way of example, pulmonary disorders or diseases including those associated with reversible airway obstruction, such as chronic obstructive pulmonary disease (e.g., chronic and whez bronchitis and emphysema), asthma, pulmonary fibrosis, allergic rhinitis, rhinorrhea, and the like.
  • muscarinic receptor antagonists include genitourinary tract disorders, such as overactive bladder or detrusor hyperactivity and their symptoms; gastrointestinal tract disorders, such as irritable bowel syndrome, diverticular disease, achalasia, gastrointestinal hypermotility disorders and diarrhea; cardiac arrhythmias, such as sinus bradycardia; Parkinson's disease; cognitive disorders, such as Alzheimer's disease; dismenorrhea; and the like.
  • the compounds of this invention are useful for treating smooth muscle disorders in mammals, including humans and their companion animals (e.g., dogs, cats etc.).
  • smooth muscle disorders include, by way of illustration, overactive bladder, chronic obstructive pulmonary disease and irritable bowel syndrome.
  • the compounds of this invention When used to treat smooth muscle disorders or other conditions mediated by muscarinic receptors, the compounds of this invention will typically be administered orally, rectally, parenterally or by inhalation in a single daily dose or in multiple doses per day.
  • the amount of active agent administered per dose or the total amount administered per day will typically be determined by the patient's physician and will depend on such factors as the nature and severity of the patients condition, the condition being treated, the age and general health of the patient, the tolerance of the patient to the active agent, the route of administration and the like.
  • suitable doses for treating smooth muscle disorders or other disorders mediated by muscarinic receptors will range from about 0.14 ⁇ g/kg/day to about 7 mg/kg/day of active agent; including from about 0.15 ⁇ g/kg/day to about 5 mg/kg/day. For an average 70 kg human, this would amount to about 10 ⁇ g per day to about 500 mg per day of active agent.
  • the compounds of this invention are useful for treating pulmonary or respiratory disorders, such as COPD or asthma, in mammals including humans. When used to treat such disorders, the compounds of this invention will typically be administered by inhalation in multiple doses per day, in a single daily dose or a single weekly dose.
  • the dose for treating a pulmonary disorder will range from about 10 ⁇ g/day to about 200 ⁇ g/day.
  • COPD includes chronic obstructive bronchitis and emphysema (see, for example, Barnes, Chronic Obstructive Pulmonary Disease, N Engl J Med 343:269-78 (2000)).
  • the compounds of this invention are optionally administered in combination with other therapeutic agents such as a ⁇ 2 - adrenoreceptor agonist; a corticosteroid, a non-steroidal anti-inflammatory agent, or combinations thereof.
  • the compounds of this invention typically have the effect of producing bronchodilation.
  • this invention is directed to a method of producing bronchodilation in a patient, the method comprising administering to a patient a bronchodilation-producing amount of a compound of the invention.
  • the therapeutically effective dose for producing bronchodilation will range from about 10 ⁇ g/day to about 200 ⁇ g/day.
  • the compounds of this invention are used to treat overactive bladder.
  • the compoxmds of this invention will typically be administered orally in a single daily dose or in multiple doses per day; preferably in a single daily dose.
  • the dose for treating overactive bladder will range from about 1.0 to about 500 mg/day.
  • the compounds of this invention are used to treat irritable bowel syndrome.
  • the compounds of this invention When used to treat irritable bowel syndrome, the compounds of this invention will typically be administered orally or rectally in a single daily dose or in multiple doses per day. Preferably, the dose for treating irritable bowel syndrome will range from about 1.0 to about 500 mg/day.
  • compounds of this invention are muscarinic receptor antagonists, such compounds are also useful as research tools for investigating or studying biological systems or samples having muscarinic receptors. Such biological systems or samples may comprise Mi, M 2 , M 3 , and/or M 5 muscarinic receptors. Any suitable biological system or sample having muscarinic receptors may be employed in such studies which may be conducted either in vitro or in vivo.
  • Representative biological systems or samples suitable for such studies include, but are not limited to, cells, cellular extracts, plasma membranes, tissue samples, mammals (such as mice, rats, guinea pigs, rabbits, dogs, pigs, etc.), and the like.
  • a biological system or sample comprising a muscarinic receptor is contacted with a muscarinic receptor-antagonizing amount of a compound of this invention.
  • the effects of antagonizing the muscarinic receptor are then determined using conventional procedures and equipment, such as radioligand binding assays and functional assays.
  • Such functional assays include ligand-mediated changes in intracellular cyclic adenosine monophosphate (cAMP), ligand-mediated changes in activity of the enzyme adenylyl cyclase (which synthesizes cAMP), ligand-mediated changes in incorporation of guanosine 5'-O-( ⁇ -thio)triphosphate ([ 35 S]GTP ⁇ S) into isolated membranes via receptor catalyzed exchange of [ 35 S]GTP ⁇ S for GDP, ligand-mediated changes in free intracellular calcium ions (measured, for example, with a fluorescence- linked imaging plate reader or FLIPR ® from Molecular Devices, h e).
  • cAMP cyclic adenosine monophosphate
  • adenylyl cyclase which synthesizes cAMP
  • ligand-mediated changes in incorporation of guanosine 5'-O-( ⁇ -thio)triphosphate [ 35 S]GTP ⁇ S
  • a compound of this invention will antagonize or decrease the activation of muscarinic receptors in any of the functional assays listed above, or assays of a similar nature.
  • a muscarinic receptor- antagonizing amount of a compound of this invention will typically range from about 0.1 nanomolar to about 100 nanomolar.
  • muscarinic receptor binding data e.g., as determined by in vitro radioligand displacement assays
  • muscarinic receptor binding data e.g., as determined by in vitro radioligand displacement assays
  • This aspect of the invention includes, as separate embodiments, both the generation of comparison data (using the appropriate assays) and the analysis of the test data to identify test compounds of interest.
  • the compounds of this invention are used to antagonize a muscarinic receptor in biological system, and a mammal in particular, such as mice, rats, guinea pigs, rabbits, dogs, pigs, humans and so forth, hi this embodiment, a therapeutically effective amount of the compound of formula I is administered to the mammal.
  • a mammal in particular, such as mice, rats, guinea pigs, rabbits, dogs, pigs, humans and so forth
  • a therapeutically effective amount of the compound of formula I is administered to the mammal.
  • the effects of antagonizing the muscarinic receptor can then determined using conventional procedures and equipment, examples of which are described above.
  • compounds of this invention have been found to be potent inhibitors of M muscarinic receptor activity.
  • this invention is directed to compounds of formula I having an inhibition dissociation constant (Kj) for the M receptor subtype of less than or equal to 10 nM; preferably, less than or equal to 5 nM; (as determined, for example, by an in vitro radioligand displacement assay). Additionally, compounds of this invention are expected to possess a desirable duration of action. Accordingly, in another specific embodiment, this invention is directed to compounds of formula I having a duration of action greater than or equal to about 24 hours. Moreover, compounds of this invention are also expected to possess reduced side effects, such as dry mouth, at efficacious doses when administered by inhalation compared to other known muscarinic receptor antagonists administered by inhalation (such as tiotropium).
  • Kj inhibition dissociation constant
  • Alto, CA Series 1100 instrument equipped with a Zorbax Bonus RP 2.1 x 50 mm column (Agilent) having a 3.5 micron particle size. Detection was by UV absorbance at 214 nm.
  • the mobile phases employed were as follows (by volume): A is ACN (2%), water (98%) and TFA (0.1%); and B is ACN (90%), water (10%) and TFA (0.1%).
  • HPLC 10-70 data was obtained using a flow rate of 0.5 mL/minute of 10 to 70% B over a 6 minute gradient (with the remainder being A).
  • HPLC 5-35 data and HPLC 10-90 data were obtained using 5 to 35% B; or 10 to 90% B over a 5 minute gradient.
  • LCMS Liquid chromatography mass spectrometry
  • Biphenyl-2-ylcarbamic Acid Piperidin-4-yl Ester Biphenyl-2-isocyanate (97.5 g, 521 mmol) and 4-hydroxy-N-benzylpiperidine (105 g, 549 mmol) were heated together at 70°C for 12 hours. The reaction mixture was then cooled to 50°C and EtOH (1 L) was added and then 6M HCl (191 mL) was added slowly. The resulting mixture was then cooled to ambient temperature and ammonium formate (98.5 g, 1.56 mol) was added and then nitrogen gas was bubbled through the solution vigorously for 20 minutes.
  • N-Benzyl-N-methylaminoacetaldehyde To a 3-necked 2-L flask was added N-benzyl-N-methylethanolamine (30.5 g, 0.182 mol), DCM (0.5 L), DIPEA (95 mL, 0.546 mol) and DMSO (41 mL, 0.728 mol). Using an ice bath, the mixture was cooled to about -10°C and sulfur trioxide pyridine- complex (87 g, 0.546 mol) was added in 4 portions over 5 minute intervals. The reaction was stirred at -10°C for 2 hours. Before removing the ice-bath, the reaction was quenched by adding water (0.5 L).
  • the title compoxmd was made by adding 4-hydroxybenzylamine hydrobromide salt to a solution of the product of Preparation 7 (500 mg, 1.06 mmol) in 10 mL of MeOH. The solution was stirred at room temperature for 30 minutes and then sodium triacetoxyborohydride (674 mg, 3.18 mmol) was added. This mixture was stirred for 2 h at room temperature and then the solvent was removed in vacuo. The residue was dissolved in a 1 : 1 solution of acetic acid and water (8 mL) and purified on reverse phase HPLC to yield 509 mg of Compound 3-1 (60% yield) as a bis(trifluoroacetate) salt.
  • Compound 7-1 was made by using the procedure described in Example 3, but substituting tyramine in place of 4-hydroxybenzylamine hydrobromide salt and 2-fluoro-4- formylbenzoic acid in place of 4-carboxybenzaldehyde. MS m/z [M + ⁇ ] calcd for C 36 H 39 FN 4 O 4 , 610.7; foxmd, 611.2.
  • Compoxmd 7-2 was made by using the procedure of Example 1 and substituting tyramine in place of 4-hydroxybenzylamine and 2-fluoro-4-formylbenzoic acid in place of 4-carboxybenzaldehyde.
  • 2-Fluoro-4-formylbenzoic acid was prepared as follows: A stirred solution of 2-fluoro-4- formylbenzoic acid (2.5 g, 15.2 mmol) in DCM (100 mL) was cooled to -78°C and to this was added dropwise DIBAL (30 mL, 45.4 mmol, 25% in toluene), using caution due to H 2 evolution. This was allowed to stir at -78 °C for 4 hours. The reaction was quenched via addition of MeOH (10 mL), using caution due to H 2 evolution.
  • Compound 8-1 was made by using the procedure of Example 1 and substituting tyramine in place of 4-hydroxybenzylamine and 5-formylthiophene-2-carboxylic acid in place of 4-carboxybenzaldehyde. MS m/z [M + ⁇ ] calcd for C 35 H 40 N 4 O 4 S, 612.8; found, 613.2.
  • Compound 8-2 was made by using the procedure described in Example 3, but substituting tyramine in place of 4-hydroxybenzylamine hydrobromide salt, and 5- formylthiophene-2-carboxylic acid in place of 4-carboxybenzaldehyde.
  • Compound 8-4 was made by using the procedure described in Example 3, but substituting tyramine in place of 4-hydroxybenzylamine hydrobromide salt, and 5- fonnylfuran-2-carboxylic acid in place of 4-carboxybenzaldehyde. MS m/z [M + ⁇ ' ] calcd for C 34 H 38 N 4 O 5 , 582.7; found, 583.2.
  • Compound 8-5 was made by using the procedure of Example 1 and substituting tyramine in place of 4-hydroxybenzylamine and 5-formylpyridine-2-carboxylic acid in place of 4-carboxybenzaldehyde.
  • Compound 9-1 was made by using the procedure of Example 1, but substituting 5- formylthiophene-2-carboxylic acid in place of 4-carboxybenzaldehyde. MS m/z [M + H + ] calcd for C 3 H 38 N 4 O 4 S, 598.8; found, 599.2.
  • Compound 9-2 was made by using the procedure described in Example 3, but substituting 5-formylthiophene-2-carboxylic acid in place of 4-carboxybenzaldehyde. MS m/z [M + H 1" ] calcd for C 33 H 36 N 4 O 4 S, 584.7; found, 585.2.
  • Compound 9-3 was made by using the procedure described in Example 3, but substituting 5-formylpyrrole-2-carboxylic acid in place of 4-carboxybenzaldehyde. MS m/z [M + H + ] calcd for C 34 H 39 N 5 O 4 , 581.7; found, 582.2.
  • Compound 9-4 was made by using the procedure of Example 1 and substituting 5- formylfuran-2-carboxylic acid in place of 4-carboxybenzaldehyde. MS m/z [M + H ] calcd for C 34 H 38 N 4 O 5 , 582.7; found, 583.2.
  • Example 13 Biphenyl-2-yl-carbamic acid l-[2-(3- ⁇ 4-[(4-hydroxybenzylamino) ; methyl]phenyl ⁇ propionylamino)ethyl]piperidin-4-yl ester. MS m/z [M + H 4 ] calcd for C 37 H 42 N 4 O 4 , 607.3; found, 606.8.
  • Example 14 Biphenyl-2-yl-carbamic acid l- ⁇ 2-[(3- ⁇ 4-[(4-hydroxybenzylamino) methyl]phenyl ⁇ propionyl)methylamino]ethyl ⁇ -piperidin-4-yl ester.
  • Assay 1 Radioligand Binding Assay A. Membrane Preparation from Cells Expressing liMu hM?, hM 3 and hM Muscarinic Receptor Subtypes CHO cell lines stably expressing cloned human hMi, hM 2 , hM 3 and I1M 4 muscarinic receptor subtypes, respectively, were grown to near confluency in medium consisting of HAM's F-12 supplemented with 10% FBS and 250 ⁇ g/mL Geneticin. The cells were grown in a 5% CO 2 , 37°C incubator and lifted with 2 mM EDTA in dPBS.
  • Cells were collected by 5 minute centrifugation at 650 x g, and cell pellets were either stored frozen at -80°C or membranes were prepared immediately.
  • cell pellets were resuspended in lysis buffer and homogenized with a Polytron PT-2100 tissue disrupter (Kinematica AG; 20 seconds x 2 bursts). Crude membranes were centrifuged at 40,000 x g for 15 minutes at 4°C. The membrane pellet was then resuspended with resuspension buffer and homogenized again with the Polytron tissue disrupter. The protein concentration of the membrane suspension was determined by the method described in Lowry, O. et al., Journal of Biochemistry 193:265 (1951). All membranes were stored frozen in aliquots at -80°C or used immediately. Aliquots of prepared I1M 5 receptor membranes were purchased directly from Perkin Elmer and stored at -80°C until use.
  • Radioligand Binding Assay on Muscarinic Receptor Subtypes M hM 2 . hM 3 , hM and hMg Radioligand binding assays were performed in 96-well microtiter plates in a total assay volume of 100 ⁇ L.
  • CHO cell membranes stably expressing either the hMi, hM 2 , hM 3 , hM 4 or hM 5 muscarinic subtype were diluted in assay buffer to the following specific target protein concentrations ( ⁇ g/well): 10 ⁇ g for hMi, 10-15 ⁇ g for hM 2 , 10-20 ⁇ g for hM 3 , 10-20 ⁇ g for hM 4 , and 10-12 ⁇ g for I1M 5 .
  • the membranes were briefly homogenized using a Polytron tissue disruptor (10 seconds) prior to assay plate addition.
  • test compounds were initially dissolved to a concentration of 400 ⁇ M in dilution buffer and then serially diluted 5x with dilution buffer to final concentrations ranging from 10 pM to 100 ⁇ M.
  • the addition order and volumes to the assay plates were as follows: 25 ⁇ L radioligand, 25 ⁇ L diluted test compound, and 50 ⁇ L membranes. Assay plates were incubated for 60 minutes at 37°C. Binding reactions were terminated by rapid filtration over GF/B glass fiber filter plates (PerkinElmer Inc., Wellesley, MA) pre-treated in 1% BSA. Filter plates were rinsed three times with wash buffer (10 mM HEPES) to remove unbound radioactivity.
  • K values were converted to pK, values to determine the geometric mean and 95% confidence intervals. These summary statistics were then converted back to Kj values for data reporting.
  • a lower K,- value indicates that the test compound has a higher binding affinity for the receptor tested.
  • Exemplary compounds of the invention that were tested in this assay typically were found to have a K, value of less than about 10 nM for the M 3 muscarinic receptor subtype in this assay, with some compounds tested having a K, value of less than about 5 nM.
  • Assay 2 Muscarinic Receptor Functional Potency Assays A. Blockade of Agonist-Mediated Inhibition of cAMP Accumulation
  • the functional potency of a test compound is determined by measuring the ability of the test compound to block oxotremorine-inhibition of forskolin-mediated cAMP accumulation in CHO-K1 cells expressing the I1M 2 receptor.
  • cAMP assays are performed in a radioimmunoassay format using the Flashplate Adenylyl Cyclase Activation Assay System with 125 I-cAMP (NEN SMP004B, PerkinElmer Life Sciences Inc., Boston, MA), according to the manufacturer's instructions.
  • Cells are rinsed once with dPBS and lifted with Trypsin-EDTA solution (0.05% trypsin/0.53 mM EDTA) as described in the Cell Culture and Membrane Preparation section above.
  • Trypsin-EDTA solution 0.05% trypsin/0.53 mM EDTA
  • the detached cells are washed twice by centrifugation at 650 x g for five minutes in 50mLs dPBS.
  • the cell pellet is then re-suspended in 10 mL dPBS, and the cells counted with a Coulter Zl Dual Particle Counter (Beckman Coulter, Fullerton, CA).
  • the cells are centrifuged again at 650 x g for five minutes and re-suspended in stimulation buffer to an assay concentration of 1.6 x 10 6 - 2.8 x 10 6 cells/mL.
  • the test compound is initially dissolved to a concentration of 400 ⁇ M in dilution buffer (dPBS supplemented with 1 mg/mL BSA (0.1%)), and then serially diluted with dilution buffer to final molar concentrations ranging from 100 ⁇ M to 0.1 nM.
  • Oxotremorine is diluted in a similar manner.
  • 25 ⁇ L forskolin 25 ⁇ M final concentration diluted in dPBS
  • 25 ⁇ L diluted oxotremorine 25 ⁇ L diluted oxotremorine
  • 50 ⁇ L cells are added to agonist assay wells.
  • 25 ⁇ L forskolin and oxotremorine 25 ⁇ M and 5 ⁇ M final concentrations, respectively, diluted in dPBS
  • 25 ⁇ L diluted test compound, and 50 ⁇ L cells are added to remaining assay wells. Reactions are incubated for 10 minutes at 37°C and stopped by addition of 100 ⁇ L ice-cold detection buffer.
  • the Cheng-Prusoff equation is used to calculate the Kj, using the EC 50 of the oxotremorine concentration- response curve and the oxotremorine assay concentration as the K D and [L], respectively.
  • the Kj values are converted to pK; values to determine the geometric mean and 95%> confidence intervals. These summary statistics are then converted back to K values for data reporting.
  • a lower K; value indicates that the test compound has a higher functional activity at the receptor tested.
  • the compounds of the invention are expected to have a Kj value of less than about 10 nM for blockade of oxotremorine-inhibition of forskolin-mediated cAMP accumulation in CHO-K1 cells expressing the hM 2 receptor.
  • the fxmctional potency of a test compound is determined by measuring the ability of the compounds to block oxotremorine-stimulated [ 35 S]GTP ⁇ S-binding in CHO-K1 cells expressing the I1M 2 receptor.
  • frozen membranes are thawed and then diluted in assay buffer with a final target tissue concentration of 5-10 ⁇ g protein per well.
  • the membranes are briefly homogenized using a Polytron PT-2100 tissue disrupter and then added to the assay plates.
  • the EC 90 value (effective concentration for 90% maximal response) for stimulation of [ 35 S]GTP ⁇ S binding by the agonist oxotremorine is determined in each experiment.
  • a test compound to inhibit oxotremorine-stimulated [ 35 S]GTP ⁇ S binding, the following is added to each well of 96 well plates: 25 ⁇ L of assay buffer with [ 35 S]GTP ⁇ S (0.4nM), 25 ⁇ L of oxotremorine(EC 90 ) and GDP (3 ⁇ M), 25 ⁇ L of diluted test compound and 25 ⁇ L CHO cell membranes expressing the hM 2 receptor.
  • the assay plates are then incubated at 37°C for 60 minutes.
  • the assay plates are filtered over 1% BSA-pretreated GF/B filters using a PerkinElmer 96-well harvester.
  • the plates are rinsed with ice-cold wash buffer for 3 x 3 seconds and then air or vacuum dried.
  • Microscint-20 scintillation liquid 50 ⁇ L is added to each well, and each plate is sealed and radioactivity counted on a topcounter (PerkinElmer).
  • Data are analyzed by nonlinear regression analysis with the GraphPad Prism Software package (GraphPad Software, Inc., San Diego, CA) using the non-linear regression, one-site competition equation.
  • the Cheng-Prusoff equation is used to calculate the Kj, using the IC 5 o values of the concentration-response curve for the test compound and the oxotremorine concentration in the assay as the K D and [L], ligand concentration, respectively.
  • a lower K; value indicates that the test compoxmd has a higher functional activity at the receptor tested.
  • the compounds of the invention are expected to have a K; value of less than about 10 nM for blockade of oxotremorine-stimulated [ 35 S]GTP ⁇ S binding in CHO-K1 cells expressing the hM 2 receptor.
  • Muscarinic receptor subtypes (Mi, M and M 5 receptors), which couple to G q proteins, activate the phosphohpase C (PLC) pathway upon agonist binding to the receptor.
  • PLC phosphohpase C
  • activated PLC hydrolyzes phosphatyl inositol diphosphate (PIP 2 ) to diacylglycerol (DAG) and phosphatidyl- 1,4,5-triphosphate (IP ), which in turn generates calcium release from intracellular stores, i.e., endoplasmic and sarcoplasmic reticulum.
  • the FLIPR (Molecular Devices, Sunnyvale, CA) assay capitalizes on this increase in intracellular calcium by using a calcium sensitive dye (Fluo-4AM, Molecular Probes, Eugene, OR) that fluoresces when free calcium binds. This fluorescence event is measured in real time by the FLIPR, which detects the change in fluorescence from a monolayer of cells cloned with human Mi and M 3 , and chimpanzee M 5 receptors.
  • Antagonist potency can be determined by the ability of antagonists to inhibit agonist-mediated increases in intracellular calcium.
  • CHO cells stably expressing the hMi, hM 3 and cM 5 receptors are seeded into 96-well FLIPR plates the night before the assay is done. Seeded cells are washed twice by Cellwash (MTX Labsystems, Lie.) with FLIPR buffer (10 mM HEPES, pH 7.4, 2 mM calcium chloride, 2.5 mM probenecid in HBSS without calcium and magnesium) to remove growth media and leaving 50 ⁇ L/well of FLIPR buffer. The cells are then incubated with 50 ⁇ L/well of 4 ⁇ M FLUO-4AM (a 2X solution was made) for 40 minutes at 37°C, 5% carbon dioxide.
  • FLIPR buffer (10 mM HEPES, pH 7.4, 2 mM calcium chloride, 2.5 mM probenecid in HBSS without calcium and magnesium
  • An oxotremorine concentration of 3 x EC F is prepared in stimulation plates such that an EC 90 concenfration of oxotremorine is added to each well in the antagonist inhibition assay plates.
  • the parameters used for the FLIPR are: exposure length of 0.4 seconds, laser strength of 0.5 watts, excitation wavelength of 488 nm, and emission wavelength of 550 nm. Baseline is determined by measuring the change in fluorescence for 10 seconds prior to addition of agonist. Following agonist stimulation, the FLIPR continuously measures the change of fluorescence every 0.5 to 1 second for 1.5 minutes to capture the maximum fluorescence change. The change of fluorescence is expressed as maximum fluorescence minus baseline fluorescence for each well.
  • the raw data is analyzed against the logarithm of drug concentration by nonlinear regression with GraphPad Prism (GraphPad Software, Inc., San Diego, CA) using the built-in model for sigmoidal dose-response.
  • Antagonist Ki values are determined by Prism using the oxotremorine EC 50 value as the K # and the oxotremorine EC 90 for the ligand concentration according to the Cheng-Prusoff equation (Cheng & Prusoff, 1973).
  • a lower Kj value indicates that the test compound has a higher functional activity at the receptor tested.
  • the compounds of the invention are expected to have a K value of less than about 10 nM for blockade of agonist-mediated calcium release in CHO cells stably expressing the hM 3 receptor.
  • Assay 3 Determination of Duration of Bronchoprotection in Guinea Pig Model of Acetylcholine-Induced Bronchoconstriction This in vivo assay was used to assess the bronchoprotective effects of test compounds exhibiting muscarinic receptor antagonist activity. Groups of six male guinea pigs (Duncan-Hartley (HsdPoc:DH) Harlan, Madison, WI) weighing between 250 and 350 g were individually identified by cage cards. Throughout the study animals were allowed access to food and water ad libitum. Test compounds were administered via inhalation over 10 minutes in a whole-body exposure dosing chamber (R&S Molds, San Carlos, CA).
  • WFI test compound or vehicle
  • nebulization approximately 1.8 mL of solution was nebulized. This was measured gravimetrically by comparing pre-and post-nebulization weights of the filled nebulizer.
  • the bronchoprotective effects of test compoxmds administered via inhalation were evaluated using whole body plethysmography at 1.5, 24, 48 and 72 hours post-dose. Forty-five minutes prior to the start of the pulmonary evaluation, each guinea pig was anesthetized with an intramuscular injection of ketamine (43.75 mg kg), xylazine (3.50 mg/kg) and acepromazine (1.05 mg/kg).
  • a 2-3 cm midline incision of the ventral aspect of the neck was made. Then, the jugular vein was isolated and cannulated with a saline-filled polyethylene catheter (PE-50, Becton Dickinson, Sparks, MD) to allow for intravenous infusions of ACh (Sigma-Aldrich, St. Louis, MO) in saline. The trachea was then dissected free and cannulated with a 14G teflon tube (#NE- 014, Small Parts, Miami Lakes, FL). If required, anesthesia was maintained by additional intramuscular injections of the aforementioned anesthetic mixture.
  • PE-50 saline-filled polyethylene catheter
  • ACh Sigma-Aldrich, St. Louis, MO
  • the depth of anesthesia was monitored and adjusted if the animal responded to pinching of its paw or if the respiration rate was greater than 100 breaths/minute.
  • the animal was placed into a plethysmograph (#PLY3114, Buxco Electronics, hie, Sharon, CT) and an esophageal pressure cannula (PE-160, Becton Dickinson, Sparks, MD) was inserted to measure pulmonary driving pressure (pressure).
  • PE-160 Becton Dickinson, Sparks, MD
  • the teflon tracheal tube was attached to the opening of the plethysmograph to allow the guinea pig to breathe room air from outside the chamber. The chamber was then sealed.
  • a heating lamp was used to maintain body temperature and the guinea pig's lungs were inflated 3 times with 4 mL of air using a 10 mL calibration syringe (#5520 Series, Hans Rudolph, Kansas City, MO) to ensure that the lower airways did not collapse and that the animal did not suffer from hyperventilation.
  • ACh (0.1 mg/mL) was infused intravenously for 1 minute from a syringe pump (sp210iw, World Precision Instruments, fric, Sarasota, FL) at the following doses and prescribed times from the start of the experiment: 1.9 ⁇ g/minute at 5 minutes, 3.8 ⁇ g/minute at 10 minutes, 7.5 ⁇ g/minute at 15 minutes, 15.0 ⁇ g/minute at 20 minutes, 30 ⁇ g/minute at 25 minutes and 60 ⁇ g/minute at 30 minutes. If resistance or compliance had not returned to baseline values at 3 minutes following each ACh dose, the guinea pig's lungs were inflated 3 times with 4 mL of air from a 10 mL calibration syringe.
  • pulmonary parameters included respiration frequency (breaths/minute), compliance (mL/cm H2O) and pulmonary resistance (cm H2O/ mL per second).
  • respiration frequency (breaths/minute)
  • compliance mL/cm H2O
  • pulmonary resistance cm H2O/ mL per second.
  • IH IH
  • Ci concenfration of ACh or histamine preceding C 2
  • C 2 concentration of ACh or histamine resulting in at least a 2-fold increase in pulmonary resistance (R j )
  • R Q Baseline
  • R 2 R L value after C 2
  • An efficacious dose was defined as a dose that limited the bronchrestriction response to a 50 ⁇ g/mL dose of ACh to a doubling of the baseline pulmonary resistance
  • test compounds having a PD 2(50) less than about 200 ⁇ g/mL for ACh- induced bronchoconstriction at 1.5 hours post-dose in this assay are preferred.
  • the compound of Example 1 was found to have a PD 2(5 o> less than about 200 ⁇ g/mL for ACh-induced bronchoconstriction at 1.5 hours post-dose.
  • Assay 4 Inhalation Guinea Pig Salivation Assay Guinea pigs (Charles River, Wilmington, MA) weighing 200-350 g were acclimated to the in-house guinea pig colony for at least 3 days following arrival.
  • Test compound or vehicle were dosed via inhalation (IH) over a 10 minute time period in a pie shaped dosing chamber (R&S Molds, San Carlos, CA). Test solutions were dissolved in sterile water and delivered using a nebulizer filled with 5.0 mL of dosing solution. Guinea pigs were restrained in the inhalation chamber for 30 minutes. During this time, guinea pigs were restricted to an area of approximately 110 cm . This space was adequate for the animals to turn freely, reposition themselves, and allow for grooming. Following 20 minutes of acclimation, guinea pigs were exposed to an aerosol generated from a LS Star Nebulizer Set (Model 22F51, PARI Respiratory Equipment, hie.
  • LS Star Nebulizer Set Model 22F51, PARI Respiratory Equipment, hie.
  • guinea pigs were evaluated at 1.5, 6, 12, 24, 48, or 72 hrs after treatment.
  • Guinea pigs were anesthetized one hour before testing with an intramuscular (IM) injection of a mixture of ketamine 43.75 mg/kg, xylazine 3.5 mg/kg, and acepromazine 1.05 mg/kg at an 0.88 mL/kg volume.
  • Animals were placed ventral side up on a heated (37°C) blanket at a 20 degree incline with their head in a downward slope.
  • the inhibition dose-response data were fitted to a four parameter logistic equation using GraphPad Prism, version 3.00 for Windows (GraphPad Software, San Diego, California) to estimate anti-sialagogue -D 50 (dose required to inhibit 50% of pilocarpine-evoked salivation).
  • the ratio of the anti-sialagogue ID 5 o to bronchoprotective -D 50 was used to compute the apparent lung selectivity index of the test compound.
  • compounds having an apparent lung selectivity index greater than about 5 are preferred, hi this assay, the compound of Example 1 had an apparent lung-selectivity index greater than about 5.
  • Assay 5 Methacholine-Induced Depressor Responses in Conscious Guinea Pigs Healthy, adult, male Sprague-Dawley guinea pigs (Harlan, Indianapolis, IN), weighing between 200 and 300 g are used in these studies. Under isoflurane anesthesia (to effect), animals are instrumented with common carotid artery and jugular vein catheters (PE-50 tubing).
  • the catheters are exteriorized utilizing a subcutaneous tunnel to the subscapular area. All surgical incisions are sutured with 4-0 Ethicon Silk and the catheters locked with heparin (1000 units/mL). Each animal is administered saline (3 mL, SC) at the end of surgery as well as buprenorphine (0.05 mg/kg, IM). Animals are allowed to recover on a heating pad before being returned to their holding rooms. Approximately 18 to 20 hours following surgery, the animals are weighed and the carotid artery catheter on each animal is connected to a transducer for recording arterial pressure. Arterial pressure and heart rate is recorded using a Biopac MP-100 Acquisition System. Animals are allowed to acclimate and stabilize for a period of 20 minutes.
  • Each animal is challenged with MCh (0.3 mg/kg, IV) administered through the jugular venous line and the cardiovascular response is monitored for 10 minutes.
  • the animals are then placed into the whole body dosing chamber, which is connected to a nebulizer containing the test compound or vehicle solution.
  • the solution is nebulized for 10 minutes using a gas mixture of breathable air and 5% carbon dioxide with a flow rate of 3 liters/minute.
  • the animals are then removed from the whole body chamber and returned to their respective cages.
  • the animals are re-challenged with MCh (0.3 mg/kg, IN) and the hemodynamic response is determined.
  • MCh produces a decrease in mean arterial pressure (MAP) and decrease in heart rate (bradycardia).
  • MAP mean arterial pressure
  • bradycardia heart rate
  • the peak decrease, from baseline, in MAP (depressor responses) is measured for each MCh challenge (before and after IH dosing).
  • the bradycardic effects are not used for analysis since these responses are not robust and reproducible.
  • the effects of treatment on the MCh responses are expressed as % inhibition (mean +/- SEM) of the control depressor responses.
  • Two-way A ⁇ ONA with the appropriate post-hoc test is used to test the effects of treatment and pre-treatment time.
  • the ratio of the anti-depressor ID 50 to bronchoprotective ID 5 o is used to compute apparent lung-selectivity of the test compound. Generally, compounds having an apparent lung-selectivity index greater than 5 are preferred. In this assay, compounds of the invention are expected to have an apparent lung-selectivity index greater than 5. While the present invention has been described with reference to specific aspects or embodiments thereof, it will be understood by those of ordinary skilled in the art that various changes can be made or equivalents can be substituted without departing from the true spirit and scope of the invention. Additionally, to the extent permitted by applicable patent statues and regulations, all publications, patents and patent applications cited herein are hereby incorporated by reference in their entirety to the same extent as if each document had been individually incorporated by reference herein.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

This invention provides compounds of formula I: (I) wherein a, b, c, m, p, s, t, W, Ar1, X1, R1, R2, R3, R4, R6, and R7 are as defined in the specification. The compounds of formula I are muscarinic receptor antagonists. The invention also provides pharmaceutical compositions containing such compounds, processes and intermediates for preparing such compounds and methods of using such compounds to treat pulmonary disorders.

Description

BIPHENYL COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS
BACKGROUND OF THE INVENTION Field of the Invention The present invention relates to novel biphenyl compounds having muscarinic receptor antagonist or anticholinergic activity. This invention also relates to pharmaceutical compositions comprising such biphenyl compounds, processes and intermediates for preparing such biphenyl compounds and methods of using such biphenyl compounds to treat pulmonary disorders.
State of the Art Pulmonary or respiratory disorders, such as chronic obstructive pulmonary disease (COPD) and asthma, afflict many millions of people worldwide and such disorders are a leading cause of morbidity and mortality. Muscarinic receptor antagonists are known to provide bronchoprotective effects and therefore, such compounds are useful for treating respiratory disorders, such as COPD and asthma. When used to treat such disorders, muscarinic receptor antagonists are typically administered by inhalation. However, even when administered by inhalation, a significant amount of the muscarinic receptor antagonist is often absorbed into the systemic circulation resulting in systemic side effects, such as dry mouth, mydriasis and cardiovascular side effects. Additionally, many inhaled muscarinic receptor antagonists have a relatively short duration of action requiring that they be administered several times per day. Such a multiple-daily dosing regime is not only inconvenient but also creates a significant risk of inadequate treatment due to patient non-compliance with the required frequent dosing schedule. Accordingly, a need exists for new muscarinic receptor antagonists. In particular, a need exists for new muscarinic receptor antagonists that having high potency and reduced systemic side effects when administered by inhalation. Additionally, a need exists for inhaled muscarinic receptor antagonists having a long duration of action thereby allowing for once-daily or even once-weekly dosing. Such compounds are expected to be particularly effective for treating pulmonary disorders, such as COPD and asthma, while reducing or eliminating side effects, such as dry-mouth and constipation.
SUMMARY OF THE INVENTION The present invention provides novel biphenyl compounds having muscarinic receptor antagonist or anticholinergic activity. Among other properties, compounds of the invention are expected to possess high potency and reduced systemic side effects when administered by inhalation and to have a long duration of action. Accordingly, in one of its composition aspects, this invention provides a compound of formula I:
Figure imgf000003_0001
I wherein: a is 0 or an integer of from 1 to 5; each R1 is independently selected from (l-4C)alkyl, (2-4C)alkenyl, (2-4C) alkynyl, (3-6C)cycloalkyl, cyano, halo, -ORla, -C(O)ORl , -SRlc, -S(O)Rld, -S(O)2Rle, - RlfRlg, -NRlhS(O)2RH, and -NRljC(O)Rl ; where each of Rla, Rlb, Rlc, Rld, Rle, Rlf, Rlg, Rlh, Rι;, R1-", and Rlk is independently hydrogen, (l-4C)alkyl or phenyl(l-4C)alkyl; b is 0 or an integer of from 1 to 4; each R2 is independently selected from (l-4C)alkyl, (2-4C)alkenyl, (2-4C)alkynyl, (3-6C)cycloalkyl, cyano, halo, -OR2a, -C(O)OR2b, -SR2c, -S(O)R2d, -S(O)2R2e, -NR2fR2g, -NR2hS(O)2R2i, and -NR2jC(O)R2k; where each of R2a, R2b, R2c, R2d, R2e, R2f, R2g, R2h, R2i, R2 , and R2k is independently hydrogen, (l-4C)alkyl or phenyl(l-4C)alkyl; W represents O or NW , where Wa is hydrogen or (l-4C)alkyl; c is 0 or an integer from 1 to 5; each R3 independently represents (l-4C)alkyl or two R3 groups are joined to form
(l-3C)alkylene, (2-3C)alkenylene or oxiran-2,3-diyl; m is 0 or 1 ; R4 is selected from hydrogen, (l-4C)alkyl, and (3-4C)cycloalkyl; s is 0, 1 or 2; Ar1 represents a phenylene group or a (3-5C)heteroarylene group containing 1 or 2 heteroatoms selected independently from oxygen, nitrogen or sulfur; wherein the phenylene or heteroarylene group is substituted with (R5)q where q is 0 or an integer from 1 to 4 and each R5 is selected independently from halo, hydroxy, (l-4C)alkyl or (l-4C)alkoxy; t is 0, 1 or 2; p is 0, 1 or 2; each R6 independently represents (l-4C)alkyl, (2-4C)alkenyl, (2-4C)alkynyl, (3-6C)cycloalkyl, cyano, nitro, halo, N,N-di(l-4C)alkylamino(2-4C)alkoxy, -OR6a, -C(O)OR6b, -SR6c, -S(O)R6d, -S(O)2R6e or -ΝR6fR6g; each of R6a, R6 , R6c, R6d, R6e, R6f and R6 is independently hydrogen, (l-4C)alkyl, (3-6C)cycloalkyl, phenyl or phenyl(l- 4C)alkyl, wherein each phenyl group is unsubstituted or substituted by 1 or 2 substituents selected independently from halo, (l-4C)alkyl and (l-4C)alkoxy; and X1 is selected from (l-3C)alkylene, -C(O)(l-3C)alkylene, (l-3C)alkyleneC(O)-, -SO2-, -SO2(l-3C)alkylene and (l-3C)alkyleneSO2-; where the alkylene group in any X1 is optionally substituted with 1 or 2 substituents independently selected from (l-4C)alkyl and -NR^R 0; wherein RXa and 503 are independently selected from hydrogen and (l-4alkyl); R7 is selected from hydrogen, (l-4C)alkyl, (3-4C)cycloalkyl, -C(O)(l-4C)alkyl, -(l-4C)alkyleneC(O)OR7a, -C(O)heterocyclyl, -C(O)CH(NH2)(l-4C)alkyleneQ, -(1- 4C)alkyleneC(O)Z, -C(O)(l-4C)alkyleneZ, and -S(O)2(l-4C)alkyleneZ; where Q is a nitrogen-containing substituent selected from -NR7 R7c and heteroaryl; Z is a nitrogen- containing substituent selected from -NR7dR7e and heterocyclyl; R7 is hydrogen or (l-4C)alkyl; each of R7b, R7c, R7d and R7e independently represents hydrogen, (l-4C)alkyl, (3-6C)cycloalkyl or hydroxyphenyl, and where (l-4C)alkyl is unsubstituted or substituted by 1 or 2 substituents selected independently from amido, cyano, furyl, hydroxyl, and methylimidazolyl; the heterocyclyl contains 1 or 2 nitrogen atoms, and is unsubstituted or substituted by 1 or 2 substituents selected independently from hydroxyl, amido, (1- 4C)alkoxy, oxo, -S(O)2(l-4C)alkyl, -(CH2)O(l-4C)alkyl, -(l-4C)alkyleneOH, -NR7fR7g or -C(O)NR7hR71, where each of R7f, R7g R7h and R71 independently represents hydrogen or (l-4C)alkyl; and the heteroaryl contains 1 or 2 nitrogen atoms; wherein each alkyl and alkoxy group in R1, Rla"lk, R2, R2a"2k, R3, R5, R6, and R6a'6g is optionally substituted with 1 to 5 fluoro substituents; or a pharmaceutically acceptable salt or solvate or stereoisomer thereof. In another of its composition aspects, this invention is directed to a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound of formula I or a pharmaceutically acceptable salt or solvate or stereoisomer thereof. Such pharmaceutical compositions may optionally contain other therapeutic agents. Accordingly, in one embodiment, this invention is directed to such a pharmaceutical composition wherein the composition further comprises a therapeutically effective amount of a steroidal anti-inflammatory agent, such as a corticosteroid; a β2 adrenergic receptor agonist; a phosphodiesterase-4 inhibitor; or a combination thereof. Compounds of this invention possess muscarinic receptor antagonist activity.
Accordingly, compounds of formula I are expected to be useful for treating pulmonary disorders, such as chronic obstructive pulmonary disease and asthma. Accordingly, in one of its method aspects, this invention is directed to a method for treating a pulmonary disorder, the method comprising administering to a patient a therapeutically effective amount of a compound of formula I or a pharmaceutically acceptable salt or solvate or stereoisomer thereof. Additionally, in another of its method aspects, this invention is directed to a method of producing bronchodilation in a patient, the method comprising administering to a patient a bronchodilation-producing amount of a compound of formula I or a pharmaceutically acceptable salt or solvate or stereoisomer thereof. This invention is also directed to a method of treating chronic obstructive pulmonary disease or asthma, the method comprising administering to a patient a therapeutically effective amount of a compound of formula I or a pharmaceutically acceptable salt or solvate or stereoisomer thereof. In another one of its method aspects, this invention is directed to a method for antagonizing a muscarinic receptor in a mammal comprising administering to the mammal, a therapeutically effective amount of the compound of formula I. Since compounds of this invention possess muscarinic receptor antagonist activity, such compounds are also useful as research tools. Accordingly, in yet another of its method aspects, this invention is directed to a method for using a compound of formula I or a pharmaceutically acceptable salt or solvate or stereoisomer thereof as a research tool for studying a biological system or sample, or for discovering new chemical compounds having muscarinic receptor antagonist activity. This invention is also directed to processes and novel intermediates useful for preparing compounds of formula I or a pharmaceutically acceptable salt or solvate or stereoisomer thereof. Accordingly, in another of its method aspects, this invention is directed to a process of preparing a compound of formula I, the process comprising: (a) reacting a compound of formula II with a compound of formula III; (b) coupling a compound of formula IN with a compound of formula N; (c) reacting a compound of formula NI with a compound of formula Nil; (d) reacting a compound of formula II with a compound of formula NIII in the presence of a reducing agent; (e) for a compound of formula I wherein X1 represents (l-3C)alkylene, reacting a compound of formula VI with a compound of formula IX in the presence of a reducing agent; or (f) for a compound of formula I wherein t is 1 , reacting a compound of formula X with a compound of formula XI in the presence of a reducing agent; and then (g) removing any protecting groups to provide a compound of formula I; wherein compounds of formula I-XI are as defined herein. ' hi one embodiment, the above process further comprises the step of forming a pharmaceutically acceptable salt of a compound of formula I. In other embodiments, this invention is directed to the other processes described herein; and to the product prepared by any of the processes described herein. This invention is also directed to a compound of formula I or a pharmaceutically acceptable salt or solvate or stereoisomer thereof, for use in therapy or as a medicament. Additionally, this invention is directed to the use of a compound of formula I or a pharmaceutically acceptable salt or solvate or stereoisomer thereof, for the manufacture of a medicament; especially for the manufacture of a medicament for the treatment of a pulmonary disorder or for antagonizing a muscarinic receptor in a mammal.
DETAILED DESCRIPTION OF THE INVENTION In one of its composition aspects, this invention is directed to novel biphenyl compounds of formula I or pharmaceutically acceptable salts or solvates or stereoisomers thereof. These compounds may contain one or more chiral centers and therefore, this invention is directed to racemic mixtures; pure stereoisomers (i.e., enantiomers or diastereomers); stereoisomer-enriched mixtures and the like unless otherwise indicated. When a particular stereoisomer is shown or named herein, it will be understood by those skilled in the art that minor amounts of other stereoisomers may be present in the compositions of this invention unless otherwise indicated, provided that the desired utility of the composition as a whole is not eliminated by the presence of such other isomers. The compounds of formula I also contain several basic groups (e.g., amino groups) and therefore, the compounds of formula I can exist as the free base or in various salt forms. All such salt forms are included within the scope of this invention. Furthermore, solvates of compounds of formula I or salts thereof are included within the scope of this invention. Additionally, where applicable, all cis-trans or E/Z isomers (geometric isomers), tautomeric forms and topoisomeric forms of the compounds of formula I are included within the scope of this invention unless otherwise specified. The compounds of formula I, as well as those compounds used in its synthesis, may also include isotopically-labeled compounds, i.e., where one or more atoms have been enriched with atoms having an atomic mass different from the atomic mass predominately found in nature. Examples of isotopes that may be incorporated into the compounds of Formula (I) include, but are not limited to, 2H, 3H, 13C, 14C, 15N, 18O and 17O. The nomenclature used herein to name the compounds of this invention is illustrated in the Examples herein. This nomenclature has been derived using the commercially-available AutoNom software (MDL, San Leandro, California). For example, compounds of formula I wherein W is O have typically been named as ester derivatives of biphenyl-2-ylcarbamic acid.
Representative Embodiments The following substituents and values are intended to provide representative examples of various aspects and embodiments of this invention. These representative values are intended to further define and illustrate such aspects and embodiments and are not intended to exclude other embodiments or to limit the scope of this invention, hi this regard, the representation that a particular value or substituent is preferred is not intended in any way to exclude other values or substituents from this invention unless specifically indicated. The values for a and b are independently 0, 1, 2, 3, 4 or 5; particularly independently 0, 1 or 2, and even more particularly 0 or 1. In one embodiment, both a and b are O. When present, each R1 may be at the 2, 3, 4, 5 or 6-position of the phenyl ring to which it is attached. Each R1 is independently selected from (l-4C)alkyl, (2-4C)alkenyl, (2-4C)alkynyl, (3-6C)cycloalkyl, cyano, halo, -ORla, -C(O)ORl , -SRlc, -S(O)Rld, -S(O)2Rle, -NRlfRlg, -NRlhS(O)2Ru, and -NRljC(O)Rlk, examples of which include methyl, fluoro, chloro, bromo, hydroxy, methoxy, amino, methylamino, dimethylamino and the like. Particular values for R1 are fluoro or chloro. When present, each R2 may be at the 3, 4, 5 or 6-position on the phenylene ring to which it is attached (where the carbon atom on the phenylene ring attached to the nitrogen atom is position 1). Each R2 is independently selected from (l-4C)alkyl, (2-4C)alkenyl, (2-4C)alkynyl, (3-6C)cycloalkyl, cyano, halo, -OR2a, -C(O)OR2 , -SR2c, -S(O)R2d, -S(O)2R2e, -NR2fR2g, -NR2hS(O)2R2i, and -NR2jC(O)R2k, examples of which include methyl, fluoro, chloro, bromo, hydroxy, methoxy, amino, methylamino, dimethylamino and the like. Particular values for R2 are fluoro or chloro. Each Rla, Rlb, Rlc, Rld, Rle, Rlf, Rlg, Rlh, R11, Rlj, and Rlk and R2a, R2 , R2c, R2d, R2e, R2f, R2g, R2h, R2i, R2j, and R2k as used in R1 and R2, respectively, is independently hydrogen, (l-4C)alkyl or phenyl(l-4C)alkyl, examples of which include hydrogen, methyl, ethyl, «-propyl, isopropyl, n-butyl, _.ec-butyl, isobutyl, tert-butyl or benzyl, h one embodiment, these groups are independently hydrogen or (l-3C)alkyl. In another embodiment, these groups are independently hydrogen, methyl or ethyl. In addition, each alkyl and alkoxy group in R1, Rla"lk, R2, and R2a"2k is optionally substituted with 1 to 5 fluoro substituents. In one embodiment of this invention, W is O. h another embodiment, W is NWa. Generally, it has been found that compounds in which W represents O exhibit particularly high affinity for muscarinic receptors. Accordingly, in a particular embodiment of this invention, W represents O. When W is NWa, Wa is hydrogen or (l-4C)alkyl, examples of which include hydrogen, methyl, ethyl, n-propyl, isopropyl, ra-butyl, sec-butyl, isobutyl and tert-butyl. In one embodiment, W is hydrogen or (l-3C)alkyl. In another embodiment, Wa is hydrogen, methyl or ethyl, particularly hydrogen or methyl, yet another embodiment, Wa is hydrogen and NWa is NH. The value for c is 0, 1, 2, 3, 4, or 5; particularly 0, 1, or 2; and more particularly 0 or 1. In one particular embodiment, c is 0. Each R3 independently represents (l-4C)alkyl or two R3 groups that are joined to foπn (l-3C)alkylene, (2-3C)alkenylene or oxiran-2,3-diyl. In one embodiment, each R3 is independently (l-4C)alkyl, such as methyl, ethyl, n-propyl, isopropyl, n-butyl, -.ec-butyl, isobutyl and tert-butyl. hi addition, each alkyl group in R3 is optionally substituted with 1 to 5 fluoro substituents. In one embodiment, each R3 is independently (1-3C) alkyl, and in another embodiment, each R is independently methyl or ethyl. In one embodiment, each R3 is at the 3, 4 or 5-ρosition on the piperidine ring (where the nitrogen atom of the piperidine ring is position 1). In a particular embodiment, R3 is at the 4-position on the piperidine ring, h another embodiment, R3 is at the 1- position of the piperidine ring, i.e., on the nitrogen atom of the piperidine ring thus forming a quaternary amine salt. In yet another embodiment, two R3 groups are joined to form a (l-3C)alkylene or (2-3C)alkenylene group. For example, two R3 groups at the 2 and 6-positions on the piperidine ring can be joined to form an ethylene bridge (i.e., the piperidine ring and the R groups form an 8-azabicyclo[3.2.1]octane ring); or two R groups at the 1 and 4-posιtιons on the piperidine ring can be joined to form an ethylene bridge (i.e., the piperidine ring and the R groups form an l-azabicyclo[2.2.2]octane ring). In this embodiment, other R groups as defined herein may also be present. In still another embodiment, two R3 groups are joined to form a oxiran-2,3-diyl group. For example, two R3 groups at the 2 and 6-positions on the piperidine ring can be joined to form a 3-oxatricyclo[3.3.1.02'4]nonane ring). In this embodiment, other R3 groups as defined herein may also be present. The value for m is 0 or 1. In one embodiment, m is 0. R4 represents hydrogen, (l-4C)alkyl, or (3-4C)cycloalkyl. Examples of (l-4C)alkyl include methyl, ethyl, n-propyl, isopropyl, n-butyl, -.ec-butyl, isobutyl and tert-butyl. Examples of (3-4C)cycloalkyl groups include cyclopropyl and cyclobutyl. In one embodiment, R4 is hydrogen or methyl, hi another embodiment, R4 is hydrogen. The value for s is 0, 1 or 2. A particular value for s is 0 or 1. In one embodiment, s is 0. Ar1 is a phenylene group or a (3-5C)heteroarylene group containing 1 or 2 heteroatoms selected independently from oxygen, nitrogen or sulfur. The phenylene or heteroarylene group may be unsubstituted (q is 0) or substituted with 1, 2, 3, or 4 (q is 1, 2, 3, or 4) R5 substituents, which are independently selected from halo, hydroxy, (l-4C)alkyl or (l-4C)alkoxy. The value for q is 0, 1, 2, 3, or 4, particularly 0, 1, 2 or 3. In one embodiment, q is 0 or 1. h addition, each alkyl and alkoxy group in R5 is optionally substituted with 1 to 5 fluoro substituents. The point of attachment is at any available carbon or heteroatom ring atom. In certain embodiments, Ar is a phenylene group attached at the meta or para position. i one embodiment Ar1 is phen-l,3-ylene or phen-l,4-ylene wherein the phenylene group is unsubstituted or substituted with 1, 2 or 3 R5 substituents. Representative R5 substituents include fluoro, chloro, bromo, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, -.ec-butyl, tert-butyl, methoxy, ethoxy, isopropoxy, difluoromethyl, trifluoromethyl, 2,2,2-trifluoroethyl and trifluoromethoxy. Particular examples of Ar1 groups in this embodiment include 2-fluorophen-l,4-ylene, 3-fluorophen-l,4-ylene, 2- chlorophen-l,4-ylene, 3-chlorophen-l,4-ylene, 2-methylphen-l,4-ylene, 3-methylphen-l,4- ylene, 2-methoxyphen-l,4-ylene, 3-methoxyphen-l,4-ylene, 2-trifluoromethoxyphen-l,4- ylene, 3-trifluoromethoxyphen-l,4-ylene, 2,3-difluorophen-l,4-ylene, 2,5-difluorophen- 1,4-ylene, 2,6-difluorophen-l,4-ylene, 2,3-dichlorophen-l,4-ylene, 2,5-dichlorophen-l,4- ylene, 2,6-dichlorophen-l,4-ylene, 2-chloro-57methoxyphen-l,4-ylene, 2-chloro-6- methoxyphen-l,4-ylene, 2-chloro-5-trifluoromethoxyphen-l,4-ylene, and 2-chloro-6- trifluoromethoxyphen- 1 ,4-ylene. In another embodiment, Ar1 is a (3-5C)heteroarylene group containing 1 or 2 heteroatoms selected independently from oxygen, nitrogen or sulfur; wherein the heteroarylene group is unsubstituted or substituted with 1 or 2 R5 substituents. Representative heteroarylene groups include divalent species of pyrrole, imidazole, thiazole, oxazole, furan, thiophene, pyrazole, isoxazole, isothiazole, pyridine, pyrazine, pyridazine and pyrimidine, where the point of attachment is at any available carbon or nitrogen ring atom. More specific examples of such Ar1 groups include 2,5-furylene, 2,4- thienylene, 2,5-thienylene, 2,5-pyridylene, 2,6-pyridylene, and 2,5-pyrrolylene. Representative R5 substituents include fluoro, chloro, methyl, ethyl, n-propyl, isopropyl, n- butyl, isobutyl, -fee-butyl, tert-butyl, methoxy, ethoxy, isopropoxy, difluoromethyl, trifluoromethyl, 2,2,2-trifluoroethyl and trifluoromethoxy. Particular examples of substituted Ar1 groups include 3-fluoro-2,5-thienylene, 3-chloro-2,5-thienylene, 3-methyl- 2,5-thienylene, 3-methoxy-2,5-thienylene, and 3-methoxy-6-chloro-2,5-pyridylene. hi one particular embodiment, Ar1 represents phen-l,3-ylene, phen-l,4-ylene, 2,4- thienylene, 2,5-thienylene, 2,5-furylene, 2,5-pyridylene, 2,6-pyridylene, or 2,5-pyrrolylene; wherein the phenylene, thienylene, furylene, pyridylene or pyrrolylene group is optionally substituted with 1 or 2 R5 substituents. In another particular embodiment, Ar1 is substituted with one R5 substituent selected from halo and (l-4C)alkoxy. The value for t is 0, 1 or 2. A particular value for t is 1. The value for p is 0, 1, or 2. Particular values for p are 0 or 1. In one embodiment, p is O. Each R6 is independently (l-4C)alkyl, (2-4C) alkenyl, (2-4C)alkynyl, (3-6C)cycloalkyl, cyano, nitro, halo, N,N-di(l-4C)alkylamino(2-4C)alkoxy, -OR6a, -C(O)OR6 , -SR6c, -S(O)R6d, -S(O)2R6e or -ΝR6fR6g. Each R6a, R6b, R6c, R6d, R6e, R6f and R6g as used in R6 is independently hydrogen, (l-4C)alkyl, (3-6C)cycloalkyl, phenyl or phenyl(l-4C)alkyl, where each phenyl group is unsubstituted or substituted by 1 or 2 substituents independently selected from halo, (l-4C)alkyl and (l-4C)alkoxy. In addition, each alkyl and alkoxy group in R6 and R6 "6g is optionally substituted with 1 to 5 fluoro substituents. In one embodiment, each R6 independently represents halo, (l-3C)alkyl, or (l-3C)alkoxy, where the alkyl and alkoxy groups are optionally substituted with 1 to 3 fluoro substituents. In another embodiment, each R6 is independently selected from fluoro, chloro, bromo, methyl, methoxy, trifluoromethyl or trifluoromethoxy. R7 represents hydrogen, (l-4C)alkyl, (3-4C)cycloalkyl, -C(O)(l-4C)alkyl, -(1- 4C)alkyleneC(O)OR7a, -C(O)heterocyclyl, -C(O)CH(ΝH2)(l -4C)alkyleneQ, -(1 -
4C)alkyleneC(O)Z, -C(O)(l-4C)alkyleneZ, and -S(O)2(l-4C)alkyleneZ. Q is a nitrogen- containing substituent selected from -NR7 R7c and heteroaryl. Z is a nitrogen-containing substituent selected from -NR7dR7e and heterocyclyl. R7a is hydrogen or (l-4C)alkyl. Each of R7b, R7c, R7d and R7e independently represents hydrogen, (l-4C)alkyl, (3-6C)cycloalkyl or hydroxyphenyl, and (l-4C)alkyl is unsubstituted or substituted by 1 or 2 substituents selected independently from amido, cyano, furyl, hydroxyl, and methylimidazolyl. The heterocyclyl contains 1 or 2 nitrogen atoms, and is unsubstituted or substituted by 1 or 2 substituents selected independently from hydroxyl, amido, (l-4C)alkoxy, oxo, -S(O)2(l- 4C)alkyl, -(CH2)O(l-4C)alkyl, -(l-4C)alkyleneOH. -NR7fR7g or -C(O)NR7hR7i, where each of R7f, R7g R7h and R71 independently represents hydrogen or (l-4C)alkyl. The heteroaryl contains 1 or 2 nitrogen atoms. The heterocyclyl and heteroaryl groups may contain other heteroatoms, in addition to the 1 or 2 nitrogen atoms. For example the heterocyclyl can be a morpholinyl group. In one embodiment, R7 represents hydrogen, (l-4C)alkyl, or (3-4C)cycloalkyl, examples of which include methyl, ethyl, n-propyl, isopropyl, n-butyl, _?ec-butyl, isobutyl, tert-butyl, cyclopropyl and cyclobutyl. In another embodiment, R7 represents hydrogen or methyl. In one embodiment, R7 is -C(O)(l-4C)alkyl, examples of which include -C(O)CH3 and -C(O)CH2CH3. In another embodiment, R7 is -(l-4C)alkyleneC(O)OR7a. Such exemplary R7 embodiments include -(CH2)2C(O)OH and -(CH2) C(O)OCH3. In yet another embodiment, R7 is -C(O)heterocyclyl. In a particular embodiment, the heterocyclyl contains 1 nitrogen atom, and is unsubstituted or substituted with a hydroxyl. Particular embodiments include where the heterocyclyl is pyrrolidinyl, hydroxypyrrolidinyl or piperidyl. In another embodiment, R7 is -C(O)CH(NH2)(l-4C)alkyleneQ. Exemplary Q embodiments include -NR7bR7c such as -NH2, and a heteroaryl such as pyridyl or imidazolyl. In a particular embodiment, R7 is -(l-4C)alkyleneC(O)Z, where Z is -NR7dR7e, for example -(CH2)2C(O)-NR7dR7e. In one embodiment, R7d and R7e are both (l-4C)alkyl, and methyl in particular. In another embodiment, R7d is hydrogen and R7e is selected from (1- 4C)alkyl (such as methyl and ethyl), (3-6C)cycloalkyl (such as cyclopropyl) and hydroxyphenyl. The (l-4C)alkyl is unsubstituted or substituted with furyl, hydroxyl or methylimidazolyl. In a particular embodiment, R7 is -(l-4C)alkyleneC(O)Z, and Z is a heterocyclyl, for example -(CH2)2C(O)heterocyclyl. In one embodiment, the heterocyclyl contains 1 nitrogen atom, such as piperidyl and is substituted with an amido. In still another embodiment, R7 is -C(O)(l-4C)alkyleneZ, where Z is -NR7dR7e, for example -C(O)CH2NR7dR7e, -C(O)(CH2)2NR7dR7e, and -C(O)(CH2)3NR7dR7e. In a particular embodiment, each of R7d and R7e independently represents hydrogen, or (1- 4C)alkyl. In another embodiment, R7d is hydrogen or methyl and R7e is (l-4C)alkyl substituted with amido, cyano, ftiryl, or hydroxyl. In still another embodiment, R7 is -C(O)(l-4C)alkyleneZ, where Z is a heterocyclyl, such as -C(O)(CH2)heterocyclyl, -C(O)(CH2)2heterocyclyl and -C(O)(CH2)3heterocyclyl. In one embodiment, the heterocyclyl contains 1 nitrogen atom such as pyrrolidinyl or piperidyl. In another embodiment, the heterocyclyl contains 2 nitrogen atoms such as piperazinyl, tetrahydropyrimidinyl and 1,4 diazepanyl. In a particular embodiment, the heterocyclyl is pyrrolidinyl, unsubstituted or substituted with amido or (l-4C)alkoxy such as methoxy. In a particular embodiment, the heterocyclyl is piperidyl unsubstituted or substituted by 1 or 2 substituents selected independently from hydroxyl, amido, or (l-4C)alkoxy such as methoxy. In a particular embodiment, the heterocyclyl is tetrahydropyrimidinyl substituted with oxo. another particular embodiment, the heterocyclyl is piperazinyl substituted with -S(O)2(l-4C)alkyl such as -S(O)2CH CH3. In yet another embodiment, the heterocyclyl is 1,4 diazepanyl substituted with oxo. In yet another embodiment, R7 is -S(O)2(l-4C)alkyleneZ. where Z is -NR7dR7e, such as -S(O)2(CH2)2NR7dR7e. hi a particular embodiment each of R7d and R7e independently represents (l-4C)alkyl, where (l-4C)alkyl is substituted with hydroxyl, for example -N(CH2CH2OH)2. In yet another embodiment, R7 is -S(O)2(l-4C)alkyleneZ, where Z is a heterocyclyl, such as -S(O)2(CH2)2 heterocyclyl. hi a particular embodiment, the heterocyclyl is piperidyl substituted with hydroxyl, -(l-4C)alkyleneOH such as -(CH2)2OH, or -C(O)NR5hR5i such as -(CO)N(CH2CH3)2. In another embodiment, the heterocyclyl is piperazinyl, substituted with oxo. X1 is selected from (l-3C)alkylene, -C(O)(l-3C)alkylene, (l-3C)alkyleneC(O)-, -SO2-, -SO2(l-3C)alkylene and (l-3C)alkyleneSO2-. The alkylene group in any X1 is optionally substituted with 1 or 2 substituents independently selected from (l-4C)alkyl and -NRX Rxb, where R a and R'5* are independently selected from hydrogen and (l-4alkyl). In one embodiment, X1 is selected from (l-3C)alkylene, -C(O)(l-3C)alkylene, (l-3C)alkyleneC(O)- or -SO2-. Examples of particular values for X1 are -CH2-, -CH CH2-, -CH2C(O)-, -C(O)CH(NH2)CH2- and -SO2-. In a particular embodiment, X1 is -CH2- or -CH2CH2. As noted in formula I, the -OH group can be located at the ortho, meta or para position. In one embodiment, the -OH group is located at the meta or para position; and in a particular embodiment, the -OH group is located at the para position. A particular group of compounds of interest are compounds of formula I wherein a, b and c are 0; and R4 is hydrogen or methyl. Another particular group of compounds of interest are compounds of formula I wherein a, b and c are 0; R4 is hydrogen or methyl; and R7 is hydrogen or methyl. Another particular group of compounds of interest are compounds of formula I wherein a, b and c are 0; R4 is hydrogen or methyl; R7 is hydrogen or methyl; and s is 0. Another particular group of compounds of interest are compounds of formula I wherein a, b and c are 0; R4 is hydrogen or methyl; R7 is hydrogen or methyl; s is 0; and t is 1. Another particular group of compounds of interest are compounds of formula I wherein a, b and c are 0; R4 is hydrogen or methyl; R7 is hydrogen or methyl; s is 0; t is 1 ; and m is 0. In another of its composition aspects, this invention provides a compound of formula la:
Figure imgf000014_0001
wherein R , R , R , R , p and q are as defined herein; or a pharmaceutically acceptable salt or solvate or stereoisomer thereofΛ Another particular group of compounds of interest are compounds of formula la wherein q is 0; or q is 1 or 2 and R5 is selected independently from halo, (l-4C)alkyl or (1-
4C)alkoxy, wherein each alkyl and alkoxy group is optionally substituted with from 1 to 3 fluoro substituents. Another particular group of compounds of interest are compoxmds of formula la wherein q is 1 and R5 is halo or (l-4C)alkoxy.
Representative Subgeneric Groupings The following subgeneric formulae and groupings are intended to provide representative examples of various aspects and embodiments of this invention and as such, they are not intended to exclude other embodiments or to limit the scope of this invention unless otherwise indicated. A particular group of compounds of formula I are those disclosed in U.S. Provisional Application No. 60/552,347, filed on March 11, 2004. This group includes compounds of formula I' and la':
Figure imgf000015_0001
wherein: a is 0 or an integer of from 1 to 3; each R1 is independently selected from
(l-4C)alkyl, (2-4C)alkenyl, (2-4C) alkynyl, (3-6C)cycloalkyl, cyano, halo, -ORla,
-C(O)ORlb, -SRlc, -S(O)Rld, -S(O)2Rle and -NRlfRlg; each of Rla, Rlb, Rlc, Rld, Rle, Rlf and Rlg is independently hydrogen, (l-4C)alkyl or phenyl(l-4C)alkyl; b is 0 or an integer of from 1 to 3; each R2 is independently selected from
(l-4C)alkyl, (2-4C)alkenyl, (2-4C)alkynyl, (3-6C)cycloalkyl, cyano, halo, -OR2a,
-C(O)OR2 , -SR2c, -S(O)R2d, -S(O)2R2e and -NR2fR2 ; each of R2a, R2b, R2c, R2d, R2e, R2f and R2g is independently hydrogen, (l-4C)alkyl or phenyl(l-4C)alkyl; W represents O or NWa, where Wa is hydrogen or (l-4C)alkyl; c is 0 or an integer from 1 to 4; each R3 independently represents (l-4C)alkyl; m is O or 1; R4 is hydrogen or (l-4C)alkyl; s is 0 or 1; Ar1 represents a phenylene group or a (3-5C)heteroarylene group containing 1 or 2 heteroatoms selected independently from oxygen, nitrogen or sulfur; wherein the phenylene or heteroarylene group is substituted with (R5)q where q is 0 or an integer from 1 to 4 and each R5 is selected independently from halo, hydroxy, (l-4C)alkyl or (1-
4C)alkoxy; t is O or 1; R7 is hydrogen or (l-4C)alkyl; X1 is selected from (l-3C)alkylene, -C(O)(l-3C)alkylene, (l-3C)alkyleneC(O)-,
-SO2-, -SO2(l-3C)alkylene and (l-3C)alkyleneSO2-; where the alkylene group in any X1 is optionally substituted with 1 or 2 substituents selected independently from (l-3C)alkyl and -NRxaRxb; wherein Rxa and Rx are selected independently from hydrogen and (l-3alkyl); p is 0, 1 or 2; and each R6 independently represents (l-4C)alkyl, (2-4C)alkenyl, (2- 4C)alkynyl, (3-6C)cycloalkyl, cyano, nitro, halo, N,N-di(l-4C)alkylamino(2-4C)alkoxy, -OR6a, -C(O)OR6 , -SR6c, -S(O)R6d, -S(O)2R6e or -ΝR6fR6 ; each of R6a, R6b, R6c, R6d, R6e, R6f and R6g is independently hydrogen, (l-4C)alkyl, phenyl or phenyl(l-4C)alkyl, wherein each phenyl group is unsubstituted or substituted by 1 or 2 substituents selected independently from halo, (l-4C)alkyl and (l-4C)alkoxy; wherein each alkyl and alkoxy group in R1, Rla_lg, R2, R2a"2g, R3, R5, R6 or R6a"6g is optionally substituted with 1 to 5 fluoro substituents; or a pharmaceutically acceptable salt or solvate or stereoisomer thereof. Particular compounds of interest include: biphenyl-2-ylcarbamic acid l-[2-({4-[(4-hydroxybenzylamino)methyl] benzoyl}methylamino)ethyl]piperidin-4-yl ester; biphenyl-2-ylcarbamic acid l-{2-[(4-{[2-(4-hydroxyphenyl)ethylamino]methyl} benzoyl)methylamino]ethyl}piperidin-4-yl ester; > biphenyl-2-ylcarbamic acid l-(2-{4-[(4-hydroxybenzylamino)methyl] benzoylamino} ethyl)piperidin-4-yl ester; biphenyl-2-ylcarbamic acid l-[2-({4-[(3-hydroxybenzylamino)methyl] benzoyl}methylamino)ethyl]piperidin-4-yl ester; biphenyl-2-ylcarbamic acid 1 -[2-(4- {[2-(4-hydroxyphenyl)ethylamino]methyl} benzoylamino)ethyl]piperidin-4-yl ester; biphenyl-2-ylcarbamic acid 1 -[2-(4- {[(4-hydroxybenzyl)methylamino]methyl} benzoylamino)ethyl]piρeridin-4-yl ester; biphenyl-2-ylcarbamic acid l-{2-[4-({[2-(4-hydroxyphenyl)ethyl]methylamino} methyl)benzoylamino] ethyl} piperidin-4-yl ester; biphenyl-2-ylcarbamic acid l-[2-(2-fluoro-4-{[2-(4-hydroxyphenyl)ethylamino] . methyl}benzoylamino)ethyl]piperidin-4-yl ester; biphenyl-2-ylcarbamic acid 1- {2-[(2-fluoro-4- {[2-(4-hydroxyphenyl)ethylamino] methyl}benzoyl)methylamino]ethyl}piperidin-4-yl ester; biphenyl-2-ylcarbamic acid 1 -[2-(4- {[2-(4-hydroxyphenyl)ethylamino]methyl} -2- methoxybenzoylamino)ethyl]piperidin-4-yl ester; biphenyl-2-ylcarbamic acid l-{2-[(4-{[2-(4-hydroxyphenyl)ethylamino]methyl}-2- methoxybenzoyl)methylamino]ethyl}piperidin-4-yl ester; biphenyl-2-ylcarbamic acid 1- {2-[(5- {[2-(4-hydroxyphenyl)ethylamino]methyl} thiophene-2-carbonyl)methylamino]ethyl}piperidin-4-yl ester; biphenyl-2-ylcarbamic acid l-{2-[(5-{[2-(4-hydroxyphenyl)ethylamino]methyl} thiophene-2-carbonyl)amino]ethyl}piperidin-4-yl ester; biphenyl-2-ylcarbamic acid 1- {2-[(5- {[2-(4-hydroxyphenyl)ethylamino]methyl} furan-2-carbonyl)methylamino]ethyl}piperidin-4-yl ester; biphenyl-2-ylcarbamic acid 1- {2-[(5- {[2-(4-hydroxyphenyl)ethylamino]methyl} fur an-2-carbonyl)amino]ethyl}piperidin-4-yl ester; biphenyl-2-ylcarbamic acid l-{2-[(5-{[2-(4-hydroxyphenyl)ethylamino]methyl} pyridine-2-carbonyl)methylamino] ethyl}piperidin-4-yl ester; biphenyl-2-ylcarbamic acid l-{2-[(5-{[2-(4-hydroxyphenyl)ethylamino]methyl}- lH-pyrrole-2-carbonyl)methylamino]ethyl}piperidin-4-yl ester; biphenyl-2-ylcarbamic acid l-[2-( {5-[(4-hydroxybenzylamino)methyl]thiophene-2- carbonyl}methylamino)ethyl]piperidin-4-yl ester; biphenyl-2-ylcarbamic acid 1 -[2-( {5-[(4-hydroxybenzylamino)methyl]thiophene-2- carbonyl}amino)ethyl]piperidin-4-yl ester; biphenyl-2-ylcarbamic acid l-[2-({5-[(4-hydroxybenzylamino)methyl]-lH-pyrrole- 2-carbonyl}methylamino)ethyl]piperidin-4-yl ester; biphenyl-2-ylcarbamic acid l-[2-({5-[(4-hydroxybenzylamino)methyl]furan-2- carbonyl}methylamino)ethyl]piperidin-4-yl ester; biphenyl-2-ylcarbamic acid l-[2-({5-[(4-hydroxybenzylamino)methyl]furan-2- carbonyl}amino)ethyl]piρeridin-4-yl ester; biphenyl-2-ylcarbamic acid l-{2-[2-(4-{[2-(4-hydroxyphenyl)ethylamino]methyl} phenyl)acetylamino]ethyl}piperidin-4-yl ester; biphenyl-2-ylcarbamic acid l-{2-[3-(4-{[2-(4-hydroxyphenyl)ethylamino]methyl} phenyl)propionylamino] ethyl}piperidin-4-yl ester; biphenyl-2-yl-carbamic acid 1 -[2-(3- {4-[(4-hydroxybenzylamino)methyl]phenyl} propionylamino)ethyl]piperidin-4-yl ester; biphenyl-2-yl-carbamic acid l-{2-[(3-{4-[(4-hydroxybenzylamino)methyl] phenyl}propionyl)methylamino] ethyl} -piperidin-4-yl ester; and biphenyl-2-yl-carbamic acid 1 - {2-[(3- {4-[(3-hydroxybenzylamino)methyl] phenyl}propionyl)methylamino]ethyl}-piperidin-4-yl ester; or a pharmaceutically acceptable salt or solvate thereof.
• Definitions When describing the compounds, compositions, methods and processes of this invention, the following terms have the following meanings unless otherwise indicated. The term "alkyl" means a monovalent saturated hydrocarbon group which may be linear or branched. Unless otherwise defined, such alkyl groups typically contain from 1 to 10 carbon atoms. Representative alkyl groups include, by ay of example, methyl, ethyl, n-propyl, isopropyl, n-butyl, -.ec-butyl, isobutyl, tert-butyl, n-pentyl, n-hexyl, n-heptyl, n- octyl, n-nonyl, n-decyl and the like. The term "alkylene" means a divalent saturated hydrocarbon group which may be linear or branched. Unless otherwise defined, such alkylene groups typically contain from 1 to 10 carbon atoms. Representative alkylene groups include, by way of example, methylene, ethane- 1,2-diyl ("ethylene"), propane- 1,2-diyl, propane- 1, 3 -diyl, butane- 1,4- diyl, pentane- 1 ,5-diyl and the like. The term "alkoxy" means a monovalent group of the formula (alkyl)-O-, where alkyl is as defined herein. Representative alkoxy groups include, by way of example, methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, -.ec-butoxy, isobutoxy, tert-butoxy and the like. The term "alkenyl" means a monovalent unsaturated hydrocarbon group which may be linear or branched and which has at least one, and typically 1, 2 or 3, carbon-carbon double bonds. Unless otherwise defined, such alkenyl groups typically contain from 2 to 10 carbon atoms. Representative alkenyl groups include, by way of example, ethenyl, n- propenyl, isopropenyl, n-but-2-enyl, n-hex-3-enyl and the like. The term "alkenylene" means a divalent alkenyl group. The term "alkynyl" means a monovalent unsaturated hydrocarbon group which may be linear or branched and which has at least one, and typically 1, 2 or 3, carbon- carbon triple bonds. Unless otherwise defined, such alkynyl groups typically contain from 2 to 10 carbon atoms. Representative alkynyl groups include, by way of example, ethynyl, n-propynyl, n-but-2-ynyl, -hex-3-ynyl and the like. The term "alkynylene" means a divalent alkynyl group. The term "aryl" means a monovalent aromatic hydrocarbon having a single ring (i.e., phenyl) or fused rings (i.e., naphthalene). Unless otherwise defined, such aryl groups typically contain from 6 to 10 carbon ring atoms. Representative aryl groups include, by way of example, phenyl and naphthalene- 1-yl, naphthalene-2-yl, and the like. The term "arylene" means a divalent aryl group. The term "azacycloalkyl" means a monovalent heterocyclic ring containing one nitrogen atom, i.e., a cycloalkyl group in which one carbon atom has been replaced with a nitrogen atom. Unless otherwise defined, such azacycloalkyl groups typically contain from 2 to 9 carbon atoms. Representative examples of an azacycloalkyl group are pyrrolidinyl and piperidinyl groups. The term "azacycloalkylene" means a divalent azacycloakyl group. Representative examples of an azacycloalkylene group are pyrrolidinylene and piperidinylene groups. The term "cycloalkyl" means a monovalent saturated carbocyclic hydrocarbon group. Unless otherwise defined, such cycloalkyl groups typically contain from 3 to 10 carbon atoms. Representative cycloalkyl groups include, by way of example, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and the like. The term "cycloalkylene" means a divalent cycloalkyl group . The term "halo" means fluoro, chloro, bromo and iodo. The term "heteroaryl" means a monovalent aromatic group having a single ring or two fused rings and containing in the ring at least one heteroatom (typically 1 to 3 heteroatoms) selected from nitrogen, oxygen or sulfur. Unless otherwise defined, such heteroaryl groups typically contain from 5 to 10 total ring atoms. Representative heteroaryl groups include, by way of example, monovalent species of pyrrole, imidazole, thiazole, oxazole, furan, thiophene, triazole, pyrazole, isoxazole, isothiazole, pyridine, pyrazine, pyridazine, pyrimidine, triazine, indole, benzofuran, benzothiophene, benzimidazole, benzthiazole, quinoline, isoquinoline, quinazoline, quinoxaline and the like, where the point of attachment is at any available carbon or nitrogen ring atom. The term "heteroarylene" means a divalent heteroaryl group. The term "heterocyclyl" or "heterocyclic" means a monovalent saturated or unsaturated (non-aromatic) group having a single ring or multiple condensed rings and containing in the ring at least one heteroatom (typically 1 to 3 heteroatoms) selected from nifrogen, oxygen or sulfur. Unless otherwise defined, such heterocyclic groups typically contain from 2 to 9 total ring carbon atoms. Representative heterocyclic groups include, by way of example, monovalent species of pyrrolidine, imidazolidine, pyrazolidine, piperidine, 1,4-dioxane, morpholine, thiomorpholine, piperazine, 3-pyrroline and the like, where the point of attachment is at any available carbon or nitrogen ring atom. The term "heterocyclene" means a divalent heterocyclyl or heterocyclic group. When a specific number of carbon atoms is intended for a particular term used herein, the number of carbon atoms is shown in parentheses preceding the term. For example, the term "(l-4C)alkyl" means an alkyl group having from 1 to 4 carbon atoms. The tenn "pharmaceutically acceptable salt" means a salt which is acceptable for administration to a patient, such as a mammal (e.g., salts having acceptable mammalian safety for a given dosage regime). Such salts can be derived from pharmaceutically acceptable inorganic or organic bases and from pharmaceutically acceptable inorganic or organic acids. Salts derived from pharmaceutically acceptable inorganic bases include ammonium, calcium, copper, ferric, ferrous, lithium, magnesium, manganic, manganous, potassium, sodium, zinc and the like. Particularly preferred are ammonium, calcium, magnesium, potassium and sodium salts. Salts derived from pharmaceutically acceptable organic bases include salts of primary, secondary and tertiary amines, including substituted amines, cyclic amines, naturally-occurring amines and the like, such as arginine, betaine, caffeine, choline, NN-dibenzylethylenediamine, diethylamine, 2-diethylaminoethanol, 2- dimethylaminoethanol, ethanolamine, ethylenediamine, N-ethylmorpholine, N- ethylpiperidine, glucamine, glucosamine, histidine, hydrabamine, isopropylamine, lysine, methylglucamine, morpholine, piperazine, piperadine,, polyamine resins, procaine, purines, theobromine, triethylamine, trimethylamine, tripropylamine, tromethamine and the like. Salts derived from pharmaceutically acceptable acids include acetic, ascorbic, benzenesulfonic, benzoic, camphosulfonic, citric, ethanesulfonic, edisylic, fumaric, gentisic, gluconic, glucoronic, glutamic, hippuric, hydrobromic, hydrochloric, isethionic, lactic, lactobionic, maleic, malic, mandelic, methanesulfonic, mucic, naphthalenesulfonic, naphthalene- 1,5 -disulfonic, naphthalene-2,6-disulfonic, nicotinic, nitric, orotic, pamoic, pantothenic, phosphoric, succinic, sulfuric, tartaric, p-toluenesulfonic, xinafoic and the like. Particularly preferred are citric, hydrobromic, hydrochloric, isethionic, maleic, naphthalene- 1,5-disulfonic, phosphoric, sulfuric and tartaric acids. The term "salt thereof means a compound formed when the hydrogen of an acid is replaced by a cation, such as a metal cation or an organic cation and the like. Preferably, the salt is a pharmaceutically acceptable salt, although this is not required for salts of intermediate compounds that are not intended for administration to a patient. The term "solvate" means a complex or aggregate formed by one or more molecules of a solute, i.e. a compound of formula I or a pharmaceutically acceptable salt thereof, and one or more molecules of a solvent. Such solvates are typically crystalline solids having a substantially fixed molar ratio of solute and solvent. Representative solvents include, by way of example, water, methanol, ethanol, isopropanol, acetic acid and the like. When the'solvent is water, the solvate formed is a hydrate. It will be appreciated that the term "or a pharmaceutically acceptable salt or solvate or stereoisomer thereof is intended to include all permutations of salts, solvates and stereoisomers, such as a solvate of a pharmaceutically acceptable salt of a stereoisomer of a compound of formula I. The term "therapeutically effective amount" means an amount sufficient to effect treatment when administered to a patient in need of treatment. The term "treating" or "treatment" as used herein means the treating or treatment of a disease or medical condition (such as COPD) in a patient, such as a mammal (particularly a human) that includes: (a) preventing the disease or medical condition from occurring, i.e., prophylactic treatment of a patient; (b) ameliorating the disease or medical condition, i.e., eliminating or causing t regression of the disease or medical condition in a patient; (c) suppressing the disease or medical condition, i.e., slowing or arresting the development of the disease or medical condition in a patient; or (d) alleviating the symptoms of the disease or medical condition in a patient. The term "leaving group" means a functional group or atom which can be displaced by another functional group or atom in a substitution reaction, such as a nucleophilic substitution reaction. By way of example, representative leaving groups include chloro, bromo and iodo groups; sulfonic ester groups, such as mesylate, tosylate, brosylate, nosylate and the like; and acyloxy groups, such as acetoxy, trifluoroacetoxy and the like. The term "protected derivatives thereof means a derivative of the specified compound in which one or more functional groups of the compound are protected from undesired reactions with a protecting or blocking group. Functional groups which may be protected include, by way of example, carboxylic acid groups, amino groups, hydroxyl groups, thiol groups, carbonyl groups and the like. Representative protecting groups for carboxylic acids include esters (such as a .-methoxybenzyl ester), amides and hydrazides; for amino groups, carbamates (such as tert-butoxycarbonyl) and amides; for hydroxyl groups, ethers and esters; for thiol groups, thioethers and thioesters; for carbonyl groups, acetals and ketals; and the like. Such protecting groups are well-known to those skilled in the art and are described, for example, in T. W. Greene and G. M. Wuts, Protecting Groups in Organic Synthesis, Third Edition, Wiley, New York, 1999, and references cited therein. The term "amino-protecting group" means a protecting group suitable for preventing undesired reactions at an amino group. Representative amino-protecting groups include, but are not limited to, tert-butoxycarbonyl (BOC), trityl (Tr), benzyloxycarbonyl (Cbz), 9-fluorenylmethoxycarbonyl (Fmoc), formyl, trimethylsilyl (TMS), tert- butyldimethylsilyl (TBS), and the like. The term "carboxy-protecting group" means a protecting group suitable for preventing undesired reactions at a carboxy group. Representative carboxy-protecting groups include, but are not limited to, esters, such as methyl, ethyl, tert-butyl, benzyl (Bn), jp-methoxybenzyl (PMB), 9-fluroenylmethyl (Fm), trimethylsilyl (TMS), tert- butyldimethylsilyl (TBS), diphenylmethyl (benzhydryl, DPM) and the like. The term "hydroxyl-protecting group" means a protecting group suitable for preventing undesirable reactions at a hydroxyl group. Representative hydroxyl-protecting groups include, but are not limited to, silyl groups including tri(l-6C)alkylsilyl groups, such as trimethylsilyl (TMS), triethylsilyl (TES), tert-butyldimethylsilyl (TBS) and the like; esters (acyl groups) including (l-6C)alkanoyl groups, such as formyl, acetyl and the like; arylmethyl groups, such as benzyl (Bn), .-methoxybenzyl (PMB), 9-fluorenylmethyl (Fm), diphenylmethyl (benzhydryl, DPM) and the like. Additionally, two hydroxyl groups can also be protected as an alkylidene group, such as prop-2-ylidine, formed, for example, by reaction with a ketone, such as acetone.
General Synthetic Procedures The biphenyl compounds of this invention can be prepared from readily available starting materials using the following general methods and procedures or by using other information readily available to those of ordinary skill in the art. Although a particular embodiment of the present invention may be shown or described herein, those skilled in the art will recognize that all embodiments or aspects of the present invention can be prepared using the methods described herein or by using other methods, reagents and starting materials known to those skilled in the art. It will also be appreciated that where typical or preferred process conditions (i.e., reaction temperatures, times, mole ratios of reactants, solvents, pressures, etc.) are given, other process conditions can also be used unless otherwise stated. While the optimum reaction conditions may vary depending on the particular reactants or solvent used, such conditions can be readily determined by one skilled in the art by routine optimization procedures. Additionally, as will be apparent to those skilled in the art, conventional protecting groups may be necessary or desired to prevent certain functional groups from undergoing undesired reactions. The choice of a suitable protecting group for a particular functional group as well as suitable conditions for protection and deprotection of such functional groups are well-known in the art. Protecting groups other than those illustrated in the procedures described herein may be used, if desired. For example, numerous protecting groups, and their introduction and removal, are described in T. W. Greene and G. M. Wuts, Protecting Groups in Organic Synthesis, Third Edition, Wiley, New York, 1999, and references cited therein. By way of illustration, the compounds of formula I can be prepared by a process comprising: (a) reacting a compound of formula II:
Figure imgf000023_0001
II or a salt thereof, with a compound of formula III:
Figure imgf000023_0002
III wherein Z represents a leaving group, and P1 represents a hydrogen atom or a hydroxyl- protecting group; (b) coupling a compound of formula IN:
Figure imgf000024_0001
IN with a compound of formula N:
Figure imgf000024_0002
N or a reactive derivative thereof, wherein P2 represents a hydrogen atom or a hydroxyl- protecting group; (c) reacting a compound of formula NI:
Figure imgf000024_0003
VI with a compoxmd of formula VII:
Figure imgf000024_0004
VII wherein Z2 represents a leaving group; and P3 represents a hydrogen atom or a hydroxyl- protecting group; - (d) reacting a compound of formula II with a compound of formula VIII:
Figure imgf000024_0005
VIII wherein P4 represents a hydrogen atom or a hydroxyl-protecting group, in the presence of a reducing agent; (e) for a compound of formula I in which X1 represents (l-3C)alkylene, reacting a compound of formula VI with a compound of formula IX:
Figure imgf000025_0001
IX wherein Xla represents a bond or (l-2C)alkylene; and P5 represents a hydrogen atom or a hydroxyl-protecting group, in the presence of a reducing agent; or (f) for a compoxmd of formula I in which t is 1 , reacting a compound of formula X:
Figure imgf000025_0002
with a compoxmd of formula XI:
Figure imgf000025_0003
XI wherein P6 represents a hydrogen atom or a hydroxyl-protecting group, in the presence of a reducing agent; (g) and then removing any protecting group P1, P2, P3, P4, P5 or P6 to provide a compound of formula I; and optionally, forming a pharmaceutically acceptable salt thereof. Generally, if a salt of one of the starting materials is used in the processes described above, such as an acid addition salt, the salt is typically neutralized before or during the reaction process. This neutralization reaction is typically accomplished by contacting the salt with one molar equivalent of a base for each molar equivalent of acid addition salt. In one embodiment of the aforementioned process, a compound of formula I is first synthesized with R7 being hydrogen, i.e., R7 is hydrogen in the compound of formula III, V, VI, VIII, XI or XII. This resulting compound can then be reacted further to replace this hydrogen with an R7 substituent selected from (l-4C)alkyl, -C(O)(l-4C)alkyl, -(1- 4C)alkyleneC(O)OR7a, -C(O)heterocyclyl, -C(O)CH(NH2)(l-4C)alkyleneQ, -(1- 4C)alkyleneC(O)Z, -C(O)(l -4C)alkyleneZ, and -S(O)2(l -4C)alkyleneZ. In process (a), the reaction between the compounds of formula II and III, the leaving represented by Z1 can be, for example, halo, such as chloro, bromo or iodo, or a sulfonic ester group, such as mesylate or tosylate. P1 can be, for example, hydrogen, tertbutyldimethylsilyl or benzyl. The reaction is conveniently performed in the presence of a base, for example, a tertiary amine such as diisopropylethylamine. Convenient solvents include nitriles, such as acetonitrile. The reaction is conveniently conducted at a temperature in the range of from 0°C to 100°C. Compounds of formula II are generally known in the art, or can be prepared by deprotecting a compound of formula XII:
Figure imgf000026_0001
XII wherein P7 represents an amino-protecting group, such as a benzyl group. Benzyl groups are conveniently removed by reduction, using a hydrogen or ammonium formate and a Group VIII metal catalyst, such as palladium. When W represents NWa, the hydrogenation is conveniently performed using Pearlman's catalyst (Pd(OH)2). Compounds of formula XII can be prepared by reacting an isocyanate compound of formula XIII:
Figure imgf000026_0002
XIII with a compound of formula XIV:
HW— NP7 XIV Compounds of formula III can be prepared starting from a corresponding compound in which Z1 represents a hydroxyl group, for example, by reaction of a halogenating agent, such as thionyl chloride, to afford a compoxmd of formula III in which Z1 represents halo, such as chloro. Compounds in which Z1 represents a hydroxyl group may be prepared, for example, by reacting a compound of formula V with an appropriate amino-substituted alcohol, such as 2-aminoethanol or 3-aminopropan-l-ol. In process (b), the reaction of a compound of formula IV with a compoxmd of formula V or reactive derivative thereof, P2 can be, for example, hydrogen, tertbutyldimethylsilyl or benzyl. By "reactive derivative" of compound V it is meant that the carboxylic acid is activated, for example, by forming an anhydride or carboxylic acid halide, such as a carboxylic acid chloride. Alternatively, the carboxylic acid can be activated using conventional carboxylic acid/amine coupling reagents, such carbodiimides, O-(7-azabenzotriazol-l-yl-NN,N',N' tetramethyluronium hexafluorophosphate (HATU) and the like. This reaction is conveniently performed under conventional amide bond- forming conditions. The process is conveniently conducted at a temperature in the range of from -10°C to l00°C. Compounds of formula IN can be prepared by reacting a compound of formula II with a compound of formula XV: OHC(CH2)mCH2ΝR4P8 XV wherein P represents hydrogen or an amino-protecting group, such as benzyl, in the presence of a reducing agent, such as sodium triacetoxyborohydride, followed if necessary by removing an ammo-protecting group P by, for example, hydrogenation in the presence ofpalladium. Compounds of formula V can be prepared by reacting a compound of formula VII with a compoxmd of formula XVI:
Figure imgf000027_0001
XVI wherein P9 represents hydrogen or a carboxyl-protecting group, such as methyl or ethyl, followed if necessary by removing the carboxyl protecting group P9. Referring to process (c), the leaving group represented by Z2 can be, for example, halo, such as chloro, bromo or iodo, or a sulfonic ester group, such as mesylate or tosylate; P can be, for example, hydrogen, tert-butyldimethylsilyl or benzyl. This reaction is conveniently performed in the presence of a base, for example, a tertiary amine such as diisopropylethylamine. Convenient solvents include nitriles, such as acetonitrile. The reaction is conveniently conducted at a temperature in the range of from 0 °C to 100 °C. The compounds of formula VI can be prepared by reacting a compound of formula
IV with a compound of formula XVII:
Figure imgf000028_0001
XVII wherein P10 represents a hydrogen atom or an amino-protecting group, such as tert- butoxycarbonyl followed, if necessary, by removing the amino-protecting group P10. The reaction is conveniently performed following, for example, the method of process (b) described herein. In process (d), the reducing agent may be, for example, hydrogen in the presence of a Group VIII metal catalyst, such as palladium, or a metal hydride reducing agent, such as a borohydride, including sodium triacetoxyborohydride. Convenient solvents include alcohols, such as methanol. The reaction is conveniently performed at a temperature in the range of from 0°C to 100°C. The compounds of formula VIII may be prepared by oxidizing a compound corresponding to formula III in which Z1 represents a hydroxyl group. Such oxidation reactions can be conducted, for example, using sulfur dioxide pyridine complex in dimethylsulfoxide in the presence of a tertiary amine, such as diisopropylethylamine. Similarly, in processes (e) and (f), the reducing agent may be, for example,' hydrogen in the presence of a Group VIII metal catalyst, such as palladium, or a metal hydride reducing agent, such as a borohydride, including sodium triacetoxyborohydride. Convenient solvents include alcohols, such as methanol. These reactions are conveniently performed at a temperature in the range of from 0°C to 100°C. Compounds of formula X can be prepared by reacting a compound of formula IV with a compound of formula X7VIII:
Figure imgf000028_0002
XVIII in the presence of a coupling agent, such as l-(3-dimethylaminopropyl)-3- ethylcarbodiimide (EDC) and 1-hydroxybenzotriazole hydrate (HOBT). As will be apparent to those skilled in the art, compounds of formula I prepared by any of steps (a) to (f) herein may be further derivatized to form other compounds of formula I using methods and reagents well-known in the art. By way of illustration, a compound of formula I may be reacted with bromine to afford a corresponding compound of formula I in which R2 and or R6 represent a bromo group. Additionally, a compound of formula I in which R7 represents a hydrogen atom may be alkylated to afford a conesponding compoxmd of formula I in which R7 represents a (1-4C) alkyl group. Certain of the intermediates described herein are believed to be novel and accordingly, such compounds are provided as further aspects of the invention including, for example, the compounds of formula III, V and VIII and salts thereof. Further details regarding specific reaction conditions and other procedures for preparing representative compounds of this invention or intermediates thereof are described in the Examples set forth below.
Pharmaceutical Compositions and Formulations The biphenyl compounds of this invention are typically administered to a patient in the form of a pharmaceutical composition or formulation. Such pharmaceutical compositions may be administered to the patient by any acceptable route of administration including, but not limited to, inhaled, oral, nasal, topical (including transdermal) and parenteral modes of administration. It will be understood that any form of the compounds of this invention, (i.e., free base, pharmaceutically acceptable salt, solvate, etc.) that is suitable for the particular mode of administration can be used in the pharmaceutical compositions discussed herein. Accordingly, in one of its composition aspects, this invention is directed to a pharmaceutical composition comprising a pharmaceutically acceptable carrier or excipient and a therapeutically effective amount of a compound of formula I, or a pharmaceutically acceptable salt or solvate or stereoisomer thereof. Optionally, such pharmaceutical compositions may contain other therapeutic and or formulating agents if desired. The pharmaceutical compositions of this invention typically contain a therapeutically effective amoxmt of a compound of the present invention or a pharmaceutically acceptable salt or solvate or stereoisomer thereof. Typically, such pharmaceutical compositions will contain from about 0.01 to about 95% by weight of the active agent; including, from about 0.01 to about 30% by weight; such as from about 0.01 to about 10% by weight of the active agent. Any conventional carrier or excipient may be used in the pharmaceutical compositions of this invention. The choice of a particular carrier or excipient, or combinations of carriers or excipients, will depend on the mode of administration being used to treat a particular patient or type of medical condition or disease state. In this regard, the preparation of a suitable pharmaceutical composition for a particular mode of administration is well within the scope of those skilled in the pharmaceutical arts. Additionally, the ingredients for such compositions are commercially available from, for example, Sigma, P.O. Box 14508, St. Louis, MO 63178. By ay of further illustration, conventional formulation techniques are described in Remington: The Science and Practice of Pharmacy, 20th Edition, Lippincott Williams & White, Baltimore, Maryland (2000); and H.C. Ansel et al., Pharmaceutical Dosage Forms and Drug Delivery Systems, 7th Edition, Lippincott Williams & White, Baltimore, Maryland (1999). Representative examples of materials which can serve as pharmaceutically acceptable carriers include, but are not limited to, the following: (1) sugars, such as lactose, glucose and sucrose; (2) starches, such as corn starch and potato starch; (3) cellulose, and its derivatives, such as sodium carboxymethyl cellulose, ethyl cellulose and cellulose acetate; (4) powdered tragacanth; (5) malt; (6) gelatin; (7) talc; (8) excipients, such as cocoa butter and suppository waxes; (9) oils, such as peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, corn oil and soybean oil; (10) glycols, such as propylene glycol; (11) polyols, such as glycerin, sorbitol, mannitol and polyethylene glycol; (12) esters, such as ethyl oleate and ethyl laurate; (13) agar; (14) buffering agents, such as magnesium hydroxide and aluminum hydroxide; (15) alginic acid; (16) pyrogen-free water; (17) isotonic saline; (18) Ringer's solution; (19) ethyl alcohol; (20) phosphate buffer solutions; (21) compressed propellant gases, such as chlorofluorocarbons and hydrofluorocarbons; and (22) other non-toxic compatible substances employed in pharmaceutical compositions. The pharmaceutical compositions of this invention are typically prepared by thoroughly and intimately mixing or blending a compound of the invention with a pharmaceutically acceptable carrier and one or more optional ingredients. If necessary or desired, the resulting uniformly blended mixture can then be shaped or loaded into tablets, capsules, pills, canisters, cartridges, dispensers and the like using conventional procedures and equipment. In one embodiment, the pharmaceutical compositions of this invention are suitable for inhaled administration. Suitable pharmaceutical compositions for inhaled administration will typically be in the form of an aerosol or a powder. Such compositions are generally administered using well-known delivery devices, such as a nebulizer inhaler, a metered-dose inhaler (MDI), a dry powder inhaler (DPI) or a similar delivery device. In a specific embodiment of this invention, the pharmaceutical composition comprising the active agent is administered by inhalation using a nebulizer inhaler. Such nebulizer devices typically produce a stream of high velocity air that causes the pharmaceutical composition comprising the active agent to spray as a mist that is carried into the patient's respiratory tract. Accordingly, when formulated for use in a nebulizer inhaler, the active agent is typically dissolved in a suitable carrier to form a solution. Alternatively, the active agent can be micronized and combined with a suitable carrier to fonn a suspension of micronized particles of respirable size, where micronized is typically defined as having about 90% or more of the particles with a diameter of less than about 10 μm. Suitable nebulizer devices are provided commercially, for example, by PARI GmbH (Starnberg, German). Other nebulizer devices include Respimat (Boehringer frige-heim) and those disclosed, for example, in U.S. Patent No. 6,123,068 to Lloyd et al. and WO 97/12687 (Eicher et al). A representative pharmaceutical composition for use in a nebulizer inhaler comprises an isotonic aqueous solution comprising from about 0.05 μg/mL to about 10 mg/mL of a compound of formula I or a pharmaceutically acceptable salt or solvate or stereoisomer thereof. hi another specific embodiment of this invention, the phannaceutical composition comprising the active agent is administered by inhalation using a dry powder inhaler. Such dry powder inhalers typically administer the active agent as a free-flowing powder that is dispersed in a patient's air-stream during inspiration, hi order to achieve a free flowing powder, the active agent is typically formulated with a suitable excipient such as lactose or starch. A representative pharmaceutical composition for use in a dry powder inhaler comprises dry lactose having a particle size between about 1 μm and about 100 μm and micronized particles of a compound of formula I, or a pharmaceutically acceptable salt or solvate or stereoisomer thereof. Such a dry powder formulation can be made, for example, by combining the lactose with the active agent and then dry blending the components. Alternatively, if desired, the active agent can be formulated without an excipient. The pharmaceutical composition is then typically loaded into a dry powder dispenser, or into inhalation cartridges or capsules for use with a dry powder delivery device. Examples of dry powder inhaler delivery devices include Diskhaler
(GlaxoSmithKline, Research Triangle Park, NC) (see, e.g., U.S. Patent No. 5,035,237 to Newell et al.); Diskus (GlaxoSmithKline) (see, e.g., U.S. Patent No. 6,378,519 to Davies et al.); Turbuhaler (AstraZeneca, Wilmington, DE) (see, e.g., U.S. Patent No. 4,524,769 to Wetterlin); Rotahaler (GlaxoSmithKline) (see, e.g., U.S. Patent No. 4,353,365 to Hallworth et al.) and Handihaler (Boehringer Ingelheim). Further examples of suitable DPI devices are described in U.S. Patent Nos. 5,415,162 to Casper et al., 5,239,993 to Evans, and 5,715,810 to Annstrong et al., and references cited therein. In yet another specific embodiment of this invention, the pharmaceutical composition comprising the active agent is administered by inhalation using a metered- dose inhaler. Such metered-dose inhalers typically discharge a measured amount of the active agent or a pharmaceutically acceptable salt or solvate or stereoisomer thereof using compressed propellant gas. Accordingly, pharmaceutical compositions administered using a metered-dose inhaler typically comprise a solution or suspension of the active agent in a liquefied propellant. Any suitable liquefied propellant may be employed including chlorofluorocarbons, such as CC13F, and hydrofluoroalkanes (HFAs), such as 1,1,1,2- tetrafluoroethane (HFA 134a) and 1,1,1,2,3,3,3-heptafluoro-n-propane, (HFA 227). Due to concerns about chlorofluorocarbons affecting the ozone layer, formulations containing HFAs are generally preferred. Additional optional components of HFA formulations include co-solvents, such as ethanol or pentane, and surfactants, such as sorbitan trioleate, oleic acid, lecithin, and glycerin. See, for example, U.S. Patent No. 5,225,183 to Purewal et al., EP 0717987 A2 (Minnesota Mining and Manufacturing Company), and WO 92/22286 (Minnesota Mining and Manufacturing Company). A representative pharmaceutical composition for use in a metered-dose inhaler comprises from about 0.01 % to about 5 % by weight of a compound of formula I, or a pharmaceutically acceptable salt or solvate or stereoisomer thereof; from about 0 % to about 20 % by weight ethanol; and from about 0 % to about 5 % by weight surfactant; with the remainder being an HFA propellant. Such compositions are typically prepared by adding chilled or pressurized hydrofluoroalkane to a suitable container containing the active agent, ethanol (if present) and the surfactant (if present). To prepare a suspension, the active agent is micronized and then combined with the propellant. The formulation is then loaded into an aerosol canister, which forms a portion of a metered-dose inhaler device. Examples of metered-dose inhaler devices developed specifically for use with HFA propellants are provided in U.S. Patent Nos. 6,006,745 to Marecki and 6,143,277 to Ashurst et al. Alternatively, a suspension formulation can be prepared by spray drying a coating of surfactant on micronized particles of the active agent. See, for example, WO 99/53901 (Glaxo Group Ltd.) and WO 00/61108 (Glaxo Group Ltd.). For additional examples of processes of preparing respirable particles, and formulations and devices suitable for inhalation dosing see U.S. Patent Nos. 6,268,533 to Gao et al., 5,983,956 to Trofast, 5,874,063 to Briggner et al., and 6,221,398 to Jakupovic et al.; and WO 99/55319 (Glaxo Group Ltd.) and WO 00/30614 (AsfraZeneca AB). In another embodiment, the pharmaceutical compositions of this invention are suitable for oral administration. Suitable pharmaceutical compositions for oral administration may be in the form of capsules, tablets, pills, lozenges, cachets, dragees, powders, granules; or as a solution or a suspension in an aqueous or non-aqueous liquid; or as an oil-in-water or water-in-oil liquid emulsion; or as an elixir or syrup; and the like; each containing a predetermined amount of a compound of the present invention as an active ingredient. When intended for oral administration in a solid dosage form (i.e., as capsules, tablets, pills and the like), the pharmaceutical compositions' of this invention will typically comprise a compound of the present invention as the active ingredient and one or more pharmaceutically acceptable carriers, such as sodium cifrate or dicalcium phosphate. Optionally or alternatively, such solid dosage forms may also comprise: (1) fillers or extenders, such as starches, lactose, sucrose, glucose, mannitol, and/or silicic acid; (2) binders, such as carboxymethylcellulose, alginates, gelatin, polyvinyl pynolidone, sucrose and/or acacia; (3) humectants, such as glycerol; (4) disintegrating agents, such as agar- agar, calcium carbonate, potato or tapioca starch, alginic acid, certain silicates, and/or sodium carbonate; (5) solution retarding agents, such as paraffin; (6) absorption accelerators, such as quaternary ammonium compounds; (7) wetting agents, such as cetyl alcohol and/or glycerol monostearate; (8) absorbents, such as kaolin and/or bentonite clay; (9) lubricants, such as talc, calcium stearate, magnesium stearate, solid polyethylene glycols, sodium lauryl sulfate, and/or mixtures thereof; (10) coloring agents; and (11) buffering agents. Release agents, wetting agents, coating agents, sweetening, flavoring and perfuming agents, preservatives and antioxidants can also be present in the pharmaceutical compositions of this invention. Examples of pharmaceutically acceptable antioxidants include: (1) water-soluble antioxidants, such as ascorbic acid, cysteine hydrochloride, sodium bisulfate, sodium metabisulfate sodium sulfite and the like; (2) oil-soluble antioxidants, such as ascorbyl palmitate, butylated hydroxyanisole (BHA), butylated hydroxytoluene (BHT), lecithin, propyl gallate, alpha-tocopherol, and the like; and (3) metal-chelating agents, such as citric acid, ethylenediamine tetraacetic acid (EDTA), sorbitol, tartaric acid, phosphoric acid, and the like. Coating agents for tablets, capsules, pills and like, include those used for enteric coatings, such as cellulose acetate phthalate (CAP), polyvinyl acetate phthalate (PVAP), hydroxypropyl methylcellulose phthalate, methacrylic acid-methacrylic acid ester copolymers, cellulose acetate trimellitate (CAT), carboxymethyl ethyl cellulose (CMEC), hydroxypropyl methyl cellulose acetate succinate (HPMCAS), and the like. If desired, the pharmaceutical compositions of the present invention may also be formulated to provide slow or controlled release of the active ingredient using, by way of example, hydroxypropyl methyl cellulose in varying proportions; or other polymer matrices, liposomes and/or microspheres. In addition, the pharmaceutical compositions of the present invention may optionally contain opacifying agents and may be formulated so that they release the active ingredient only, or preferentially, in a certain portion of the gastrointestinal tract, optionally, in a delayed manner. Examples of embedding compositions which can be used include polymeric substances and waxes. The active ingredient can also be in micro- encapsulated form, if appropriate, with one or more of the above-described excipients. Suitable liquid dosage forms for oral administration include, by way of illustration, pharmaceutically acceptable emulsions, microemulsions, solutions, suspensions, syrups and elixirs. Such liquid dosage forms typically comprise the active ingredient and an inert diluent, such as, for example, water or other solvents, solubilizing agents and emulsifiers, such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, oils (e.g., cottonseed, groundnut, corn, germ, olive, castor and sesame oils), glycerol, tetrahydrofuryl alcohol, polyethylene glycols and fatty acid esters of sorbitan, and mixtures thereof. Suspensions, in addition to the active ingredient, may contain suspending agents such as, for example, ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminium metahydroxide, bentonite, agar-agar and tragacanth, and mixtures thereof. When intended for oral administration, the pharmaceutical compositions of this invention are preferably packaged in a unit dosage form. The term "unit dosage form" means a physically discrete unit suitable for dosing a patient, i.e., each unit containing a predetermined quantity of active agent calculated to produce the desired therapeutic effect either alone or in combination with one or more additional units. For example, such unit dosage forms maybe capsules, tablets, pills, and the like. The compounds of this invention can also be administered transdermally using known transdermal delivery systems and excipients. For example, a compound of this invention can be admixed with permeation enhancers, such as propylene glycol, polyethylene glycol monolaurate, azacycloalkan-2-ones and the like, and incorporated into a patch or similar delivery system. Additional excipients including gelling agents, emulsifiers and buffers, may be used in such transdermal compositions if desired. The pharmaceutical compositions of this invention may also contain other therapeutic agents that are co-administered with a compound of formula I, or pharmaceutically acceptable salt or solvate or stereoisomer thereof. For example, the pharmaceutical compositions of this invention may further comprise one or more therapeutic agents selected from other bronchodilators (e.g., PDE3 inhibitors, adenosine 2b modulators and β2 adrenergic receptor agonists); anti-inflammatory agents (e.g., steroidal anti-inflammatory agents, such as corticosteroids; non-steroidal anti-inflammatory agents (NSAIDs), and PDE4 inhibitors); other muscarinic receptor, antagonists (i.e., antichlolinergic agents); antiinfective agents (e.g., Gram positive and Gram negative antibiotics or antivirals); antihistamines; protease inhibitors; and afferent blockers (e.g., D2 agonists and neurokinin modulators), hi one particular aspect of the invention, the compound of the invention is co-administered with a β adrenergic receptor agonist and a steroidal anti-inflammatory agent. The other therapeutic agents can be used in the form of pharmaceutically acceptable salts or solvates. Additionally, if appropriate, the other therapeutic agents can be used as optically pure stereoisomers. Representative β2 adrenergic receptor agonists that can be used in combination with the compounds of this invention include, but are not limited to, salmeterol, salbutamol, formoterol, salmefamol, fenoterol, terbutaline, albuterol, isoetharine, metaproterenol, bitolterol, pirbuterol, levalbuterol and the like, or pharmaceutically acceptable salts thereof. Other β2 adrenergic receptor agonists that can be used in combination with the compounds of this invention include, but are not limited to, 3-(4-{[6-({(2R)-2-hydroxy-2-[4-hydroxy- 3-(hydroxymethyl)-phenyl]ethyl} amino)-hexyl]oxy}butyl)benzenesulfonamide and 3-(-3- {[7-({(2R)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl}-amino)heptyl]oxy}- propyl)benzenesulfonamide and related compounds disclosed in WO 02/066422 (Glaxo Group Ltd.); 3-[3-(4- {[6-([(2R)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl] ethyl}amino)hexyl]oxy}butyl)-phenyl]imidazolidine-2,4-dione and related compounds disclosed in WO 02/070490 (Glaxo Group Ltd.); 3-(4-{[6-({(2R)-2-[3-(formylamino)-4- hydroxyphenyl] -2-hydroxyethyl} amino)hexyl]oxy}butyl)-benzenesulfonamide, 3-(4- {[6- ({(2S)-2-[3-(fonnylamino)-4-hydroxyphenyl]-2-hyo-roxyethyl}-ιmino)hexyl]oxy}butyl)- benzenesulfonamide, 3-(4-{[6-({(2R S)-2-[3-(formylamino)-4-hydroxyphenyl]-2- hydroxyethyl} amino)hexyl]oxy}butyl)-benzenesulfonamide, N-(tert-butyl)-3-(4- {[6- ({(2R)-2-[3-(formyiamino)-4-hydroxyphenyl]-2-hydroxyethyl}amino)hexyl]- oxy}butyl)benzenesulfonamide, N-(tert-butyl)-3-(4- {[6-( {(2S)-2-[3-(fonnylamino)-4- hydroxyphenyl]-2-hydroxyethyl}amino)-hexyl]oxy}butyl)-benzenesulfonamide, N-(tert- butyl)-3-(4-{[6-({(2R S)-2-[3-(formylamino)-4-hydroxyphenyl]-2-hydroxyethyl} amino) hexyl]oxy}butyl)benzenesulfonamide and related compounds disclosed in WO 02/076933 (Glaxo Group Ltd.); 4-{(lR)-2-[(6-{2-[(2,6-dichlorobenzyl)oxy]ethoxy}frexyl)amino]-l- hydroxyethyl} -2-(hydroxymethyl)ρhenol and related compounds disclosed in WO 03/024439 (Glaxo Group Ltd.); N-{2-[4-((R)-2-hydroxy-2-phenylethylamino)phenyl]. ethyl} -(R)-2-hydroxy-2-(3-formamido-4-hydroxyphenyl)ethylamine and related; compounds disclosed in U.S. Patent No. 6,576,793 to Moran et al.; N-{2-[4-(3-phenyl-4- methoxyphenyl)aminophenyl]ethyl}-(R)-2-hydroxy-2-(8-hydroxy-2(lH)-quinolinon-5- yl)ethylamine and related compounds disclosed in U.S. Patent No. 6,653,323 to Moran et al.; and pharmaceutically acceptable salts thereof. In a particular embodiment, the β2- adrenoreceptor agonist is a crystalline monohydrochloride salt of N-{2-[4-((R)-2-hydroxy- 2-phenylethylamino)phenyl]ethyl}-(R)-2-hydroxy-2-(3-formamido-4-hydroxyphenyl) ethylamine. When employed, the β2-adrenoreceptor agonist will be present in the pharmaceutical composition in a therapeutically effective amount. Typically, the β2- adrenoreceptor agonist will be present in an amount sufficient to provide from about 0.05 μg to about 500 μg per dose. Representative steroidal anti-inflammatory agents that can be used in combination with the compounds of this invention include, but are not limited to, methyl prednisolone, prednisolone, dexamethasone, fluticasone propionate, 6α,9α-difluoro-17α-[(2-furanyl carbonyl)oxy]-l lβ-hydroxy-16α-methyl-3-oxoandrosta-l,4-diene-17β-carbothioic acid S- fluoromethyl ester, 6α,9α-difluoro-l lβ-hydroxy-16α-methyl-3-oxo-17α-ρroρionyloxy- androsta-l,4-diene-17β-carbothioic acid S-(2-oxo-tetrahydrofuran-3S-yl) ester, beclomethasone esters (e.g., the 17-propionate ester or the 17,21-dipropionate ester), budesonide, flunisolide, mometasone esters (e.g., the furoate ester), triamcinolone acetonide, rofleponide, ciclesonide, butixocort propionate, RPR- 106541, ST- 126 and the like, or pharmaceutically-acceptable salts thereof. When employed, the steroidal anti- inflammatory agent will be present in the pharmaceutical composition in a therapeutically effective amount. Typically, the steroidal anti-inflammatory agent will be present in an amount sufficient to provide from about 0.05 μg to about 500 μg per dose. An exemplary combination is a compound of formula I, or pharmaceutically acceptable salt or solvate or stereoisomer thereof, co-administered with salmeterol as the β2 adrenergic receptor agonist, and fluticasone propionate as the steroidal anti-inflammatory agent. Another exemplary combination is a compound of formula I, or pharmaceutically acceptable salt or solvate or stereoisomer thereof, co-administered with a crystalline monohydrochloride salt of N- {2-[4-((R)-2-hydroxy-2-phenylethylamino)phenyl]ethyl} -(R)- 2-hydroxy-2-(3-formamido-4-hydroxyphenyl)ethylamine as the β2-adrenoreceptor agonist, and 6α,9α-difluoro-17α-[(2-furanylcarbonyl)oxy]-l lβ-hydroxy-16α-methyl-3-oxoandrosta- l,4-diene-17β-carbothioic acid S-fluoromethyl ester as the steroidal anti-inflammatory agent. Other suitable combinations include, for example, other anti-inflammatory agents, e.g., NSAIDs (such as sodium cromoglycate; nedocromil sodium; phosphodiesterase (PDE) inhibitors (e.g., theophylline, PDE4 inhibitors or mixed PDE3/PDE4 inhibitors); leukotriene antagonists (e.g., monteleukast); inhibitors of leukotriene synthesis; iΝOS inhibitors; protease inhibitors, such as tryptase and elastase inhibitors; beta-2 integrin antagonists and adenosine receptor agonists or antagonists (e.g., adenosine 2a agonists); cytokine antagonists (e.g., chemokine antagonists such as, an interleukin antibody (αlL antibody), specifically, an αIL-4 therapy, an αIL-13 therapy, or a combination thereof); or inhibitors of cytokine synthesis. For example, representative phosphodiesterase-4 (PDE4) inhibitors or mixed PDE3/PDE4 inhibitors that can be used in combination with the compounds of tins invention include, but are not limited to cis 4-cyano-4-(3-cyclopentyloxy-4- methoxyphenyl)cyclohexan-l -carboxylic acid, 2-carbomethoxy-4-cyano-4-(3- cyclopropylmethoxy-4-difluoromethoxyphenyl)cyclohexan-l-one; c._?-[4-cyano-4-(3- cyclopropylmethoxy-4-difluoromethoxyphenyl)cyclohexan-l-ol]; ct-?-4-cyano-4-[3- (cyclopentyloxy)-4-methoxyphenyl] cyclohexane- 1 -carboxylic acid and the like, or phaimaceutically acceptable salts thereof. Other representative PDE4 or mixed PDE4/PDE3 inhibitors include AWD-12-281 (elbion); NCS-613 (INSERM); D-4418 (Chiroscience and Schering-Plough); CI-1018 or PD-168787 (Pfizer); benzodioxole compounds disclosed in WO99/16766 (Kyowa Hakko); K-34 (Kyowa Hakko); V-11294A (Napp); roflumilast (Byk-Gulden); pthalazinone compounds disclosed in WO99/47505 (Byk-Gulden); Pumafentrine (Byk-Gulden, now Altana); arofylline (Almirall- Prodesfarma); NM554/UM565 (Nernalis); T-440 (Tanabe Seiyaku); and T2585 (Tanabe Seiyaku). Representative muscarinic antagonists (i.e., anticholinergic agents) that can be used in combination with, and in addition to, the compounds of this invention include, but are not limited to, atropine, atropine sulfate, atropine oxide, methylatropine nitrate, homatropine hydrobromide, hyoscyamine (d, I) hydrobromide, scopolamine hydrobromide, ipratropium bromide, oxitropium bromide, tiofropium bromide, methantheline, propantheline bromide, anisotropine methyl bromide, clidinium bromide, copyrrolate (Robinul), isopropamide iodide, mepenzolate bromide, tridihexethyl chloride (Pathilone), hexocyclium methylsulfate, cyclopentolate hydrochloride, tropicamide, trihexyphenidyl hydrochloride, pirenzepine, telenzepine, AF-DX 116 and methoctramine and the like, or a pharmaceutically acceptable salt thereof; or, for those compounds listed as a salt, alternate pharmaceutically acceptable salt thereof. Representative antihistamines (i.e., Hi -receptor antagonists) that can be used in combination with the compounds of this invention include, but are not limited to, ethanolamines, such as carbinoxamine maleate, clemastine fumarate, diphenylhydramine hydrochloride and dimenhydrinate; ethylenediamines, such as pyrilamine amleate, tripelei amine hydrochloride and tripelennamine cifrate; alkylamines, such as chlorpheniramine and acrivastine; piperazines, such as hydroxyzine hydrochloride, hydroxyzine pamoate, cyclizine hydrochloride, cyclizine lactate, meclizine hydrochloride and cetirizine hydrochloride; piperidines, such as astemizole, levocabastine hydrochloride, loratadine or its descarboethoxy analogue, terfenadine and fexofenadine hydrochloride; azelastine hydrochloride; and the like, or a pharmaceutically acceptable salt thereof; or, for those compoxmds listed as a salt, alternate pharmaceutically acceptable salt thereof. Suitable doses for the other therapeutic agents administered in combination with a compound of the invention are in the range of about 0.05 μg/day to about 100 mg/day. The following formulations illustrate representative pharmaceutical compositions of the present invention:
Formulation Example A A dry powder for administration by inhalation is prepared as follows: Ingredients Amount Compound of the invention 0.2 mg Lactose 25 mg
Representative Procedure: The compound of the invention is micronized and then blended with lactose. This blended mixture is then loaded into a gelatin inhalation cartridge. The contents of the cartridge are administered using a powder inhaler. Formulation Example B A dry powder formulation for use in a dry powder inhalation device is prepared as follows: Representative Procedure: A pharmaceutical composition is prepared having a bulk formulation ratio of micronized compound of the invention to lactose of 1 :200. The composition is packed into a dry powder inhalation device capable of delivering between about 10 μg and about 100μg of the compound of the invention per dose.
Formulation Example C A dry powder for administration by inhalation in a metered dose inlialer is prepared as follows: Representative Procedure: A suspension containing 5 wt% of a compound of the invention and 0.1 wt% lecithin is prepared by dispersing 10 g of the compound of the invention as micronized particles with mean size less than 10 μm in a solution formed from 0.2 g of lecithin dissolved in 200 mL of demineralized water. The suspension is spray dried and the resulting material is micronized to particles having a mean diameter less than 1.5 μm. The particles are loaded into cartridges with pressurized 1,1,1,2-tetrafluoroethane.
Formulation Example D A pharmaceutical composition for use in a metered dose inhaler is prepared as follows: Representative Procedure: A suspension containing 5 wt% compound of the invention, 0.5 wt% lecithin, and 0.5 wt% trehalose is prepared by dispersing 5 g of active ingredient as micronized particles with mean size less than 10 μm in a colloidal solution formed from 0.5 g of trehalose and 0.5 g of lecithin dissolved in 100 mL of demineralized water. The suspension is spray dried and the resulting material is micronized to particles having a mean diameter less than 1.5 μm. The particles are loaded into canisters with pressurized 1,1,1 ,2-tetrafluoroethane.
Formulation Example E A pharmaceutical composition for use in a nebulizer inhaler is prepared as follows: Representative Procedure: An aqueous aerosol formulation for use in a nebulizer is prepared by dissolving 0.1 mg of the compound of the invention in 1 mL of a 0.9 % sodium chloride solution acidified with citric acid. The mixture is stirred and sonicated until the active ingredient is dissolved. The pH of the solution is adjusted to a value in the range of from 3 to 8 by the slow addition of NaOH.
Formulation Example F Hard gelatin capsules for oral administration are prepared as follows: Ingredients Amount Compound of the invention 250 mg Lactose (spray-dried) 200 mg Magnesium stearate 10 mg
Representative Procedure: The ingredients are thoroughly blended and then loaded into a hard gelatin capsule (460 mg of composition per capsule).
Formulation Example G ispension for oral administration is prepared as follows: Ingredients Amount Compound of the invention 1.0 g Fumaric acid 0.5 g Sodium chloride 2.0 g Methyl paraben 0.15 g Propyl paraben 0.05 g Granulated sugar 25.5 g Sorbitol (70% solution) 12.85 g Veegum k (Nanderbilt Co.) 1.0 g Flavoring 0.035 mL Ingredients Amount Colorings 0.5 mg Distilled water q.s. to 100 mL
Representative Procedure: The ingredients are mixed to form a suspension containing 100 mg of active ingredient per 10 mL of suspension.
Formulation Example H An injectable formulation is prepared as follows: Ingredients Amount Compound of the invention 0.2 g Sodium acetate buffer solution (0.4 M) 2.0 mL HCl (0.5 N) or NaOH (0.5 N) q.s. to pH 4 Water (distilled, sterile) q.s. to 20 mL
Representative Procedure: The above ingredients are blended and the pH is adjusted to 4 ± 0.5 using 0.5 N HCl or 0.5 N NaOH.
Utility The biphenyl compounds of this invention are expected to be useful as muscarinic receptor antagonists and therefore, such compounds are expected to be useful for treating medical conditions mediated by muscarinic receptors, i.e., medical conditions which are ameliorated by treatment with a muscarinic receptor antagonist. Such medical conditions include, by way of example, pulmonary disorders or diseases including those associated with reversible airway obstruction, such as chronic obstructive pulmonary disease (e.g., chronic and wheezy bronchitis and emphysema), asthma, pulmonary fibrosis, allergic rhinitis, rhinorrhea, and the like. Other medical conditions that can be treated with muscarinic receptor antagonists are genitourinary tract disorders, such as overactive bladder or detrusor hyperactivity and their symptoms; gastrointestinal tract disorders, such as irritable bowel syndrome, diverticular disease, achalasia, gastrointestinal hypermotility disorders and diarrhea; cardiac arrhythmias, such as sinus bradycardia; Parkinson's disease; cognitive disorders, such as Alzheimer's disease; dismenorrhea; and the like. In one embodiment, the compounds of this invention are useful for treating smooth muscle disorders in mammals, including humans and their companion animals (e.g., dogs, cats etc.). Such smooth muscle disorders include, by way of illustration, overactive bladder, chronic obstructive pulmonary disease and irritable bowel syndrome. When used to treat smooth muscle disorders or other conditions mediated by muscarinic receptors, the compounds of this invention will typically be administered orally, rectally, parenterally or by inhalation in a single daily dose or in multiple doses per day. The amount of active agent administered per dose or the total amount administered per day will typically be determined by the patient's physician and will depend on such factors as the nature and severity of the patients condition, the condition being treated, the age and general health of the patient, the tolerance of the patient to the active agent, the route of administration and the like. Typically, suitable doses for treating smooth muscle disorders or other disorders mediated by muscarinic receptors will range from about 0.14 μg/kg/day to about 7 mg/kg/day of active agent; including from about 0.15 μg/kg/day to about 5 mg/kg/day. For an average 70 kg human, this would amount to about 10 μg per day to about 500 mg per day of active agent. h a specific embodiment, the compounds of this invention are useful for treating pulmonary or respiratory disorders, such as COPD or asthma, in mammals including humans. When used to treat such disorders, the compounds of this invention will typically be administered by inhalation in multiple doses per day, in a single daily dose or a single weekly dose. Generally, the dose for treating a pulmonary disorder will range from about 10 μg/day to about 200 μg/day. As used herein, COPD includes chronic obstructive bronchitis and emphysema (see, for example, Barnes, Chronic Obstructive Pulmonary Disease, N Engl J Med 343:269-78 (2000)). When used to treat a pulmonary disorder, the compounds of this invention are optionally administered in combination with other therapeutic agents such as a β2- adrenoreceptor agonist; a corticosteroid, a non-steroidal anti-inflammatory agent, or combinations thereof. When administered by inhalation, the compounds of this invention typically have the effect of producing bronchodilation. Accordingly, in another of its method aspects, this invention is directed to a method of producing bronchodilation in a patient, the method comprising administering to a patient a bronchodilation-producing amount of a compound of the invention. Generally, the therapeutically effective dose for producing bronchodilation will range from about 10 μg/day to about 200 μg/day. hi another embodiment, the compounds of this invention are used to treat overactive bladder. When used to treat overactive bladder, the compoxmds of this invention will typically be administered orally in a single daily dose or in multiple doses per day; preferably in a single daily dose. Preferably, the dose for treating overactive bladder will range from about 1.0 to about 500 mg/day. In yet another embodiment, the compounds of this invention are used to treat irritable bowel syndrome. When used to treat irritable bowel syndrome, the compounds of this invention will typically be administered orally or rectally in a single daily dose or in multiple doses per day. Preferably, the dose for treating irritable bowel syndrome will range from about 1.0 to about 500 mg/day. Since compounds of this invention are muscarinic receptor antagonists, such compounds are also useful as research tools for investigating or studying biological systems or samples having muscarinic receptors. Such biological systems or samples may comprise Mi, M2, M3, and/or M5 muscarinic receptors. Any suitable biological system or sample having muscarinic receptors may be employed in such studies which may be conducted either in vitro or in vivo. Representative biological systems or samples suitable for such studies include, but are not limited to, cells, cellular extracts, plasma membranes, tissue samples, mammals (such as mice, rats, guinea pigs, rabbits, dogs, pigs, etc.), and the like. In this embodiment, a biological system or sample comprising a muscarinic receptor is contacted with a muscarinic receptor-antagonizing amount of a compound of this invention. The effects of antagonizing the muscarinic receptor are then determined using conventional procedures and equipment, such as radioligand binding assays and functional assays. Such functional assays include ligand-mediated changes in intracellular cyclic adenosine monophosphate (cAMP), ligand-mediated changes in activity of the enzyme adenylyl cyclase (which synthesizes cAMP), ligand-mediated changes in incorporation of guanosine 5'-O-(γ-thio)triphosphate ([35S]GTPγS) into isolated membranes via receptor catalyzed exchange of [35S]GTPγS for GDP, ligand-mediated changes in free intracellular calcium ions (measured, for example, with a fluorescence- linked imaging plate reader or FLIPR® from Molecular Devices, h e). A compound of this invention will antagonize or decrease the activation of muscarinic receptors in any of the functional assays listed above, or assays of a similar nature. A muscarinic receptor- antagonizing amount of a compound of this invention will typically range from about 0.1 nanomolar to about 100 nanomolar. Additionally, the compounds of this invention can be used as research tools for discovering new compounds that have muscarinic receptor antagonist activity, h this embodiment, muscarinic receptor binding data (e.g., as determined by in vitro radioligand displacement assays) for a test compound or a group of test compounds is compared to the muscarinic receptor binding data for a compound of this invention to identify those test compoxmds that have about equal or superior muscarinic receptor binding, if any. This aspect of the invention includes, as separate embodiments, both the generation of comparison data (using the appropriate assays) and the analysis of the test data to identify test compounds of interest. In another embodiment, the compounds of this invention are used to antagonize a muscarinic receptor in biological system, and a mammal in particular, such as mice, rats, guinea pigs, rabbits, dogs, pigs, humans and so forth, hi this embodiment, a therapeutically effective amount of the compound of formula I is administered to the mammal. The effects of antagonizing the muscarinic receptor can then determined using conventional procedures and equipment, examples of which are described above. Among other properties, compounds of this invention have been found to be potent inhibitors of M muscarinic receptor activity. Accordingly, in a specific embodiment, this invention is directed to compounds of formula I having an inhibition dissociation constant (Kj) for the M receptor subtype of less than or equal to 10 nM; preferably, less than or equal to 5 nM; (as determined, for example, by an in vitro radioligand displacement assay). Additionally, compounds of this invention are expected to possess a desirable duration of action. Accordingly, in another specific embodiment, this invention is directed to compounds of formula I having a duration of action greater than or equal to about 24 hours. Moreover, compounds of this invention are also expected to possess reduced side effects, such as dry mouth, at efficacious doses when administered by inhalation compared to other known muscarinic receptor antagonists administered by inhalation (such as tiotropium). These properties, as well as the utility of the compounds of this invention, can be demonstrated using various in vitro and in vivo assays well-known to those skilled in the art. For example, representative assays are described in further detail in the following Examples. EXAMPLES The following Preparations and Examples illustrate specific embodiments of this invention. In these examples, the following abbreviations have the following meanings: AC adenylyl cyclase ACh acetylcholine ACN acetonitrile BSA bovine serum albumin cAMP 3 '-5' cyclic adenosine monophosphate CHO Chinese hamster ovary cM5 cloned chimpanzee M5 receptor DCM dichloromethane (i.e., methylene chloride) DIPEA NN-diisopropylethylamine dPBS Dulbecco 's phosphate buffered saline DMSO dimethyl sulfoxide EDTA ethylenediaminetetraacetic acid EtOAc ethyl acetate EtOH ethanol FBS fetal bovine serum FLIPR fluorometric imaging plate reader HATU O-(7-azabenzotriazol-l-yl-NNN',N'-tetramethyluronium hexafluorophosphate HEPES 4-(2-hydroxyethyl)-l-piperazineethanesulfonic acid HOBT 1-hydroxybenzotriazole hydrate hMi cloned human Mi receptor hM cloned human M2 receptor hM3 cloned human M receptor hM4 cloned human M4 receptor hM5 cloned human M5 receptor HPLC high-performance liquid chromatography MCh methylcholine MeOH methanol TFA trifluoroacetic acid Any other abbreviations used herein but not defined have their standard, generally accepted meaning. Unless noted otherwise, all materials, such as reagents, starting materials and solvents, were purchased from commercial suppliers (such as Aldrich, Fluka, Sigma and the like) and were used without further purification. Unless otherwise indicated, HPLC analysis was conducted using an Agilent (Palo
Alto, CA) Series 1100 instrument equipped with a Zorbax Bonus RP 2.1 x 50 mm column (Agilent) having a 3.5 micron particle size. Detection was by UV absorbance at 214 nm. The mobile phases employed were as follows (by volume): A is ACN (2%), water (98%) and TFA (0.1%); and B is ACN (90%), water (10%) and TFA (0.1%). HPLC 10-70 data was obtained using a flow rate of 0.5 mL/minute of 10 to 70% B over a 6 minute gradient (with the remainder being A). Similarly, HPLC 5-35 data and HPLC 10-90 data were obtained using 5 to 35% B; or 10 to 90% B over a 5 minute gradient. Liquid chromatography mass spectrometry (LCMS) data were obtained with an Applied Biosystems (Foster City, CA) Model API-150EX instrument. LCMS 10-90 data was obtained using 10 to 90% Mobile Phase B over a 5 minute gradient. Small-scale purification was conducted using an API 150EX Prep Workstation system from Applied Biosystems. The mobile phases employed were as follows (by volume): A is water and 0.05% TFA; and B is ACN and 0.05% TFA. For arrays (typically about 3 to 50 mg recovered sample size) the following conditions were used: 20 mL/min flow rate; 15 min gradients and a 20 mm x 50 mm Prism RP column with 5 micron particles (Thermo Hypersil-Keystone, Bellefonte, PA). For larger scale purifications (typically greater than 100 mg crude sample), the following conditions were used: 60 mL/min flow rate; 30 min gradients and a 41.4 mm x 250 mm Microsorb BDS column with 10 micron particles (Varian, Palo Alto, CA).
Preparation 1 Biphenyl-2-ylcarbamic Acid Piperidin-4-yl Ester Biphenyl-2-isocyanate (97.5 g, 521 mmol) and 4-hydroxy-N-benzylpiperidine (105 g, 549 mmol) were heated together at 70°C for 12 hours. The reaction mixture was then cooled to 50°C and EtOH (1 L) was added and then 6M HCl (191 mL) was added slowly. The resulting mixture was then cooled to ambient temperature and ammonium formate (98.5 g, 1.56 mol) was added and then nitrogen gas was bubbled through the solution vigorously for 20 minutes. Palladium on activated carbon (20 g, 10 wt% dry basis) was then added and the reaction mixture was heated at 40°C for 12 hours, and then filtered through a pad of Celite. The solvent was then removed under reduced pressure and IM HCl (40 mL) was added to the crude residue. The pH of the mixture was then adjusted with IO N NaOH to pH 12. The aqueous layer was extracted with EtOAc (2 x 150 mL) and the organic layer was dried (magnesium sulfate), filtered and the solvent removed under reduced pressure to give 155 g of the title intermediate (100% yield). HPLC (10-70) Rt = 2.52; m/z [M + H+] calcd for Cι8H20N2O2, 297.15; found, 297.3.
Preparation 2 N-Benzyl-N-methylaminoacetaldehyde To a 3-necked 2-L flask was added N-benzyl-N-methylethanolamine (30.5 g, 0.182 mol), DCM (0.5 L), DIPEA (95 mL, 0.546 mol) and DMSO (41 mL, 0.728 mol). Using an ice bath, the mixture was cooled to about -10°C and sulfur trioxide pyridine- complex (87 g, 0.546 mol) was added in 4 portions over 5 minute intervals. The reaction was stirred at -10°C for 2 hours. Before removing the ice-bath, the reaction was quenched by adding water (0.5 L). The aqueous layer was separated and the organic layer was washed with water (0.5 L) and brine (0.5 L) and then dried over magnesium sulfate and filtered to provide the title compound which was used without further purification. Preparation 3 BiphenyI-2-yIcarbamic Acid l-[2-(Benzylmethylamino)ethyI]piperidin-4-yl Ester To a 2-L flask, containing the product of Preparation 2 in DCM (0.5 L) was added the product of Preparation 1 (30 g, 0.101 mol) followed by sodium triacetoxyborohydride (45 g, 0.202 mol). The reaction mixture was stirred overnight and then quenched by the addition of 1 Ν HCl (0.5 L) with vigorous stirring. Three layers were observed and the aqueous layer was removed. After washing with IN ΝaOH (0.5 L), a homogenous organic layer was obtained which was then washed with a saturated solution of aqueous ΝaCl (0.5 L), dried over magnesium sulfate, filtered and the solvent removed under reduced pressure. The residue was purified by dissolving it in a minimal amount of isopropanol and cooling this solution to 0°C to form a solid which was collected and washed with cool isopropanol to provide 42.6 g of the title compound (95% yield). MS m/z: [M + H+] calcd for C28H33Ν3O2, 444.3; found, 444.6. Rf = 3.51 min (10-70 ACN: H2O, reverse phase HPLC). Preparation 4 BiphenyI-2-yIcarbamic Acid l-(2-Methylaminoethyl)piperidin-4-yI Ester To a Parr hydrogenation flask was added the product of Preparation 3 (40 g, 0.09 mol) and EtOH (0.5 L). The flask was flushed with nitrogen gas and palladium on activated carbon (15g, 10 wt% (dry basis), 37% wt/wt) was added along with acetic acid (20 mL). The mixture was kept on the Parr hydrogenator under a hydrogen atmosphere (-50 psi) for 3 hours. The mixture was then filtered and washed with EtOH. The filtrate was condensed and the residue was dissolved in a minimal amount of DCM. Isopropyl acetate (10 volumes) was added slowly to form a solid which was collected to provide 22.0 g of the title compound (70% yield). MS m/z [M + H+] calcd for C2ιH27N3O2, 354.2; found, 354.3. Rf = 2.96 min (10-70 ACN: H2O, reverse phase HPLC).
Preparation 5 Biphenyl-2-ylcarbamic Acid l-{2~[(4-Formylbenzoyl) methyIammo]ethyI}piperidin-4-yI Ester To a three-necked 1-L flask was added 4-carboxybenzaldehyde (4.77 g, 31.8 mmol), EDC (6.64 g, 34.7 mmol), HOBT (1.91 g, 31.8 mmol), and DCM (200 mL). When the mixture was homogenous, a solution of the product of Preparation 4 (10 g, 31.8 mmol) in DCM (100 mL) was added slowly. The reaction mixture was stfrred at room temperature for 16 hours and then washed with water (1 x 100 mL), IN HCl (5 x 60 mL), IN NaOH (1 x 100 mL) brine (1 x 50mL), dried over sodium sulfate, filtered and concentrated to afford 12.6 g of the title compoxmd (92% yield; 85% purity based on HPLC). MS m/z: [M + H+] calcd for C29H3ιN3O4, 486.2; found, 486.4. R 3.12 min (10- 70 ACN: H2O, reverse phase HPLC).
Example 1 Biphenyl-2-ylcarbamic Acid l-[2-({4-[(4-Hydroxybenzylamino)methyl] benzoyI}methylamino)ethyI]piperidin-4-yI Ester
Figure imgf000048_0001
To a stirred solution of the product of Preparation 5 (400 mg, 0.82 mmol) in a 1:1 solution of DCM/MeOH (10 mL) was added 4-hydroxybenzylamine hydrobromide (187 mg of free base, 1.24 mmol), titanium isopropoxide (366 μL, 1.24 mmol), and sodium triacetoxyborohydride (275 mg, 1.24 mmol). The mixture was stirred for 2 days and then the solvent was removed under reduced pressure. A 1 :1 solution of acetic acid and water (8.0 mL) was added to the reaction mixture. The mixture was chromatographed on reverse-phase HPLC (gradient elution, 10-50% ACN/H2O) to afford 370 mg of the title compound (55 % yield) as a bis(trifluoroacetate) salt. MS m/z [M + H+] calcd for C36H40N4O4, 593.3; found, 593.5. R = 3.57 min (10-70 ACN: H2O, reverse phase HPLC). Example 2 Biphenyl-2-yIcarbamic Acid l-{2~[(4-{[2-(4-Hydroxyphenyl)ethylamino] methyI}benzoyl)methylamino] ethyl}piperidin-4-yl Ester
Figure imgf000049_0001
Using the procedure of Example 1 and substituting tyramine in place of 4-hydroxybenzylamine, 350 mg of the title compound (51 % yield) were prepared as a bis(trifluoroacetate) salt. MS m/z [M + H+] calcd for C37H4 N4O4, 607.3; found, 607.5. R/ = 3.60 (10-70 ACN: H2O, reverse phase HPLC).
Preparation 6 BiphenyI-2-yIcarbamic Acid l-(2-Aminoethyl)piperidin-4-yl Ester A mixture of the product of Preparation 1 (5g, 16.95mmol), 2-(tert-butoxy- carbonylamino)ethyl bromide (4.18g, 18.64 mmol) and DIPEA (8.84 mL, 50.85 mmol) in 100 mL of ACN was stirred at 50°C overnight. The reaction mixture was cooled to room temperature and then concentrated. The residue was dissolved in 100 L of DCM and washed with a 1 : 1 solution of brine and IN HCl (100 mL). The organic layer was dried over magnesium sulfate, filtered and concentrated and the residue was then treated with 100 mL of 20% TFA in DCM at room temperature for 3 h. The solvent and TFA were removed under reduced pressure. The residue was taken up in 100 mL of DCM and washed with 100 mL of IN NaOH. The organic layer was dried over magnesium sulfate, filtered and concentrated to provide 4.66 g of the title intermediate (86% yield), which was used without further purification.
Preparation 7 Biphenyl-2-ylcarbamic Acid l-{2-[(4-FormyIbenzoyl)amino]ethyl}piperidin-4-yl Ester A mixture of 4-carboxybenzaldehyde (0.95 g, 6.35 mmol) and HATU (3.02 g, 7.94 mmol) in 55 mL of DCM was stirred at room temperature for 1 h and then the product of Preparation 6 (3g, 5.29 mmol) and DIPEA (4.6 mL, 26.45 mmol) were added. The resulting mixture was stύred at room temperature for 2 h and then diluted with 100 mL of DCM and washed with saturated sodium bicarbonate (150 mL) and brine (150 mL). The organic layer was dried over magnesium sulfate, filtered and concentrated to provide 2.3 g of the title intermediate (92% yield), which was used without further purification.
Example 3 Biphenyl-2-ylcarbamic Acid l-(2-{4-[(4-HydroxybenzyIamino) methyI]benzoyIamino}etIιyl)piperidin-4-yI Ester
Figure imgf000050_0001
The title compoxmd was made by adding 4-hydroxybenzylamine hydrobromide salt to a solution of the product of Preparation 7 (500 mg, 1.06 mmol) in 10 mL of MeOH. The solution was stirred at room temperature for 30 minutes and then sodium triacetoxyborohydride (674 mg, 3.18 mmol) was added. This mixture was stirred for 2 h at room temperature and then the solvent was removed in vacuo. The residue was dissolved in a 1 : 1 solution of acetic acid and water (8 mL) and purified on reverse phase HPLC to yield 509 mg of Compound 3-1 (60% yield) as a bis(trifluoroacetate) salt. MS m/z: [M + H+] calcd for C35H38N4O4, 579.3; found, 579.3. Example 4 Biphenyl-2-ylcarbamic Acid l-[2-(4-{[2-(4-Hydroxyphenyl) ethylamino]methyl}benzoylamino)ethyl]piperidin-4-yl Ester
Figure imgf000051_0001
Following the procedure described in Example 3, but substituting tyramine
(218 mg, 1.59 mmol) in place of 4-hydroxybenzylamine hydrobromide salt, 517 mg of the title compound (59.4% yield) was prepared as a bis(trifluoroacetate) salt. MS m/z: [M + H+] calcd for C36H40N4O4, 593.3; found, 593.5. Example 5 Biphenyl-2-ylcarbamic Acid l-[2-(4-{[(4-Hydroxybenzyl) methylamino] methyl}benzoylamino)ethyl]piperidin-4-yl Ester
Figure imgf000051_0002
To a solution of the product of Example 3 (50 mg, 0.06 mmol) in 1 mL of MeOH was added zinc chloride (4 mg, 0.03 mmol) followed by formaldehyde (37% aqueous solution, 25 μL, 0.3 mmol). The solution was stirred at room temperature for 20 min and then sodium cyanoborohydride (4 mg, 0.06 mmol) was added. The resulting mixture was stirred at room temperature for 2 h and then the solvent was removed in vacuo. The crude product was purified by reverse phase HPLC to obtain 34 mg of the title compound (69% yield) as a bis(trifluoroacetate) salt. MS m/z [M + H "] calcd for C36H40N4O4, 593.3; found, 593.7. Example 6 Biphenyl-2-ylcarbamic Acid l-{2-[4-({[2-(4-Hydroχyphenyl)ethyl] methylamino}methyl)benzoylamino]ethyl}piperidin-4-yl Ester
Figure imgf000052_0001
Using the procedure of Example 5, but substituting the product of Example 4 in place of the product of Example 3, 25 mg of the title compound (50% yield) was prepared as a bis(trifluoroacetate) salt. MS m/z: [M + H+] calcd for C37H42N4O4, 607.3; foxmd, 607.7.
Example 7
Figure imgf000052_0002
Compoxmds having various R and R5 groups were synthesized as follows.
Figure imgf000052_0003
Compound 7-1 was made by using the procedure described in Example 3, but substituting tyramine in place of 4-hydroxybenzylamine hydrobromide salt and 2-fluoro-4- formylbenzoic acid in place of 4-carboxybenzaldehyde. MS m/z [M + ϊ ] calcd for C36H39FN4O4, 610.7; foxmd, 611.2. Compoxmd 7-2 was made by using the procedure of Example 1 and substituting tyramine in place of 4-hydroxybenzylamine and 2-fluoro-4-formylbenzoic acid in place of 4-carboxybenzaldehyde. MS m/z [M + H+] calcd for C37H4ιFN4O4, 624.8; found, 625.2. 2-Fluoro-4-formylbenzoic acid was prepared as follows: A stirred solution of 2-fluoro-4- formylbenzoic acid (2.5 g, 15.2 mmol) in DCM (100 mL) was cooled to -78°C and to this was added dropwise DIBAL (30 mL, 45.4 mmol, 25% in toluene), using caution due to H2 evolution. This was allowed to stir at -78 °C for 4 hours. The reaction was quenched via addition of MeOH (10 mL), using caution due to H2 evolution. The organic layer was then washed with IN HCl (100 mL), water (100 mL), NaCl (sat.) (100 mL), dried over MgSO4 and then filtered. The solvent removed under reduced pressure. The crude material was sufficiently pure to use without further purification. 2-Fluoro-4-formylbenzoic acid was obtained in 78% yield (2.0 g, 11.9 mmol). Compound 7-3 was made using the procedures described herein and substituting tyramine in place of 4-hydroxybenzylamine. MS m/z [M + H+] calcd for C37ϊ_42N4O5, 622.8; found, 623.2. Compound 7-4 was made using the procedures described herein and substituting tyramine in place of 4-hydroxybenzylamine. MS m/z [M + H+] calcd for C38H-t N4Os, 636.8; found, 637.2.
Example 8
Figure imgf000053_0001
Compounds having various R4 and Ar1 groups were synthesized as follows.
Figure imgf000053_0002
Figure imgf000054_0001
Compound 8-1 was made by using the procedure of Example 1 and substituting tyramine in place of 4-hydroxybenzylamine and 5-formylthiophene-2-carboxylic acid in place of 4-carboxybenzaldehyde. MS m/z [M + ϊ ] calcd for C35H40N4O4S, 612.8; found, 613.2. Compound 8-2 was made by using the procedure described in Example 3, but substituting tyramine in place of 4-hydroxybenzylamine hydrobromide salt, and 5- formylthiophene-2-carboxylic acid in place of 4-carboxybenzaldehyde. MS m/z [M + H calcd for C34H38N4O4S, 598.8; found, 599.2. Compound 8-3 was made by using the procedure of Example 1 and substituting tyramine in place of 4-hydroxybenzylamine and 5-formylfuran-2-carboxylic acid in place of 4-carboxybenzaldehyde. MS m/z [M + ϊt] calcd for C35H40N4O5, 596.7; found, 597.2. Compound 8-4 was made by using the procedure described in Example 3, but substituting tyramine in place of 4-hydroxybenzylamine hydrobromide salt, and 5- fonnylfuran-2-carboxylic acid in place of 4-carboxybenzaldehyde. MS m/z [M + ϊ '] calcd for C34H38N4O5, 582.7; found, 583.2. Compound 8-5 was made by using the procedure of Example 1 and substituting tyramine in place of 4-hydroxybenzylamine and 5-formylpyridine-2-carboxylic acid in place of 4-carboxybenzaldehyde. MS m/z [M + H+] calcd for C 6H4ιN5O4, 607.8; foxmd, 608.4. Compound 8-6 was made by using the procedure of Example 1 and substituting tyramine in place of 4-hydroxybenzylamine and 5-formylpyrrole-2-carboxylic acid in place of 4-carboxybenzaldehyde. MS m/z [M + Ε ] calcd for C35H4ιN5O4, 595.7; found, 596.2. The preparation of 5-formylpyrrole-2-carboxylic acid was done according to Org. Biomol. Chem. 1(12);2103-2110 (2003). Example 9
Figure imgf000055_0001
Compounds having various R4 and Ar1 groups were synthesized as follows.
Figure imgf000055_0002
Compound 9-1 was made by using the procedure of Example 1, but substituting 5- formylthiophene-2-carboxylic acid in place of 4-carboxybenzaldehyde. MS m/z [M + H+] calcd for C3 H38N4O4S, 598.8; found, 599.2. Compound 9-2 was made by using the procedure described in Example 3, but substituting 5-formylthiophene-2-carboxylic acid in place of 4-carboxybenzaldehyde. MS m/z [M + H1"] calcd for C33H36N4O4S, 584.7; found, 585.2. Compound 9-3 was made by using the procedure described in Example 3, but substituting 5-formylpyrrole-2-carboxylic acid in place of 4-carboxybenzaldehyde. MS m/z [M + H+] calcd for C34H39N5O4, 581.7; found, 582.2. Compound 9-4 was made by using the procedure of Example 1 and substituting 5- formylfuran-2-carboxylic acid in place of 4-carboxybenzaldehyde. MS m/z [M + H ] calcd for C34H38N4O5, 582.7; found, 583.2. Compound 9-5 was made by using the procedure described in Example 3, and substituting 5-formylfuran-2-carboxylic acid in place of 4-carboxybenzaldehyde. MS m/z [M + H+] calcd for C33H36N4O5, 568.7; found, 569.2.
Example 10 Biphenyl-2-ylcarbamic Acid l-{2-[2-(4-{[2-(4-hydroxyphenyl) ethylamino] methyl}phenyl)acetylamino] ethyl}piperidin-4-yl Ester
Figure imgf000056_0001
The title compound was made by using the procedure described in Example 3, but substituting tyramine in place of 4-hydroxybenzylamine hydrobromide salt and by substituting (4-formylphenyl)acetic acid in place of 4-carboxybenzaldehyde. MS m/z [M + H+] calcd for C37H42N4O4, 606.3; found, 600.8. The preparation of (4-formylρhenyl)acetic acid was as follows: 4-formylphenyl)- acetic acid methyl ester was prepared as described in Chem. Commun. 7:669-670 (2001). To a solution of (4-formylphenyl)acetic acid methyl ester (2.76 g, 14.4 mmol) in 40 mL of MeOH was added IN NaOH (30 ml). The solution was stirred at room temperature for 16 hours and then the MeOH was removed in vacuo. The aqueous layer was then washed with EtOAc (40 mL), followed by wash with DCM (40 mL). The aqueous layer was then acidified to pH=l using IN HCl. The product was extracted using DCM washes (3 X 50 mL) and the organic layer washed with water (100 L), NaCl (sat.) (100 mL), dried over MgSO4 and then filtered. The solvent removed under reduced pressure. The crude material was sufficiently pure to use without further purification. 4-formylphenyl)acetic acid was obtained in 78% yield (2.0 g, 11.2 mmol).
Example 11 Biphenyl-2-ylcarbamic Acid l-{2-[3-(4-{[2-(4-hydroxyphenyl) ethyIammo]methyl}phenyl)propionylammo]ethyl}piperidm-4-yl Ester
Figure imgf000056_0002
The title compound was made by using the procedure described in Example 3, but substitμting tyramine in place of 4-hydroxybenzylamine hydrobromide salt and by substituting 3-(4-formyl-phenyl)-propionic acid in place of 4-carboxybenzaldehyde. MS m/z [M + H+] calcd for C38E_44N4O4, 620.34; found, 620.8. The preparation of 3-(4- formylphenyl)propionic acid was done according to Tetrahedron 52(20^:6913-6930 (2001).
Example 12 Biphenyl-2-ylcarbamic Acid l-[2-({4-[(3-hydroxybenzylamino) methyl]benzoyl}methylamino)ethyl]piperidin-4-yl Ester
Figure imgf000057_0001
The title compound was made by using the procedure of Example 1 and substituting 3-hydroxybenzylamine in place of 4-hydroxybenzylamine. MS m/z [M + ϊ ] calcd for C36H40N4O4, 592.7; found, 593.4.
Example 13 - Biphenyl-2-yl-carbamic acid l-[2-(3-{4-[(4-hydroxybenzylamino) ; methyl]phenyl}propionylamino)ethyl]piperidin-4-yl ester. MS m/z [M + H4] calcd for C37H42N4O4, 607.3; found, 606.8. Example 14 - Biphenyl-2-yl-carbamic acid l-{2-[(3-{4-[(4-hydroxybenzylamino) methyl]phenyl}propionyl)methylamino]ethyl}-piperidin-4-yl ester. MS m/z: [M + H+] calcd for C38H44N4O4, 621.4; found, 620.8. Example 15 - Biphenyl-2-yl-carbamic acid l-{2-[(3-{4-[(3-hydroxybenzylamino) methyl]phenyl}propionyl)methylamino] ethyl} -piperidin-4-yl ester. MS m/z: [M + H ] calcd for C38H44N4O4, 621.4; found, 620.8.
Assay 1 Radioligand Binding Assay A. Membrane Preparation from Cells Expressing liMu hM?, hM3 and hM Muscarinic Receptor Subtypes CHO cell lines stably expressing cloned human hMi, hM2, hM3 and I1M4 muscarinic receptor subtypes, respectively, were grown to near confluency in medium consisting of HAM's F-12 supplemented with 10% FBS and 250 μg/mL Geneticin. The cells were grown in a 5% CO2, 37°C incubator and lifted with 2 mM EDTA in dPBS. Cells were collected by 5 minute centrifugation at 650 x g, and cell pellets were either stored frozen at -80°C or membranes were prepared immediately. For membrane preparation, cell pellets were resuspended in lysis buffer and homogenized with a Polytron PT-2100 tissue disrupter (Kinematica AG; 20 seconds x 2 bursts). Crude membranes were centrifuged at 40,000 x g for 15 minutes at 4°C. The membrane pellet was then resuspended with resuspension buffer and homogenized again with the Polytron tissue disrupter. The protein concentration of the membrane suspension was determined by the method described in Lowry, O. et al., Journal of Biochemistry 193:265 (1951). All membranes were stored frozen in aliquots at -80°C or used immediately. Aliquots of prepared I1M5 receptor membranes were purchased directly from Perkin Elmer and stored at -80°C until use.
B. Radioligand Binding Assay on Muscarinic Receptor Subtypes M hM2. hM3, hM and hMg Radioligand binding assays were performed in 96-well microtiter plates in a total assay volume of 100 μL. CHO cell membranes stably expressing either the hMi, hM2, hM3, hM4 or hM5 muscarinic subtype were diluted in assay buffer to the following specific target protein concentrations (μg/well): 10 μg for hMi, 10-15 μg for hM2, 10-20 μg for hM3, 10-20 μg for hM4, and 10-12 μg for I1M5. The membranes were briefly homogenized using a Polytron tissue disruptor (10 seconds) prior to assay plate addition. Saturation binding studies for determining Kp values of the radioligand were performed using L-[N- methyl-3H]scopolamine methyl chloride ([3H]-ΝMS) (TRK666, 84.0 Ci/mmol, Amersham Pharmacia Biotech, Buckinghamshire, England) at concentrations ranging from 0.001 nM to 20 nM. Displacement assays for determination of K,- values of test compounds were performed with [3H]-NMS at 1 nM and eleven different test compound concentrations.
The test compounds were initially dissolved to a concentration of 400 μM in dilution buffer and then serially diluted 5x with dilution buffer to final concentrations ranging from 10 pM to 100 μM. The addition order and volumes to the assay plates were as follows: 25 μL radioligand, 25 μL diluted test compound, and 50 μL membranes. Assay plates were incubated for 60 minutes at 37°C. Binding reactions were terminated by rapid filtration over GF/B glass fiber filter plates (PerkinElmer Inc., Wellesley, MA) pre-treated in 1% BSA. Filter plates were rinsed three times with wash buffer (10 mM HEPES) to remove unbound radioactivity. Plates were then air dried, and 50 μL Microscint-20 liquid scintillation fluid (PerkinElmer Inc., Wellesley, MA) was added to each well. The plates were then counted in a PerkinElmer Topcount liquid scintillation counter (PerkinElmer Inc., Wellesley, MA). Binding data were analyzed by nonlinear regression analysis with the GraphPad Prism Software package (GraphPad Software, Inc., San Diego, CA) using the one-site competition model. K, values for test compounds were calculated from observed IC50 values and the Kχ> value of the radioligand using the Cheng-Prusoff equation (Cheng Y; Prusoff W. H. Biochemical Pharmacology 22(23 :3099-108 (1973)). K values were converted to pK, values to determine the geometric mean and 95% confidence intervals. These summary statistics were then converted back to Kj values for data reporting. In this assay, a lower K,- value indicates that the test compound has a higher binding affinity for the receptor tested. Exemplary compounds of the invention that were tested in this assay, typically were found to have a K, value of less than about 10 nM for the M3 muscarinic receptor subtype in this assay, with some compounds tested having a K, value of less than about 5 nM.
Assay 2 Muscarinic Receptor Functional Potency Assays A. Blockade of Agonist-Mediated Inhibition of cAMP Accumulation In this assay, the functional potency of a test compound is determined by measuring the ability of the test compound to block oxotremorine-inhibition of forskolin-mediated cAMP accumulation in CHO-K1 cells expressing the I1M2 receptor. cAMP assays are performed in a radioimmunoassay format using the Flashplate Adenylyl Cyclase Activation Assay System with 125I-cAMP (NEN SMP004B, PerkinElmer Life Sciences Inc., Boston, MA), according to the manufacturer's instructions. Cells are rinsed once with dPBS and lifted with Trypsin-EDTA solution (0.05% trypsin/0.53 mM EDTA) as described in the Cell Culture and Membrane Preparation section above. The detached cells are washed twice by centrifugation at 650 x g for five minutes in 50mLs dPBS. The cell pellet is then re-suspended in 10 mL dPBS, and the cells counted with a Coulter Zl Dual Particle Counter (Beckman Coulter, Fullerton, CA). The cells are centrifuged again at 650 x g for five minutes and re-suspended in stimulation buffer to an assay concentration of 1.6 x 106 - 2.8 x 106 cells/mL. The test compound is initially dissolved to a concentration of 400 μM in dilution buffer (dPBS supplemented with 1 mg/mL BSA (0.1%)), and then serially diluted with dilution buffer to final molar concentrations ranging from 100 μM to 0.1 nM. Oxotremorine is diluted in a similar manner. To measure oxotremorine inhibition of AC activity, 25 μL forskolin (25 μM final concentration diluted in dPBS), 25 μL diluted oxotremorine, and 50 μL cells are added to agonist assay wells. To measure the ability of a test compound to block oxofremorine- inhibited AC activity, 25 μL forskolin and oxotremorine (25 μM and 5 μM final concentrations, respectively, diluted in dPBS), 25 μL diluted test compound, and 50 μL cells are added to remaining assay wells. Reactions are incubated for 10 minutes at 37°C and stopped by addition of 100 μL ice-cold detection buffer. Plates are sealed, incubated overnight at room temperature and counted the next morning on a PerkinElmer TopCount liquid scintillation counter (PerkinElmer Inc., Wellesley, MA). The amoxmt of cAMP produced (pmol well) is calculated based on the counts observed for the samples and cAMP standards, as described in the manufacturer's user manual. Data are analyzed by nonlinear regression analysis with the GraphPad Prism Software package (GraphPad Software, Inc., San Diego, CA) using the non-linear regression, one-site competition equation. The Cheng-Prusoff equation is used to calculate the Kj, using the EC50 of the oxotremorine concentration- response curve and the oxotremorine assay concentration as the KD and [L], respectively. The Kj values are converted to pK; values to determine the geometric mean and 95%> confidence intervals. These summary statistics are then converted back to K values for data reporting. In this assay, a lower K; value indicates that the test compound has a higher functional activity at the receptor tested. The compounds of the invention are expected to have a Kj value of less than about 10 nM for blockade of oxotremorine-inhibition of forskolin-mediated cAMP accumulation in CHO-K1 cells expressing the hM2 receptor.
B. Blockade of Agonist-Mediated T35S1GTPγS Binding In tins assay, the fxmctional potency of a test compound is determined by measuring the ability of the compounds to block oxotremorine-stimulated [35S]GTPγS-binding in CHO-K1 cells expressing the I1M2 receptor. At the time of use, frozen membranes are thawed and then diluted in assay buffer with a final target tissue concentration of 5-10 μg protein per well. The membranes are briefly homogenized using a Polytron PT-2100 tissue disrupter and then added to the assay plates. The EC90 value (effective concentration for 90% maximal response) for stimulation of [35S]GTPγS binding by the agonist oxotremorine is determined in each experiment. To determine the ability of a test compound to inhibit oxotremorine-stimulated [35S]GTPγS binding, the following is added to each well of 96 well plates: 25 μL of assay buffer with [35S]GTPγS (0.4nM), 25 μL of oxotremorine(EC90) and GDP (3 μM), 25 μL of diluted test compound and 25 μL CHO cell membranes expressing the hM2 receptor. The assay plates are then incubated at 37°C for 60 minutes. The assay plates are filtered over 1% BSA-pretreated GF/B filters using a PerkinElmer 96-well harvester. The plates are rinsed with ice-cold wash buffer for 3 x 3 seconds and then air or vacuum dried. Microscint-20 scintillation liquid (50 μL) is added to each well, and each plate is sealed and radioactivity counted on a topcounter (PerkinElmer). Data are analyzed by nonlinear regression analysis with the GraphPad Prism Software package (GraphPad Software, Inc., San Diego, CA) using the non-linear regression, one-site competition equation. The Cheng-Prusoff equation is used to calculate the Kj, using the IC5o values of the concentration-response curve for the test compound and the oxotremorine concentration in the assay as the KD and [L], ligand concentration, respectively. In this assay, a lower K; value indicates that the test compoxmd has a higher functional activity at the receptor tested. The compounds of the invention are expected to have a K; value of less than about 10 nM for blockade of oxotremorine-stimulated [35S]GTPγS binding in CHO-K1 cells expressing the hM2 receptor. C. Blockade of Agonist-Mediated Calcium Release via FLIPR Assays Muscarinic receptor subtypes (Mi, M and M5 receptors), which couple to Gq proteins, activate the phosphohpase C (PLC) pathway upon agonist binding to the receptor. As a result, activated PLC hydrolyzes phosphatyl inositol diphosphate (PIP2) to diacylglycerol (DAG) and phosphatidyl- 1,4,5-triphosphate (IP ), which in turn generates calcium release from intracellular stores, i.e., endoplasmic and sarcoplasmic reticulum. The FLIPR (Molecular Devices, Sunnyvale, CA) assay capitalizes on this increase in intracellular calcium by using a calcium sensitive dye (Fluo-4AM, Molecular Probes, Eugene, OR) that fluoresces when free calcium binds. This fluorescence event is measured in real time by the FLIPR, which detects the change in fluorescence from a monolayer of cells cloned with human Mi and M3, and chimpanzee M5 receptors. Antagonist potency can be determined by the ability of antagonists to inhibit agonist-mediated increases in intracellular calcium. For FLIPR calciu 'stimulation assays, CHO cells stably expressing the hMi, hM3 and cM5 receptors are seeded into 96-well FLIPR plates the night before the assay is done. Seeded cells are washed twice by Cellwash (MTX Labsystems, Lie.) with FLIPR buffer (10 mM HEPES, pH 7.4, 2 mM calcium chloride, 2.5 mM probenecid in HBSS without calcium and magnesium) to remove growth media and leaving 50 μL/well of FLIPR buffer. The cells are then incubated with 50 μL/well of 4 μM FLUO-4AM (a 2X solution was made) for 40 minutes at 37°C, 5% carbon dioxide. Following the dye incubation period, cells are washed two times with FLIPR buffer, leaving a final volume of 50 μL/well. To determine antagonist potency, the dose-dependent stimulation of intracellular Ca2+ release for oxotremorine is first determined so that antagonist potency can later be measured against oxotremorine stimulation at an EC 0 concentration. Cells are first incubated with compound dilution buffer for 20 minutes, followed by agonist addition, which is performed by the FLIPR. An EC90 value for oxotremorine is generated according to the method detailed in the FLIPR measurement and data reduction section below, in conjunction with the formula ECF = ((F/100-F)Λ1/H) * EC50. An oxotremorine concentration of 3 x ECF is prepared in stimulation plates such that an EC90 concenfration of oxotremorine is added to each well in the antagonist inhibition assay plates. The parameters used for the FLIPR are: exposure length of 0.4 seconds, laser strength of 0.5 watts, excitation wavelength of 488 nm, and emission wavelength of 550 nm. Baseline is determined by measuring the change in fluorescence for 10 seconds prior to addition of agonist. Following agonist stimulation, the FLIPR continuously measures the change of fluorescence every 0.5 to 1 second for 1.5 minutes to capture the maximum fluorescence change. The change of fluorescence is expressed as maximum fluorescence minus baseline fluorescence for each well. The raw data is analyzed against the logarithm of drug concentration by nonlinear regression with GraphPad Prism (GraphPad Software, Inc., San Diego, CA) using the built-in model for sigmoidal dose-response. Antagonist Ki values are determined by Prism using the oxotremorine EC50 value as the K# and the oxotremorine EC90 for the ligand concentration according to the Cheng-Prusoff equation (Cheng & Prusoff, 1973). In tins assay, a lower Kj value indicates that the test compound has a higher functional activity at the receptor tested. The compounds of the invention are expected to have a K value of less than about 10 nM for blockade of agonist-mediated calcium release in CHO cells stably expressing the hM3 receptor.
Assay 3 Determination of Duration of Bronchoprotection in Guinea Pig Model of Acetylcholine-Induced Bronchoconstriction This in vivo assay was used to assess the bronchoprotective effects of test compounds exhibiting muscarinic receptor antagonist activity. Groups of six male guinea pigs (Duncan-Hartley (HsdPoc:DH) Harlan, Madison, WI) weighing between 250 and 350 g were individually identified by cage cards. Throughout the study animals were allowed access to food and water ad libitum. Test compounds were administered via inhalation over 10 minutes in a whole-body exposure dosing chamber (R&S Molds, San Carlos, CA). The dosing chambers were arranged so that an aerosol was simultaneously delivered to 6 individual chambers from a central manifold. Guinea pigs were exposed to an aerosol of a test compound or vehicle (WFI). These aerosols were generated from aqueous solutions using an LC Star Nebulizer Set (Model 22F51, PAR! Respiratory Equipment, Inc. Midlothian, VA) driven by a mixture of gases (CO2 = 5%, O2 = 21% and N2 = 74%) at a pressure of 22 psi. The gas flow through the nebulizer at this operating pressure was approximately 3 L/minute. The generated aerosols were driven into the chambers by positive pressure. No dilution air was used during the delivery of aerosolized solutions. During the 10 minute nebulization, approximately 1.8 mL of solution was nebulized. This was measured gravimetrically by comparing pre-and post-nebulization weights of the filled nebulizer. The bronchoprotective effects of test compoxmds administered via inhalation were evaluated using whole body plethysmography at 1.5, 24, 48 and 72 hours post-dose. Forty-five minutes prior to the start of the pulmonary evaluation, each guinea pig was anesthetized with an intramuscular injection of ketamine (43.75 mg kg), xylazine (3.50 mg/kg) and acepromazine (1.05 mg/kg). After the surgical site was shaved and cleaned with 70% alcohol, a 2-3 cm midline incision of the ventral aspect of the neck was made. Then, the jugular vein was isolated and cannulated with a saline-filled polyethylene catheter (PE-50, Becton Dickinson, Sparks, MD) to allow for intravenous infusions of ACh (Sigma-Aldrich, St. Louis, MO) in saline. The trachea was then dissected free and cannulated with a 14G teflon tube (#NE- 014, Small Parts, Miami Lakes, FL). If required, anesthesia was maintained by additional intramuscular injections of the aforementioned anesthetic mixture. The depth of anesthesia was monitored and adjusted if the animal responded to pinching of its paw or if the respiration rate was greater than 100 breaths/minute. Once the cannulations were complete, the animal was placed into a plethysmograph (#PLY3114, Buxco Electronics, hie, Sharon, CT) and an esophageal pressure cannula (PE-160, Becton Dickinson, Sparks, MD) was inserted to measure pulmonary driving pressure (pressure). The teflon tracheal tube was attached to the opening of the plethysmograph to allow the guinea pig to breathe room air from outside the chamber. The chamber was then sealed. A heating lamp was used to maintain body temperature and the guinea pig's lungs were inflated 3 times with 4 mL of air using a 10 mL calibration syringe (#5520 Series, Hans Rudolph, Kansas City, MO) to ensure that the lower airways did not collapse and that the animal did not suffer from hyperventilation. Once it was determined that baseline values were within the range 0.3 - 0.9 mL/cm H2O for compliance and within the range 0.1 - 0 99 cm H2O/mL per second for resistance, the pulmonary evaluation was initiated. A Buxco pulmonary measurement computer progam enabled the collection and derivation of pulmonary values. Starting this program initiated the experimental protocol and data collection. The changes in volume over time that occur within the plethysmograph with each breath were measured via a Buxco pressure transducer. By integrating this signal over time, a measurement of flow was calculated for each breath. This signal, together with the pulmonary driving pressure changes, which were collected using a Sensym pressure transducer (#TRD4100), was connected via a Buxco (MAX 2270) preamplifier to a data collection interface (#'s SFT3400 and SFT3813). All other pulmonary parameters were derived from these two inputs. Baseline values were collected for 5 minutes, after which time the guinea pigs were challenged with ACh. ACh (0.1 mg/mL) was infused intravenously for 1 minute from a syringe pump (sp210iw, World Precision Instruments, fric, Sarasota, FL) at the following doses and prescribed times from the start of the experiment: 1.9 μg/minute at 5 minutes, 3.8 μg/minute at 10 minutes, 7.5 μg/minute at 15 minutes, 15.0 μg/minute at 20 minutes, 30 μg/minute at 25 minutes and 60 μg/minute at 30 minutes. If resistance or compliance had not returned to baseline values at 3 minutes following each ACh dose, the guinea pig's lungs were inflated 3 times with 4 mL of air from a 10 mL calibration syringe. Recorded pulmonary parameters included respiration frequency (breaths/minute), compliance (mL/cm H2O) and pulmonary resistance (cm H2O/ mL per second). Once the pulmonary function measurements were completed at minute 35 of this protocol, the guinea pig was removed from the plethysmograph and euthanized by carbon dioxide asphyxiation. The data were evaluated in one or both of the following ways: (a) Pulmonary resistance (RL, cm H2O/mL per second) was calculated from the ratio of "change in pressure" to "the change in flow." The RL response to ACh (60 μg/min,
IH) was computed for the vehicle and the test compound groups. The mean ACh response in vehicle-treated animals, at each pre-treatment time, was calculated and used to compute % inhibition of ACh response, at the conesponding pre-treatment time, at each test compound dose, hihibition dose-response curves for 'RL' were fitted with a four parameter logistic equation using GraphPad Prism, version 3.00 for Windows (GraphPad Software, San Diego, California) to estimate bronchoprotective ID5o (dose required to inhibit the ACh (60 μg/min) bronchoconstrictor response by 50%). The equation used was as follows: Y = Min + (Max-Min)/(1 + 10 ((Io ID50"X)* Hills,ope)) where X is the logarithm of dose, Y is the response (% Inhibition of ACh induced increase in RL). Y starts at Min and approaches asymptotically to Max with a sigmoidal shape. (b) The quantity PD , which is defined as the amount of ACh or histamine needed to cause a doubling of the baseline pulmonary resistance, was calculated using the pulmonary resistance values derived from the flow and the/>re-?_?-.re over a range of ACh or histamine challenges using the following equation (which is derived from a equation used to calculate PC20 values described in American Thoracic Society. Guidelines for methacholine and exercise challenge testing - 1999. Am JRespir Crit Care Med. 161: 309- 329 (2000)): PD2 = antilog [ log Ci + flog C2. log CI)(2RQ - RQ i R2 - R1 where: Ci = concenfration of ACh or histamine preceding C2 C2 = concentration of ACh or histamine resulting in at least a 2-fold increase in pulmonary resistance (Rj) RQ = Baseline RL value R- = RL value after Cj R2 = RL value after C2 An efficacious dose was defined as a dose that limited the bronchrestriction response to a 50 μg/mL dose of ACh to a doubling of the baseline pulmonary resistance
Statistical analysis of the data was performed using a two-tailed Students t-test. A E-value <0.05 was considered significant. Generally, test compounds having a PD2(50) less than about 200 μg/mL for ACh- induced bronchoconstriction at 1.5 hours post-dose in this assay are preferred. For example, the compound of Example 1 was found to have a PD2(5o> less than about 200 μg/mL for ACh-induced bronchoconstriction at 1.5 hours post-dose. Assay 4 Inhalation Guinea Pig Salivation Assay Guinea pigs (Charles River, Wilmington, MA) weighing 200-350 g were acclimated to the in-house guinea pig colony for at least 3 days following arrival. Test compound or vehicle were dosed via inhalation (IH) over a 10 minute time period in a pie shaped dosing chamber (R&S Molds, San Carlos, CA). Test solutions were dissolved in sterile water and delivered using a nebulizer filled with 5.0 mL of dosing solution. Guinea pigs were restrained in the inhalation chamber for 30 minutes. During this time, guinea pigs were restricted to an area of approximately 110 cm . This space was adequate for the animals to turn freely, reposition themselves, and allow for grooming. Following 20 minutes of acclimation, guinea pigs were exposed to an aerosol generated from a LS Star Nebulizer Set (Model 22F51, PARI Respiratory Equipment, hie. Midlothian, VA) driven by house air at a pressure of 22 psi. Upon completion of nebulization, guinea pigs were evaluated at 1.5, 6, 12, 24, 48, or 72 hrs after treatment. Guinea pigs were anesthetized one hour before testing with an intramuscular (IM) injection of a mixture of ketamine 43.75 mg/kg, xylazine 3.5 mg/kg, and acepromazine 1.05 mg/kg at an 0.88 mL/kg volume. Animals were placed ventral side up on a heated (37°C) blanket at a 20 degree incline with their head in a downward slope. A 4-ply 2 x 2 inch gauze pad (Nu-Gauze General-use sponges, Johnson and Johnson, Arlington, TX) was inserted in the guinea pig's mouth. Five minutes later, the muscarinic agonist pilocarpine (3.0 mg/kg, SC) was administered and the gauze pad was immediately discarded and replaced by a new pre- weighed gauze pad. Saliva was collected for 10 minutes, at which point the gauze pad was weighed and the difference in weight recorded to determine the amount of accumulated saliva (in mg). The mean amount of saliva collected for animals receiving the vehicle and each dose of test compound was calculated. The vehicle group mean was considered to be 100% salivation. Results were calculated using result means (n = 3 or greater). Confidence intervals (95%) were calculated for each dose at each time point using two-way ANOVA. This model is a modified version of the procedure described in Rechter, "Estimation of anticholinergic drug effects in mice by antagonism against pilocarpine-induced salivation" Ata Pharmacol Toxicol 24:243-254 (1996). The mean weight of saliva in vehicle-treated animals, at each pre-treatment time, was calculated and used to compute % inhibition of salivation, at the corresponding pre- treatment time, at each dose. The inhibition dose-response data were fitted to a four parameter logistic equation using GraphPad Prism, version 3.00 for Windows (GraphPad Software, San Diego, California) to estimate anti-sialagogue -D50 (dose required to inhibit 50% of pilocarpine-evoked salivation). The equation used was as follows: Y = Min + (Max-Min)/(1 + 10 ((log ID50'X)* Hillslope) ) where X is the logarithm of dose, Y is the response (% inhibition of salivation). Y starts at Min and approaches asymptotically to Max with a sigmoidal shape. The ratio of the anti-sialagogue ID5o to bronchoprotective -D50 was used to compute the apparent lung selectivity index of the test compound. Generally, compounds having an apparent lung selectivity index greater than about 5 are preferred, hi this assay, the compound of Example 1 had an apparent lung-selectivity index greater than about 5. Assay 5 Methacholine-Induced Depressor Responses in Conscious Guinea Pigs Healthy, adult, male Sprague-Dawley guinea pigs (Harlan, Indianapolis, IN), weighing between 200 and 300 g are used in these studies. Under isoflurane anesthesia (to effect), animals are instrumented with common carotid artery and jugular vein catheters (PE-50 tubing). The catheters are exteriorized utilizing a subcutaneous tunnel to the subscapular area. All surgical incisions are sutured with 4-0 Ethicon Silk and the catheters locked with heparin (1000 units/mL). Each animal is administered saline (3 mL, SC) at the end of surgery as well as buprenorphine (0.05 mg/kg, IM). Animals are allowed to recover on a heating pad before being returned to their holding rooms. Approximately 18 to 20 hours following surgery, the animals are weighed and the carotid artery catheter on each animal is connected to a transducer for recording arterial pressure. Arterial pressure and heart rate is recorded using a Biopac MP-100 Acquisition System. Animals are allowed to acclimate and stabilize for a period of 20 minutes. Each animal is challenged with MCh (0.3 mg/kg, IV) administered through the jugular venous line and the cardiovascular response is monitored for 10 minutes. The animals are then placed into the whole body dosing chamber, which is connected to a nebulizer containing the test compound or vehicle solution. The solution is nebulized for 10 minutes using a gas mixture of breathable air and 5% carbon dioxide with a flow rate of 3 liters/minute. The animals are then removed from the whole body chamber and returned to their respective cages. At 1.5 and 24 h post-dosing, the animals are re-challenged with MCh (0.3 mg/kg, IN) and the hemodynamic response is determined. Thereafter, the animals are euthanized with sodium pentobarbital (150 mg/kg, IN). MCh produces a decrease in mean arterial pressure (MAP) and decrease in heart rate (bradycardia). The peak decrease, from baseline, in MAP (depressor responses) is measured for each MCh challenge (before and after IH dosing). The bradycardic effects are not used for analysis since these responses are not robust and reproducible. The effects of treatment on the MCh responses are expressed as % inhibition (mean +/- SEM) of the control depressor responses. Two-way AΝONA with the appropriate post-hoc test is used to test the effects of treatment and pre-treatment time. The ratio of the anti-depressor ID50 to bronchoprotective ID5o is used to compute apparent lung-selectivity of the test compound. Generally, compounds having an apparent lung-selectivity index greater than 5 are preferred. In this assay, compounds of the invention are expected to have an apparent lung-selectivity index greater than 5. While the present invention has been described with reference to specific aspects or embodiments thereof, it will be understood by those of ordinary skilled in the art that various changes can be made or equivalents can be substituted without departing from the true spirit and scope of the invention. Additionally, to the extent permitted by applicable patent statues and regulations, all publications, patents and patent applications cited herein are hereby incorporated by reference in their entirety to the same extent as if each document had been individually incorporated by reference herein.

Claims

WHAT IS CLAIMED IS: 1. A compound of formula I:
Figure imgf000069_0001
I wherein: a is 0 or an integer of from 1 to 5; each R1 is independently selected from (l-4C)alkyl, (2-4C)alkenyl, (2-4C)alkynyl, (3-6C)cycloalkyl, cyano, halo, -ORla, -C(O)ORl , -SRlc, -S(O)Rld, -S(O)2Rle, -NRlfRl , -NRlhS(O)2RH, and -NRljC(O)Rlk; where each of Rla, Rlb, Rlc, Rld, Rle, Rlf, Rlg, Rlh, RH, Rl , and Rlk is independently hydrogen, (l-4C)alkyl or phenyl(l-4C)alkyl; b is 0 or an integer of from 1 to 4; each R2 is independently selected from (l-4C)alkyl, (2-4C)alkenyl, (2-4C) alkynyl, (3-6C)cycloalkyl, cyano, halo, -OR2a, -C(O)OR2b, -SR2c, -S(O)R2d, -S(O)2R2e, -NR2fR2g, -NR2hS(O)2R2i, and -NR2jC(O)R2k; where each of R2a, R2b, R2c, R2d, R2e, R2f, R2g, R2h, R2i, R2j, and R2 is independently hydrogen, (l-4C)alkyl or phenyl(l-4C)alkyl; W represents O or NWa, where Wa is hydrogen or (l-4C)alkyl; c is 0 or an integer from 1 to 5; each R3 independently represents (l-4C)alkyl or two R3 groups are joined to form (l-3C)alkylene, (2-3C)alkenylene or oxiran-2,3-diyl; m is O or 1; R4 is selected from hydrogen, (l-4C)alkyl, and (3-4C)cycloalkyl; s is 0, 1 or 2; Ar1 represents a phenylene group or a (3-5C)heteroarylene group containing 1 or 2 heteroatoms selected independently from oxygen, nitrogen or sulfur; wherein the phenylene or heteroarylene group is substituted with (R5)q where q is 0 or an integer from 1 to 4 and each R5 is selected independently from halo, hydroxy, (l-4C)alkyl or (l-4C)alkoxy; t is 0, 1 or 2; p is 0, 1 or 2; each R6 independently represents (l-4C)alkyl, (2-4C)alkenyl, (2-4C)alkynyl, (3-6C)cycloalkyl, cyano, nitro, halo, N,N-di(l-4C)alkylamino(2-4C)alkoxy, -OR6a, -C(O)OR6b, -SR6c, -S(O)R6d, -S(O)2R6e or -ΝR6fR6g; each of R6a, R6 , R6c, R6d, R6e, R6f and R6g is independently hydrogen, (l-4C)alkyl, (3-6C)cycloalkyl, phenyl or phenyl(l- 4C)alkyl, wherein each phenyl group is unsubstituted or substituted by 1 or 2 substituents selected independently from halo, (l-4C)alkyl and (l-4C)alkoxy; and X1 is selected from (l-3C)alkylene, -C(O)(l-3C)alkylene, (l-3C)alkyleneC(O)-, -SO2-, -SO2(l-3C)alkylene and (l-3C)alkyleneSO2~; where the alkylene group in any X1 is optionally substituted with 1 or 2 substituents independently selected from (l-4C)alkyl and -NR^R*0; wherein RXa and R5* are independently selected from hydrogen and (l-4alkyl); R7 is selected from hydrogen, (l-4C)alkyl, (3-4C)cycloalkyl, -C(O)(l-4C)alkyl, -(l-4C)alkyleneC(O)OR7a, -C(O)heterocyclyl, -C(O)CH(NH2)(l-4C)alkyleneQ, -(1- 4C)alkyleneC(O)Z, -C(O)(l-4C)alkyleneZ, and -S(O)2(l-4C)alkyleneZ; where Q is a nitrogen-containing substituent selected from -NR7 R7c and heteroaryl; Z is a nitrogen- containing substituent selected from -NR7dR7e and heterocyclyl; R7a is hydrogen or
(l-4C)alkyl; each of R7 , R7c, R7d and R7e independently represents hydrogen, (l-4C)alkyl, (3-6C)cycloalkyl or hydroxyphenyl, and where (l-4C)alkyl is unsubstituted or substituted by 1 or 2 substituents selected independently from amido, cyano, fxxryl, hydroxyl, and methylimidazolyl; the heterocyclyl contains 1 or 2 nitrogen atoms, and is unsubstituted or substituted by 1 or 2 substituents selected independently from hydroxyl, amido, (1-
4C)alkoxy, oxo, -S(O)2(l-4C)alkyl, -(CH2)O(l-4C)alkyl, -(l-4C)alkyleneOH, -NR7fR7g or -C(O)NR7hR71, where each of R7f, R7g R7h and R7! independently represents hydrogen or (l-4C)alkyl; and the heteroaryl contains 1 or 2 nitrogen atoms; wherein each alkyl and alkoxy group in R1, Rla k, R2, R2a"2k, R3, R6, and R6a"6g is optionally substituted with 1 to 5 fluoro substituents; or a pharmaceutically acceptable salt or solvate or stereoisomer thereof.
2. The compound of Claim 1, wherein a, b and c each represent 0.
3. The compound of Claim 1 , wherein W represents O.
4. The compound of Claim 1, wherein m is 0, and t is 1.
5. The compoxmd of Claim 1, wherein s is 0.
6. The compound of Claim 1, wherein Ar1 represents phen-l,3-ylene, phen- 1,4-ylene, 2,4-thienylene, 2,5-thienylene, 2,5-furylene, 2,5-pyridylene, 2,6-pyridylene, or 2,5-pynolylene; wherein the phenylene, thienylene, furylene, pyridylene or pynolylene group is optionally substituted with 1 or 2 R5 substituents.
7. The compound of Claim 6 wherein q is 1 and R5 is selected from halo and (l-4C)alkoxy.
8. The compound of Claim 1, wherein X1 is selected from -CH2- and -CH2CH2- .
9. The compound of Claim 1 , wherein p is 0.
10. The compound of any one of Claims 1 to 9, wherein R4 is hydrogen or methyl.
11. The compound of any one of Claims 1 to 9, wherein R is hydrogen or methyl.
12. The compound of Claim 1, selected from: biphenyl-2-ylcarbamic acid 1 -[2-( {4-[(4-hydroxybenzylamino)methyl] benzoyl}methylamino)ethyl]piperidin-4-yl ester; biphenyl-2-ylcarbamic acid l-{2-[(4-{[2-(4-hydroxyphenyl)ethylamino]methyl} benzoyl)methylamino] ethyl}piperidin-4-yl ester; biphenyl-2-ylcarbamic acid l-(2-{4-[(4-hydroxybenzylamino)methyl] benzoylamino} ethyl)piperidin-4-yl ester; biphenyl-2-ylcarbamic acid 1 -[2-( {4-[(3 -hydroxybenzylamino)methyl]benzoyl} methylamino)ethyl]piperidin-4-yl ester; biphenyl-2-ylcarbamic acid l-[2-(4- {[2-(4-hydroxyphenyl)ethylamino]methyl} benzoylamino)ethyl]piperidin-4-yl ester; biphenyl-2-ylcarbamic acid 1 -[2-(4- {[(4-hydroxybenzyl)methylamino]methyl} benzoylamino)ethyl]piperidin-4-yl ester; biphenyl-2-ylcarbamic acid l-{2-[4-({[2-(4-hydroxyphenyl)ethyl]methylamino} methyl)benzoylamino] ethyl}ρiperidin-4-yl ester; biphenyl-2-ylcarbamic acid 1 -[2-(2-fluoro-4- {[2-(4-hydroxyphenyl)ethylamino] methyl}benzoylamino)ethyl]piperidin-4-yl ester; biphenyl-2-ylcarbamic acid l-{2-[(2-fluoro-4-{[2-(4-hydroxyphenyl)ethylamino] methyl}benzoyl)methylamino]ethyl}piperidin-4-yl ester; biphenyl-2-ylcarbamic acid l-[2-(4-{[2-(4-hydroxyphenyl)ethylamino]methyl}-2- methoxybenzoylamino)ethyl]piperidin-4-yl ester; biphenyl-2-ylcarbamic acid l-{2-[(4-{[2-(4-hydroxyphenyl)ethylamino]methyl}-2- methoxybenzoyl)methylamino] ethyl}piperidin-4-yl ester; biphenyl-2-ylcarbamic acid l-{2-[(5-{[2-(4-hydroxyphenyl)ethylamino]methyl} thiophene-2-carbonyl)methylamino] ethyl} piperidin-4-yl ester; biphenyl-2-ylcarbamic acid l-{2-[(5-{[2-(4-hydroxyphenyl)ethylamino]methyl} thiophene-2-carbonyl)amino]ethyl}piperidin-4-yl ester; biphenyl-2-ylcarbamic acid l-{2-[(5-{[2-(4-hydroxyphenyl)ethylamino]methyl} furan-2-carbonyl)methylamino] ethyl}piperidin-4-yl ester; biphenyl-2-ylcarbamic acid 1- {2-[(5- {[2-(4-hydroxyphenyl)ethylamino]methyl} furan-2-carbonyl)amino]ethyl}piperidin-4-yl ester; biphenyl-2-ylcarbamic acid l-{2-[(5-{[2-(4-hydroxyphenyl)ethylamino]methyl} pyridine-2-carbonyl)methylamino]ethyl}piperidin-4-yl ester; biphenyl-2-ylcarbamic acid 1 - {2- [(5 - { [2-(4-hydroxyphenyl)ethylamino]methyl} - lH-pyrrole-2-carbonyl)methylamino]ethyl}piperidin-4-yl ester; biphenyl-2-ylcarbamic acid l-[2-({5-[(4-hydroxybenzylamino)methyl]thiophene-2- carbonyl}methylamino)ethyl]piperidin-4-yl ester; biphenyl-2-ylcarbamic acid 1 -[2-( {5-[(4-hydroxybenzylamino)methyl]thiophene-2- carbonyl} amino)ethyl]piperidin-4-yl ester; biphenyl-2-ylcarbamic acid 1 -[2-( {5-[(4-hydroxybenzylamino)methyl]- lH-pynole- 2-carbonyl} methylamino)ethyl]piperidin-4-yl ester; biphenyl-2-ylcarbamic acid l-[2-({5-[(4-hydroxybenzylamino)methyl]furan-2- carbonyl}methylamino)ethyl]piperidin-4-yl ester; biphenyl-2-ylcarbamic acid 1 -[2-( {5-[(4-hydroxybenzylamino)methyl]furan-2- carbonyl} amino)ethyl]piperidin-4-yl ester; biphenyl-2-ylcarbamic acid l-{2-[2-(4-{[2-(4-hydroxyphenyl)ethylamino]methyl} phenyl)acetylamino]ethyl}piperidin-4-yl ester; biphenyl-2-ylcarb amic acid 1 - {2- [3 -(4- { [2-(4-hydroxyphenyl)ethylamino]methyl} phenyl)propionylamino] ethyl} piperidin-4-yl ester; biphenyl-2-yl-carbamic acid l-[2-(3-{4-[(4-hydroxybenzylamino)methyl]phenyl} propionylamino)ethyl]piperidin-4-yl ester; biphenyl-2-yl-carbamic acid 1 - {2-[(3- {4-[(4-hydroxybenzylamino)methyl] phenyl} propionyl)methylamino] ethyl} -piperidin-4-yl ester; and biphenyl-2-yl-carbamic acid 1- {2-[(3- {4-[(3-hydroxybenzylamino)methyl] phenyl}propionyl)methylamino]ethyl}-piperidin-4-yl ester; or a pharmaceutically acceptable salt or solvate thereof.
13. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound as claimed in any one of Claims 1 to 12.
14. The pharmaceutical composition of Claim 13, wherein the composition further comprises a therapeutically effective amount of an agent selected from β2 adrenergic receptor agonists, steroidal anti-inflammatory agents, phosphodiesterase-4 inhibitors, and combinations thereof.
15. The pharmaceutical composition of Claim 14, wherein the composition comprises a therapeutically effective amount of a β2 adrenergic receptor agonist and a steroidal anti-inflammatory agent.
16. A process for preparing a compound as claimed in any one of Claims 1 to 12, the process comprising: (a) reacting a compound of formula II:
Figure imgf000073_0001
π or a salt thereof, with a compound of formula III:
Figure imgf000074_0001
III wherein Z1 represents a leaving group, and P represents a hydrogen atom or a hydroxyl- protecting group; (b) coupling a compound of formula IN:
Figure imgf000074_0002
IN with a compound of formula N:
Figure imgf000074_0003
V or a reactive derivative thereof, wherein P2 represents a hydrogen atom or a hydroxyl- protecting group; (c) reacting a compound of formula VI:
Figure imgf000074_0004
VI with a compoxmd of formula VII:
Figure imgf000074_0005
VII wherein Z2 represents a leaving group; and P -.3J represents a hydrogen atom or a hydroxyl- protecting group; (d) reacting a compound of formula II with a compound of formula VIII:
Figure imgf000075_0001
VIII wherein P4 represents a hydrogen atom or a hydroxyl-protecting group, in the presence of a reducing agent; or (e) for a compound of formula I in which X1 represents (l-3C)alkylene, reacting a compound of formula VI with a compound of formula IX:
Figure imgf000075_0002
IX wherein Xla represents a bond or (l-2C)alkylene; and P5 represents a hydrogen atom or a hydroxyl-protecting group, in the presence of a reducing agent; (f) for a compound of formula I in which t is 1 , reacting a compound of formula X:
Figure imgf000075_0003
X with a compoxmd of formula XI:
Figure imgf000075_0004
XI wherein P6 represents a hydrogen atom or a hydroxyl-protecting group, in the presence of a reducing agent; and then (g) removing any protecting group P1, ?2, P3, P4, P5, or P6 to provide a compound of formula I.
17. The process of Claim 16, wherein the process further comprises forming a pharmaceutically acceptable salt of the compound of formula I.
18. The product prepared by the process of Claim 16 or 17.
19. A method of studying a biological system or sample comprising a muscarinic receptor, the method comprising: (a) contacting the biological system or sample with a compound of any one of Claims 1 to 12; and (b) determining the effects caused by the compound on the biological system or sample.
20. A compound of any one of Claims 1 to 12 for use in therapy or as a medicament.
21. A compound of any one of Claims 1 to 12 for treatment of a pulmonary disorder.
22. A compound of any one of Claims 1 to 12 for antagonizing a muscarinic receptor in a mammal.
23. Medicament containing a compound of any one of Claims 1 to 12.
24. Use of a compound of any one of Claims 1 to 12 for the manufacture of a medicament.
25. The use of Claim 24, wherein the medicament is for the treatment of a pulmonary disorder.
26. The use of Claim 24, wherein the medicament is for antagonizing a muscarinic receptor in a mammal.
PCT/US2005/008007 2004-03-11 2005-03-10 Biphenyl compounds useful as muscarinic receptor antagonists WO2005087733A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP05725269A EP1723108A1 (en) 2004-03-11 2005-03-10 Biphenyl compounds useful as muscarinic receptor antagonists
JP2007503019A JP2007528412A (en) 2004-03-11 2005-03-10 Biphenyl compounds useful as muscarinic receptor antagonists

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US55234704P 2004-03-11 2004-03-11
US60/552,347 2004-03-11

Publications (1)

Publication Number Publication Date
WO2005087733A1 true WO2005087733A1 (en) 2005-09-22

Family

ID=34961325

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/008007 WO2005087733A1 (en) 2004-03-11 2005-03-10 Biphenyl compounds useful as muscarinic receptor antagonists

Country Status (4)

Country Link
US (2) US7265133B2 (en)
EP (1) EP1723108A1 (en)
JP (1) JP2007528412A (en)
WO (1) WO2005087733A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006099167A1 (en) * 2005-03-10 2006-09-21 Theravance, Inc. Biphenyl compounds useful as muscarinic receptor antagonists

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6693202B1 (en) * 1999-02-16 2004-02-17 Theravance, Inc. Muscarinic receptor antagonists
PE20040950A1 (en) * 2003-02-14 2005-01-01 Theravance Inc BIPHENYL DERIVATIVES AS AGONISTS OF ß2-ADRENERGIC RECEPTORS AND AS ANTAGONISTS OF MUSCARINAL RECEPTORS
US7456199B2 (en) * 2004-03-11 2008-11-25 Theravance, Inc. Biphenyl compounds useful as muscarinic receptor antagonists
US7524962B2 (en) * 2004-03-11 2009-04-28 Theravance, Inc. Biphenyl compounds useful as muscarinic receptor antagonists
WO2005087737A1 (en) 2004-03-11 2005-09-22 Theravance, Inc. Biphenyl compounds useful as muscarinic receptor antagonists
TWI341836B (en) 2004-03-11 2011-05-11 Theravance Inc Biphenyl compounds useful as muscarinic receptor antagonists
WO2005087736A1 (en) * 2004-03-11 2005-09-22 Theravance, Inc. Biphenyl compounds useful as muscarinic receptor antagonists
EP1723108A1 (en) * 2004-03-11 2006-11-22 Theravance, Inc. Biphenyl compounds useful as muscarinic receptor antagonists
TW200538095A (en) * 2004-03-11 2005-12-01 Theravance Inc Biphenyl compounds useful as muscarinic receptor antagonists
WO2006099032A1 (en) * 2005-03-10 2006-09-21 Theravance, Inc. Biphenyl compounds useful as muscarinic receptor antagonists
WO2006099031A1 (en) * 2005-03-10 2006-09-21 Theravance, Inc. Biphenyl compounds useful as muscarinic receptor antagonists
US7659403B2 (en) 2005-03-10 2010-02-09 Theravance, Inc. Biphenyl compounds useful as muscarinic receptor antagonists
TW200714587A (en) * 2005-03-10 2007-04-16 Theravance Inc Biphenyl compounds useful as muscarinic receptor antagonists
JP2008546695A (en) 2005-06-13 2008-12-25 セラヴァンス， インコーポレーテッド Biphenyl compounds useful as muscarinic receptor antagonists
CN113563255B (en) * 2020-04-29 2023-08-18 成都倍特药业股份有限公司 Preparation method of remifloxacin intermediate
US11596612B1 (en) 2022-03-08 2023-03-07 PTC Innovations, LLC Topical anesthetics

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001042212A1 (en) * 1999-12-07 2001-06-14 Theravance, Inc. Carbamate derivatives having muscarinic receptor antagonist activity
WO2001042213A1 (en) * 1999-12-07 2001-06-14 Theravance, Inc. Urea compounds having muscarinic receptor antagonist activity

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7545894A (en) 1993-09-02 1995-03-22 Yamanouchi Pharmaceutical Co., Ltd. Carbamate derivative and medicine containing the same
KR970701174A (en) 1994-02-10 1997-03-17 오노다 마사요시 Novel carbamate derivative and medicinal composition containing the same
SG80041A1 (en) 1998-06-08 2001-04-17 Advanced Medicine Inc Muscarinic receptor antagonists
US6693202B1 (en) * 1999-02-16 2004-02-17 Theravance, Inc. Muscarinic receptor antagonists
DE19933926A1 (en) * 1999-07-20 2001-01-25 Boehringer Ingelheim Pharma Biphenyl derivatives, their preparation and their use as medicines
DK1345937T3 (en) 2000-12-22 2006-01-16 Almirall Prodesfarma Ag Quinuclidine carbamate derivatives and their use as M3 antagonists
US6656694B2 (en) * 2001-01-11 2003-12-02 Theravance, Inc. Method for identifying a ligand for a biological substrate
US20030018019A1 (en) * 2001-06-23 2003-01-23 Boehringer Ingelheim Pharma Kg Pharmaceutical compositions based on anticholinergics, corticosteroids and betamimetics
UY27927A1 (en) 2002-08-06 2003-12-31 Glaxo Group Ltd ACETILCOLINE M3 MUSCARINIC RECEIVER ANTAGONISTS
PE20040950A1 (en) * 2003-02-14 2005-01-01 Theravance Inc BIPHENYL DERIVATIVES AS AGONISTS OF ß2-ADRENERGIC RECEPTORS AND AS ANTAGONISTS OF MUSCARINAL RECEPTORS
ES2329586T3 (en) 2003-11-21 2009-11-27 Theravance, Inc. COMPOUNDS THAT HAVE AGONIST ACTIVITY OF THE BETA2 ADRENERGIC RECEIVER AND ANTAGONIST OF THE MUSCARINE RECEIVER.
TW200538095A (en) 2004-03-11 2005-12-01 Theravance Inc Biphenyl compounds useful as muscarinic receptor antagonists
US7524962B2 (en) 2004-03-11 2009-04-28 Theravance, Inc. Biphenyl compounds useful as muscarinic receptor antagonists
US7456199B2 (en) 2004-03-11 2008-11-25 Theravance, Inc. Biphenyl compounds useful as muscarinic receptor antagonists
WO2005087736A1 (en) 2004-03-11 2005-09-22 Theravance, Inc. Biphenyl compounds useful as muscarinic receptor antagonists
EP1723109A1 (en) 2004-03-11 2006-11-22 Theravance, Inc. Biphenyl compounds useful as muscarinic receptor antagonists
EP1723108A1 (en) * 2004-03-11 2006-11-22 Theravance, Inc. Biphenyl compounds useful as muscarinic receptor antagonists
WO2005087737A1 (en) 2004-03-11 2005-09-22 Theravance, Inc. Biphenyl compounds useful as muscarinic receptor antagonists
TWI341836B (en) 2004-03-11 2011-05-11 Theravance Inc Biphenyl compounds useful as muscarinic receptor antagonists
TW200714587A (en) 2005-03-10 2007-04-16 Theravance Inc Biphenyl compounds useful as muscarinic receptor antagonists
WO2006099031A1 (en) 2005-03-10 2006-09-21 Theravance, Inc. Biphenyl compounds useful as muscarinic receptor antagonists
JP2008538104A (en) * 2005-03-10 2008-10-09 セラヴァンス， インコーポレーテッド Biphenyl compounds useful as muscarinic receptor antagonists

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001042212A1 (en) * 1999-12-07 2001-06-14 Theravance, Inc. Carbamate derivatives having muscarinic receptor antagonist activity
WO2001042213A1 (en) * 1999-12-07 2001-06-14 Theravance, Inc. Urea compounds having muscarinic receptor antagonist activity

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006099167A1 (en) * 2005-03-10 2006-09-21 Theravance, Inc. Biphenyl compounds useful as muscarinic receptor antagonists

Also Published As

Publication number Publication date
EP1723108A1 (en) 2006-11-22
US7265133B2 (en) 2007-09-04
JP2007528412A (en) 2007-10-11
US20050203138A1 (en) 2005-09-15
US20070265310A1 (en) 2007-11-15
US7851632B2 (en) 2010-12-14

Similar Documents

Publication Publication Date Title
EP1723114B1 (en) Biphenyl compounds useful as muscarinic receptor antagonists
US8329911B2 (en) Biphenyl compounds useful as muscarinic receptor antagonists
US7265133B2 (en) Biphenyl compounds useful as muscarinic receptor antagonists
US7851631B2 (en) Biphenyl compounds useful as muscarinic receptor antagonists
US7868175B2 (en) Biphenyl compounds useful as muscarinic receptor antagonists
US7524962B2 (en) Biphenyl compounds useful as muscarinic receptor antagonists
US20050203137A1 (en) Biphenyl compounds useful as muscarinic receptor antagonists
WO2005087735A1 (en) Biphenyl compounds useful as muscarinic receptor antagonists
EP1723115A1 (en) Biphenyl compounds useful as muscarinic receptor antagonists
WO2006098997A1 (en) Biphenyl compounds useful as muscarinic receptor antagonists

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2007503019

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2005725269

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

WWP Wipo information: published in national office

Ref document number: 2005725269

Country of ref document: EP